

**This Page Is Inserted by IFW Operations  
and is not a part of the Official Record**

## **BEST AVAILABLE IMAGES**

**Defective images within this document are accurate representation of  
The original documents submitted by the applicant.**

**Defects in the images may include (but are not limited to):**

- **BLACK BORDERS**
- **TEXT CUT OFF AT TOP, BOTTOM OR SIDES**
- **FADED TEXT**
- **ILLEGIBLE TEXT**
- **SKEWED/SLANTED IMAGES**
- **COLORED PHOTOS**
- **BLACK OR VERY BLACK AND WHITE DARK PHOTOS**
- **GRAY SCALE DOCUMENTS**

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning documents *will not* correct images,  
please do not report the images to the  
Image Problem Mailbox.**

**THIS PAGE BLANK (USPTO)**


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :	A1	(11) International Publication Number: WO 97/46675
C12N 15/12, C07K 14/705, 16/28, G01N 33/68, C07F 9/30, C12N 15/11, A01K 67/027		(43) International Publication Date: 11 December 1997 (11.12.97)
(21) International Application Number: PCT/EP97/01370		MICKEL, Stuart, John [GB/CH]; Heinisbodenweg 11, CH-4415 Lausen (CH).
(22) International Filing Date: 19 March 1997 (19.03.97)		(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).
(30) Priority Data:		(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, SG, SI, SK, TR, TT, UA, US, UZ, VN, YU, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).
08/655,716 30 May 1996 (30.05.96) US		
08/756,091 22 November 1996 (22.11.96) US		
(60) Parent Application or Grant		
(63) Related by Continuation		
US 08/756,091 (CIP)		
Filed on 22 November 1996 (22.11.96)		
(71) Applicant (for all designated States except US): NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).		
(72) Inventors; and		Published
(75) Inventors/Applicants (for US only): KAUPMANN, Clemens [DE/DE]; Dinkelbergstrasse 9, D-79540 Lörrach (DE). BETTLER, Bernhard [CH/CH]; Kurzelängeweg 9a, CH-4123 Allschwil (CH). BITTIGER, Helmut [DE/DE]; Stadtstrasse 87A, D-79104 Freiburg (DE). FRÖSTL, Wolfgang [AT/CH]; Holbeinstrasse 18/3, CH-4051 Basel (CH).		With international search report.

(54) Title: METABOTROPIC GABA[B] RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES



## (57) Abstract.

The present invention provides purified GABA<sub>B</sub> receptors and receptor proteins derived from rat and human sources, as well as nucleic acids which encode such proteins. The proteins and nucleic acids of the invention share significant homology with the GABA<sub>B</sub> receptor and the DNA encoding it as specifically disclosed herein. The invention moreover provides methods for isolating other members of the GABA<sub>B</sub> receptor family using DNA cloning technology and probes derived from the sequences provided herein, as well as novel members of the GABA<sub>B</sub> receptor family isolated by such methods. Furthermore, the invention relates to the use of GABA<sub>B</sub> receptors and receptor proteins and cells transformed with a gene encoding a GABA<sub>B</sub> receptor protein in a method for identifying and characterising compounds which modulate the activity of the GABA<sub>B</sub> receptor, such as GABA<sub>B</sub> receptor agonists and antagonists, which may be useful as pharmacological agents for the treatment of disorders associated with the central and peripheral nervous systems.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.


AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SK	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**PCT**WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

## INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification <sup>6</sup> :		A1	(11) International Publication Number:	WO 97/46675
C12N 15/12, C07K 14/705, 16/28, G01N 33/68, C07F 9/30, C12N 15/11, A01K 67/027			(43) International Publication Date:	11 December 1997 (11.12.97)
(21) International Application Number:	PCT/EP97/01370			MICKEL, Stuart, John [GB/CH]; Heinisbodenweg 11, CH-4415 Lausen (CH).
(22) International Filing Date:	19 March 1997 (19.03.97)			(74) Agent: ROTH, Bernhard, M.; Novartis AG, Patent- und Markenabteilung, Klybeckstrasse 141, CH-4002 Basel (CH).
(30) Priority Data:	08/655,716 30 May 1996 (30.05.96) US			
	08/756,091 22 November 1996 (22.11.96) US			
(60) Parent Application or Grant				
(63) Related by Continuation				
US Filed on	08/756,091 (CIP)			
	22 November 1996 (22.11.96)			
(71) Applicant (for all designated States except US):	NOVARTIS AG [CH/CH]; Schwarzwaldallee 215, CH-4058 Basel (CH).			
(72) Inventors; and			Published	
(75) Inventors/Applicants (for US only):	KAUPMANN, Clemens [DE/DE]; Dinkelbergstrasse 9, D-79540 Lörrach (DE). BETTLER, Bernhard [CH/CH]; Kurzelängeweg 9a, CH-4123 Allschwil (CH). BITTIGER, Helmut [DE/DE]; Stadtstrasse 87A, D-79104 Freiburg (DE). FRÖSTL, Wolfgang [AT/CH]; Holbeinstrasse 18/3, CH-4051 Basel (CH).		With international search report.	

(54) Title: METABOTROPIC GABA[B] RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES



## (57) Abstract.

The present invention provides purified GABA<sub>B</sub> receptors and receptor proteins derived from rat and human sources, as well as nucleic acids which encode such proteins. The proteins and nucleic acids of the invention share significant homology with the GABA<sub>B</sub> receptor and the DNA encoding it as specifically disclosed herein. The invention moreover provides methods for isolating other members of the GABA<sub>B</sub> receptor family using DNA cloning technology and probes derived from the sequences provided herein, as well as novel members of the GABA<sub>B</sub> receptor family isolated by such methods. Furthermore, the invention relates to the use of GABA<sub>B</sub> receptors and receptor proteins and cells transformed with a gene encoding a GABA<sub>B</sub> receptor protein in a method for identifying and characterising compounds which modulate the activity of the GABA<sub>B</sub> receptor, such as GABA<sub>B</sub> receptor agonists and antagonists, which may be useful as pharmacological agents for the treatment of disorders associated with the central and peripheral nervous systems.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LI	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

**METABOTROPIC GABA(B) RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES**

The present invention relates to nucleic acids encoding proteins of the GABA<sub>B</sub> receptor family, as well as proteins encoded thereby and the use of such proteins for the development of pharmacological agents.

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter found in the brain and peripheral nervous system. Receptors for GABA have been divided into two subfamilies, the GABA<sub>A</sub> and GABA<sub>B</sub> receptors. Of these, GABA<sub>A</sub> receptors are involved in fast inhibitory signal transmission, whilst GABA<sub>B</sub> receptors appear to be involved in modulation of neurotransmission. Pre-synaptic GABA<sub>B</sub> receptors influence the release of neurotransmitters and neuropeptides such as GABA, glutamate, noradrenaline, dopamine, 5-hydroxytryptamine, substance P, cholecystokinin and somatostatin, while post-synaptic GABA<sub>B</sub> receptors are coupled to potassium channels via G proteins and mediate late inhibitory post-synaptic potentials (IPSPs). The effect of the activation of both subtypes of the GABA<sub>B</sub> receptor is to modulate synaptic transmission.

GABA<sub>B</sub> receptors are located throughout the central and peripheral nervous systems (see Ong and Kerr, *Life Sciences*, (1990) 46, 1489-1501; Bowery *et al.*, *Drug Res.* (1992) 42(1), 2a, 215-223), and are thus involved in the regulation of a wide variety of neurally-controlled physiological responses, from memory and learning to muscle contraction. This makes the GABA<sub>B</sub> receptor a target for pharmaceutical agents intended to treat central and peripheral neural disorders, and indeed a variety of GABA<sub>B</sub> agonists and antagonists are known and have been proposed for use in therapy (Bittiger *et al.*, in *GABA: Receptors, Transporters and Metabolism*, Tanaka, C., and Bowery, N.G. (Eds). Birkhäuser Verlag Basel/Switzerland (1996), 297-305; Bittiger *et al.*, *Trends Pharmacol. Sci.*, 14, 391-394, 1993; Froestl *et al.*, *J. Med. Chem.*, 38, 3297-3312, 1995; Froestl *et al.*, *Ibid.*, 3313-3331). For example, in Alzheimer's disease and other dementias such as Age Associated Memory Impairment and Multi Infarct Dementia, loss of cognitive function is associated with reduced levels of a number of neurotransmitters in the brain. In particular, a deficit in L-glutamate is expected to cause a major loss of cognitive functions, since L-glutamate appears to be crucially involved in the processes underlying memory formation and learning. GABA acts directly at many synapses to reduce the release of L-glutamate by acting on GABA<sub>B</sub> hetero-receptors. Thus, GABA<sub>B</sub> receptor antagonists are indicated for the treatment of dementias,

- 2 -

and indeed have been shown to improve cognitive functions in animal studies. In addition, GABA<sub>B</sub> receptor antagonists are expected to be active in psychiatric and neurological disorders such as depression, anxiety and epilepsy (Bittiger *et al.*, 1993, 1996, Op. Cit.; Froestl *et al.*, 1995, Op. Cit.). GABA<sub>B</sub> receptor agonists are known as antispastic agents, and in peripheral nervous system applications, agonists are expected to be beneficial in bronchial inflammation, asthma and coughing (Bertrand *et al.*, Am. J. Resp. Crit. Care Med. 149, A900, 1994). GABA is moreover associated with activity in the intestine, the cardiovascular system, gall and urinary bladders, and a variety of other tissues (Ong and Kerr, Op. Cit.).

GABA action in each of the above cases is known to be mediated by GABA<sub>B</sub> receptors, making the receptors targets for pharmacological agents designed to treat a number of disorders.

Despite the advanced state of molecular biology and protein purification technology, and the evident desirability of obtaining a purified GABA<sub>B</sub> receptor for pharmacological studies, the GABA<sub>B</sub> receptor previously has not been cloned or purified to homogeneity. A previous report of its partial purification (Nakayasu *et al.*, J. Biol. Chem., 268, 8658-8664, 1993) appears to have been inaccurate, relating to an 80 kDa protein, which we now know to be too small. In order to be able to clone the GABA<sub>B</sub> receptor, we have developed a number of GABA<sub>B</sub> receptor-specific ligands. By expression cloning using one such highly selective GABA<sub>B</sub> receptor ligand labelled to high specific radioactivity, we have now cloned different GABA<sub>B</sub> receptors from rat and human sources, sequenced them and expressed the respective recombinant receptors in mammalian cell culture.

#### Summary of the Invention

The present invention provides purified GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, as well as nucleic acids which encode such proteins. The proteins and nucleic acids of the invention share significant homology with the GABA<sub>B</sub> receptors and the DNAs encoding them as specifically disclosed herein. In particular, there are provided two GABA<sub>B</sub> receptor proteins designated GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b which are distinct variants of GABA<sub>B</sub> isolated from rat. The respective cDNA and derived amino acid sequences are set forth in SEQ ID Nos. 1, 2, and 5, 6, respectively. Furthermore, there are provided two human GABA<sub>B</sub> receptor clones termed GABA<sub>B</sub>R1a/b (representing a partial receptor clone) and GABA<sub>B</sub>R1b (representing a full-length receptor clone) isolated from human sources.

**METABOTROPIC GABA(B) RECEPTORS, RECEPTOR-SPECIFIC LIGANDS AND THEIR USES**

The present invention relates to nucleic acids encoding proteins of the GABA<sub>B</sub> receptor family, as well as proteins encoded thereby and the use of such proteins for the development of pharmacological agents.

Gamma-aminobutyric acid (GABA) is the major inhibitory neurotransmitter found in the brain and peripheral nervous system. Receptors for GABA have been divided into two subfamilies, the GABA<sub>A</sub> and GABA<sub>B</sub> receptors. Of these, GABA<sub>A</sub> receptors are involved in fast inhibitory signal transmission, whilst GABA<sub>B</sub> receptors appear to be involved in modulation of neurotransmission. Pre-synaptic GABA<sub>B</sub> receptors influence the release of neurotransmitters and neuropeptides such as GABA, glutamate, noradrenaline, dopamine, 5-hydroxytryptamine, substance P, cholecystokinin and somatostatin, while post-synaptic GABA<sub>B</sub> receptors are coupled to potassium channels via G proteins and mediate late inhibitory post-synaptic potentials (IPSPs). The effect of the activation of both subtypes of the GABA<sub>B</sub> receptor is to modulate synaptic transmission.

GABA<sub>B</sub> receptors are located throughout the central and peripheral nervous systems (see Ong and Kerr, *Life Sciences*, (1990) 46, 1489-1501; Bowery *et al.*, *Drug Res.* (1992) 42(1), 2a, 215-223), and are thus involved in the regulation of a wide variety of neurally-controlled physiological responses, from memory and learning to muscle contraction. This makes the GABA<sub>B</sub> receptor a target for pharmaceutical agents intended to treat central and peripheral neural disorders, and indeed a variety of GABA<sub>B</sub> agonists and antagonists are known and have been proposed for use in therapy (Bittiger *et al.*, in *GABA: Receptors, Transporters and Metabolism*, Tanaka, C., and Bowery, N.G. (Eds). Birkhäuser Verlag Basel/Switzerland (1996), 297-305; Bittiger *et al.*, *Trends Pharmacol. Sci.*, 14, 391-394, 1993; Froestl *et al.*, *J. Med. Chem.*, 38, 3297-3312, 1995; Froestl *et al.*, *Ibid.*, 3313-3331). For example, in Alzheimer's disease and other dementias such as Age Associated Memory Impairment and Multi Infarct Dementia, loss of cognitive function is associated with reduced levels of a number of neurotransmitters in the brain. In particular, a deficit in L-glutamate is expected to cause a major loss of cognitive functions, since L-glutamate appears to be crucially involved in the processes underlying memory formation and learning. GABA acts directly at many synapses to reduce the release of L-glutamate by acting on GABA<sub>B</sub> hetero-receptors. Thus, GABA<sub>B</sub> receptor antagonists are indicated for the treatment of dementias,

- 2 -

and indeed have been shown to improve cognitive functions in animal studies. In addition, GABA<sub>B</sub> receptor antagonists are expected to be active in psychiatric and neurological disorders such as depression, anxiety and epilepsy (Bittiger *et al.*, 1993, 1996, Op. Cit.; Froestl *et al.*, 1995, Op. Cit.). GABA<sub>B</sub> receptor agonists are known as antispastic agents, and in peripheral nervous system applications, agonists are expected to be beneficial in bronchial inflammation, asthma and coughing (Bertrand *et al.*, Am. J. Resp. Crit. Care Med. 149, A900, 1994). GABA is moreover associated with activity in the intestine, the cardiovascular system, gall and urinary bladders, and a variety of other tissues (Ong and Kerr, Op. Cit.).

GABA action in each of the above cases is known to be mediated by GABA<sub>B</sub> receptors, making the receptors targets for pharmacological agents designed to treat a number of disorders.

Despite the advanced state of molecular biology and protein purification technology, and the evident desirability of obtaining a purified GABA<sub>B</sub> receptor for pharmacological studies, the GABA<sub>B</sub> receptor previously has not been cloned or purified to homogeneity. A previous report of its partial purification (Nakayasu *et al.*, J. Biol. Chem., 268, 8658-8664, 1993) appears to have been inaccurate, relating to an 80 kDa protein, which we now know to be too small. In order to be able to clone the GABA<sub>B</sub> receptor, we have developed a number of GABA<sub>B</sub> receptor-specific ligands. By expression cloning using one such highly selective GABA<sub>B</sub> receptor ligand labelled to high specific radioactivity, we have now cloned different GABA<sub>B</sub> receptors from rat and human sources, sequenced them and expressed the respective recombinant receptors in mammalian cell culture.


#### Summary of the Invention

The present invention provides purified GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, as well as nucleic acids which encode such proteins. The proteins and nucleic acids of the invention share significant homology with the GABA<sub>B</sub> receptors and the DNAs encoding them as specifically disclosed herein. In particular, there are provided two GABA<sub>B</sub> receptor proteins designated GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b which are distinct variants of GABA<sub>B</sub> isolated from rat. The respective cDNA and derived amino acid sequences are set forth in SEQ ID Nos. 1, 2, and 5, 6, respectively. Furthermore, there are provided two human GABA<sub>B</sub> receptor clones termed GABA<sub>B</sub>R1a/b (representing a partial receptor clone) and GABA<sub>B</sub>R1b (representing a full-length receptor clone) isolated from human sources.


- 3 -

The respective cDNA and derived amino acid sequences are set forth in SEQ ID Nos. 3, 4, and 7, 8, respectively.

The GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins of the invention show specific binding to one or more of the selective GABA<sub>B</sub> receptor antagonists of Formula I and Formula II:




[<sup>125</sup>I]CGP 62413




[<sup>125</sup>I]CGP 71872

The invention accordingly provides the compounds of Formula I and Formula II. Moreover, binding of the these selective GABA<sub>B</sub> receptor antagonists may be competed with other selective GABA<sub>B</sub> receptor agonists or antagonists, such as the compound of Formula III and Formula IV:



CGP 54626A

- 4 -



IV

**CGP 35348**

The invention moreover provides methods for isolating other members of the GABA<sub>B</sub> receptor family using DNA cloning technology and probes derived from the sequences provided herein, as well as novel members of the GABA<sub>B</sub> receptor family isolated by such methods.

Furthermore, the invention relates to the use of GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins and cells transformed with a gene encoding such a GABA<sub>B</sub> receptor or receptor protein in a method for identifying and characterising compounds which modulate the activity of the GABA<sub>B</sub> receptor(s), such as GABA<sub>B</sub> receptor agonists and antagonists, which may be useful as pharmacological agents for the treatment of disorders associated with the central and peripheral nervous systems. In particular, GABA<sub>B</sub> receptor antagonists can e.g. be useful as cognition enhancers, nootropics, antidepressants and anxiolytics for the treatment of cerebral insufficiency, depression, anxiety, epilepsy of the petit mal type, schizophrenia and myopia, whereas GABA<sub>B</sub> receptor agonists can e.g. be useful in the treatment of disorders such as spasticity, trigeminal neuralgia, asthma, cough, emesis, ulcers, urinary incontinence and cocaine addiction.


#### Brief Description of the Figures

Figure 1a depicts the expression of the recombinant GABA<sub>B</sub>R1a receptor in COS1 cells. Membranes from rat cortex membranes (lane 1) and COS1 cells transfected with the GABA<sub>B</sub>R1a rat-cDNA (lanes 2 and 3) are labelled with the photoaffinity ligand [<sup>125</sup>I]CGP 71872. Autoradiography of a 6% SDS gel with 25μg protein loaded per lane is shown. Lanes 1 and 2: Specific binding with 0.6nM [<sup>125</sup>I]CGP 71872. Lane 3: Control experiment where specific binding with 0.6nM [<sup>125</sup>I]CGP 71872 is competed with 1μM of unlabeled CGP 54626A (an antagonist specific for GABA<sub>B</sub> receptors). The apparent molecular weight of native and recombinant GABA<sub>B</sub> receptors are estimated from gel mobilities relative to those


- 3 -

The respective cDNA and derived amino acid sequences are set forth in SEQ ID Nos. 3, 4, and 7, 8, respectively.

The GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins of the invention show specific binding to one or more of the selective GABA<sub>B</sub> receptor antagonists of Formula I and Formula II:




[<sup>125</sup>I]CGP 62413



[<sup>125</sup>I]CGP 71872


The invention accordingly provides the compounds of Formula I and Formula II. Moreover, binding of the these selective GABA<sub>B</sub> receptor antagonists may be competed with other selective GABA<sub>B</sub> receptor agonists or antagonists, such as the compound of Formula III and Formula IV:



CGP 54626A

III

- 4 -



IV

**CGP 35348**

The invention moreover provides methods for isolating other members of the GABA<sub>B</sub> receptor family using DNA cloning technology and probes derived from the sequences provided herein, as well as novel members of the GABA<sub>B</sub> receptor family isolated by such methods.

Furthermore, the invention relates to the use of GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins and cells transformed with a gene encoding such a GABA<sub>B</sub> receptor or receptor protein in a method for identifying and characterising compounds which modulate the activity of the GABA<sub>B</sub> receptor(s), such as GABA<sub>B</sub> receptor agonists and antagonists, which may be useful as pharmacological agents for the treatment of disorders associated with the central and peripheral nervous systems. In particular, GABA<sub>B</sub> receptor antagonists can e.g. be useful as cognition enhancers, nootropics, antidepressants and anxiolytics for the treatment of cerebral insufficiency, depression, anxiety, epilepsy of the petit mal type, schizophrenia and myopia, whereas GABA<sub>B</sub> receptor agonists can e.g. be useful in the treatment of disorders such as spasticity, trigeminal neuralgia, asthma, cough, emesis, ulcers, urinary incontinence and cocaine addiction.

#### Brief Description of the Figures

Figure 1a depicts the expression of the recombinant GABA<sub>B</sub>R1a receptor in COS1 cells. Membranes from rat cortex membranes (lane 1) and COS1 cells transfected with the GABA<sub>B</sub>R1a rat-cDNA (lanes 2 and 3) are labelled with the photoaffinity ligand [<sup>125</sup>I]CGP 71872. Autoradiography of a 6% SDS gel with 25μg protein loaded per lane is shown. Lanes 1 and 2: Specific binding with 0.6nM [<sup>125</sup>I]CGP 71872. Lane 3: Control experiment where specific binding with 0.6nM [<sup>125</sup>I]CGP 71872 is competed with 1μM of unlabeled CGP 54626A (an antagonist specific for GABA<sub>B</sub> receptors). The apparent molecular weight of native and recombinant GABA<sub>B</sub> receptors are estimated from gel mobilities relative to those

- 5 -

of SDS-PAGE standards (BioRad). Figure 1b additionally shows the results for COS1 cells transfected with the GABA<sub>B</sub>R1b rat-cDNA (lane 3).

Figure 2 shows the inhibition of [<sup>125</sup>I]CGP 64213 binding to GABA<sub>B</sub> receptors in membranes from rat cerebral cortex (open symbols) and recombinant GABA<sub>B</sub>R1a receptors in membranes from COS 1 cells (closed symbols) by the GABA<sub>B</sub> receptor antagonists CGP 54626A (●), CGP 64213 (▲) and CGP 35348 (■).

Figure 3 shows the inhibition of [<sup>125</sup>I]CGP 64213 binding to GABA<sub>B</sub> receptors in membranes from rat cerebral cortex (open symbols) and recombinant GABA<sub>B</sub>R1a receptors in membranes from COS 1 cells (closed symbols) by the GABA<sub>B</sub> receptor agonists GABA (○), L-baclofen (▲) and APPA 3-(aminopropyl-phosphinic acid) (■).

Figure 4 shows photoaffinity crosslinking of GABA<sub>B</sub> receptor proteins. Cell membranes of the tissues indicated are photoaffinity-labelled with [<sup>125</sup>I]CGP71872 and subjected to SDS-PAGE and autoradiography. *a, b*, Selectivity of the photoaffinity ligand [<sup>125</sup>I]CGP71872. *a*, Differential distribution of GABA<sub>B</sub> receptor variants of 130K and 100K in tissues of the nervous system. [<sup>125</sup>I]CGP71872 binding is inhibited by addition of 1 µM of CGP54626A, a selective GABA<sub>B</sub> receptor antagonist. *b*, Competition of [<sup>125</sup>I]CGP71872 labelling by different ligands. Incubation of membrane extracts with the photoaffinity ligand is carried out in the presence of competitor substances at the concentrations indicated. *c*, GABA<sub>B</sub> receptors are N-glycosylated. Photoaffinity-labelled rat cortex cell membranes are incubated with 0.4 units N-glycosidase F or 0.6 milliunits O-glycosidase (Boehringer Mannheim). *d*, Photolabelling of GABA<sub>B</sub> receptors from different species. Brain tissues from the species indicated are labelled as described hereinbelow. In the case of *Drosophila melanogaster* and *Haemonchus concordus* whole animals are analysed.

Figure 5 shows the results of assays concerning pharmacological properties of native and recombinant GABA<sub>B</sub> receptors. GABA<sub>B</sub>R1a mediates inhibition of adenylate cyclase. HEK293 c IIIs stably expressing GABA<sub>B</sub>R1a are treated with 20 µM forskolin (Fsk) to stimulate cAMP formation (100%). Fsk induced cAMP accumulation is reduced significantly ( $2P < 0.001$ ; Dunnett's *t*-test) upon simultaneous addition of 300 µM L-baclofen. The effect of L-baclofen is antagonised in the presence of 10 µM CGP54626A. Preincubation of the cells

- 6 -

with 10 ng/ml pertussis toxin (PTX) for 15-20 h completely abolishes the effect of L-baclofen. No L-baclofen response is observed in non-transfected HEK293 cells (insert). Bars represent mean values +S.E.M. of at least three independent experiments performed in quadruplicate.

#### Detailed Description of the Invention

The invention relates to purified GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, nucleic acids coding therefore and various applications thereof. Before the present invention, the GABA<sub>B</sub> receptor has not been available in purified form, but only as crude membrane preparations. For the first time, the present invention enables the production of different but related GABA<sub>B</sub> receptors in a substantially purified form, by means of recombinant DNA technology. In general, it is expected that such proteins in glycosylated form will have an observed molecular weight of between 100 and 130 kDa, whereas the unglycosylated forms will have an observed molecular weight of between 90 and 110 kDa, respectively.

GABA<sub>B</sub> receptors according to the invention are G-protein coupled modulators of neurotransmitter activity which are responsive to GABA. They may be defined by binding to labelled ligands which are selective for GABA<sub>B</sub> receptors, in particular [<sup>125</sup>I]CGP 62413 and [<sup>125</sup>I]CGP 71872. Functional studies are moreover possible in which a recombinant GABA<sub>B</sub> receptor is expressed in cell systems containing G-proteins and effectors such as ionic channels which can be activated by GABA and GABA<sub>B</sub> receptor agonists.

Proteins according to the invention may be defined electrophysiologically in transgenic or knockout animals, for example in terms of their responsiveness in assays for the GABA<sub>B</sub> receptor(s) which are known in the art, such as the measurement of late IPSPs (inhibitory post-synaptic potentials), paired-pulse inhibition or (-)-baclofen-induced depression of field EPSPs (excitatory post-synaptic potentials). GABA<sub>B</sub> receptors are responsible for the observation of IPSPs as a result of indirect coupling to potassium channels in neurons, so established agonists and antagonists of GABA<sub>B</sub> receptors may be used to determine the presence of GABA<sub>B</sub> receptors in neuronal preparations by assaying for their effect on IPSPs.

Advantageously, however, GABA<sub>B</sub> receptor proteins according to the invention are assessed by their susceptibility to CGP64213 and CGP71872 as measured by paired-pulse widening of field EPSPs. Both said compounds abolish paired-pulse widening normally associated with GABA<sub>B</sub> receptors, since they are effective GABA<sub>B</sub> autoreceptor antagonists.

- 5 -

of SDS-PAGE standards (BioRad). Figure 1b additionally shows the results for COS1 cells transfected with the GABA<sub>B</sub>R1b rat-cDNA (lane 3).

Figure 2 shows the inhibition of [<sup>125</sup>I]CGP 64213 binding to GABA<sub>B</sub> receptors in membranes from rat cerebral cortex (open symbols) and recombinant GABA<sub>B</sub>R1a receptors in membranes from COS 1 cells (closed symbols) by the GABA<sub>B</sub> receptor antagonists CGP 54626A (●), CGP 64213 (▲) and CGP 35348 (■).

Figure 3 shows the inhibition of [<sup>125</sup>I]CGP 64213 binding to GABA<sub>B</sub> receptors in membranes from rat cerebral cortex (open symbols) and recombinant GABA<sub>B</sub>R1a receptors in membranes from COS 1 cells (closed symbols) by the GABA<sub>B</sub> receptor agonists GABA (○), L-baclofen (▲) and APPA 3-(aminopropyl-phosphinic acid) (■).

Figure 4 shows photoaffinity crosslinking of GABA<sub>B</sub> receptor proteins. Cell membranes of the tissues indicated are photoaffinity-labelled with [<sup>125</sup>I]CGP71872 and subjected to SDS-PAGE and autoradiography. *a, b*, Selectivity of the photoaffinity ligand [<sup>125</sup>I]CGP71872. *a*, Differential distribution of GABA<sub>B</sub> receptor variants of 130K and 100K in tissues of the nervous system. [<sup>125</sup>I]CGP71872 binding is inhibited by addition of 1 μM of CGP54626A, a selective GABA<sub>B</sub> receptor antagonist. *b*, Competition of [<sup>125</sup>I]CGP71872 labelling by different ligands. Incubation of membrane extracts with the photoaffinity ligand is carried out in the presence of competitor substances at the concentrations indicated. *c*, GABA<sub>B</sub> receptors are N-glycosylated. Photoaffinity-labelled rat cortex cell membranes are incubated with 0.4 units N-glycosidase F or 0.6 milliunits O-glycosidase (Boehringer Mannheim). *d*, Photolabelling of GABA<sub>B</sub> receptors from different species. Brain tissues from the species indicated are labelled as described hereinbelow. In the case of *Drosophila melanogaster* and *Haemonchus concortus* whole animals are analysed.

Figure 5 shows the results of assays concerning pharmacological properties of native and recombinant GABA<sub>B</sub> receptors. GABA<sub>B</sub>R1a mediates inhibition of adenylate cyclase. HEK293 cells stably expressing GABA<sub>B</sub>R1a are treated with 20 μM forskolin (Fsk) to stimulate cAMP formation (100%). Fsk induced cAMP accumulation is reduced significantly ( $2P < 0.001$ ; Dunnett's *t*-test) upon simultaneous addition of 300 μM L-baclofen. The effect of L-baclofen is antagonised in the presence of 10 μM CGP54626A. Preincubation of the cells

with 10 ng/ml pertussis toxin (PTX) for 15-20 h completely abolishes the effect of L-baclofen. No L-baclofen response is observed in non-transfected HEK293 cells (insert). Bars represent mean values +S.E.M. of at least three independent experiments performed in quadruplicate.

#### Detailed Description of the Invention

The invention relates to purified GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, nucleic acids coding therefore and various applications thereof. Before the present invention, the GABA<sub>B</sub> receptor has not been available in purified form, but only as crude membrane preparations. For the first time, the present invention enables the production of different but related GABA<sub>B</sub> receptors in a substantially purified form, by means of recombinant DNA technology. In general, it is expected that such proteins in glycosylated form will have an observed molecular weight of between 100 and 130 kDa, whereas the unglycosylated forms will have an observed molecular weight of between 90 and 110 kDa, respectively.

GABA<sub>B</sub> receptors according to the invention are G-protein coupled modulators of neurotransmitter activity which are responsive to GABA. They may be defined by binding to labelled ligands which are selective for GABA<sub>B</sub> receptors, in particular [<sup>125</sup>I]CGP 62413 and [<sup>125</sup>I]CGP 71872. Functional studies are moreover possible in which a recombinant GABA<sub>B</sub> receptor is expressed in cell systems containing G-proteins and effectors such as ionic channels which can be activated by GABA and GABA<sub>B</sub> receptor agonists.

Proteins according to the invention may be defined electrophysiologically in transgenic or knockout animals, for example in terms of their responsiveness in assays for the GABA<sub>B</sub> receptor(s) which are known in the art, such as the measurement of late IPSPs (inhibitory post-synaptic potentials), paired-pulse inhibition or (-)-baclofen-induced depression of field EPSPs (excitatory post-synaptic potentials). GABA<sub>B</sub> receptors are responsible for the observation of IPSPs as a result of indirect coupling to potassium channels in neurons, so established agonists and antagonists of GABA<sub>B</sub> receptors may be used to determine the presence of GABA<sub>B</sub> receptors in neuronal preparations by assaying for their effect on IPSPs.

Advantageously, however, GABA<sub>B</sub> receptor proteins according to the invention are assessed by their susceptibility to CGP64213 and CGP71872 as measured by paired-pulse widening of field EPSPs. Both said compounds abolish paired-pulse widening normally associated with GABA<sub>B</sub> receptors, since they are effective GABA<sub>B</sub> autoreceptor antagonists.

Preferably, therefore, the activation of GABA<sub>B</sub> receptor proteins according to the invention is specifically inhibited by CGP64213 and CGP71872. Examples of specific inhibition by these compounds are set out hereinbelow.

As used herein, the term "GABA<sub>B</sub> receptor(s)" refers to the proteins whose sequences are substantially those set forth in SEQ ID Nos. 2 and 8, while the term "GABA<sub>B</sub> receptor proteins" includes derivatives and variants such as e.g. splice variants thereof which are related structurally and/or functionally to the GABA<sub>B</sub> receptor(s). Preferred GABA<sub>B</sub> receptor proteins according to the invention are e.g. those set forth in SEQ ID Nos. 4 and 6, and share at least one common structural determinant with the GABA<sub>B</sub> receptors having the amino acid sequences set forth in SEQ ID Nos. 2 and 8, respectively. "Common structural determinant" means that the derivative in question comprises at least one structural feature of the GABA<sub>B</sub> receptors set out in SEQ ID Nos. 2 and 8. Structural features includes possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring or denatured GABA<sub>B</sub> receptor polypeptide or fragment thereof, possession of amino acid sequence identity with the GABA<sub>B</sub> receptor(s) and features having common a structure/function relationship. Thus the GABA<sub>B</sub> receptor proteins as provided by the present invention include amino acid mutants, glycosylation variants and other covalent derivatives of the GABA<sub>B</sub> receptor(s) which retain the physiological and/or physical properties of the GABA<sub>B</sub> receptor(s).

Further included within the scope of the term "GABA<sub>B</sub> receptor proteins" are naturally occurring variants of the GABA<sub>B</sub> receptor(s) found within a particular species, preferably a mammal. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of the GABA<sub>B</sub> receptor gene. Variants according to the invention have the same basic function as the GABA<sub>B</sub> receptor(s), but may possess divergent characteristics consistent with their nature as variants. For example, it is expected that the GABA<sub>B</sub> receptors are members of a family of GABA<sub>B</sub> receptor proteins, the isolation and characterisation of which is enabled for the first time by the present invention. Different members of the GABA<sub>B</sub> receptor family may be expected to have different activity profiles, possibly according to differences in their tissue-specific localisation and role in modulating neuronal signalling.

Moreover, the present invention enables the isolation and characterisation of further GABA<sub>B</sub> receptors, GABA<sub>B</sub> receptor proteins and GABA<sub>B</sub> receptor protein-encoding nucleic acids from any species, including man. The provision of sequence data enables the person skilled in the art to apply standard hybridisation methodology, as is known in the art and set

out by way of example hereinbelow, to isolate any desired GABA<sub>B</sub> receptor-encoding nucleic acid.

The invention further comprises derivatives of the GABA<sub>B</sub> receptor(s), which retain at least one common structural determinant of the GABA<sub>B</sub> receptor(s). For example, derivatives include molecules wherein the protein of the invention is covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Such a moiety may be a detectable moiety such as an enzyme or a radioisotope.

Derivatives which retain common structural determinants can be fragments of the GABA<sub>B</sub> receptor(s). Fragments of the GABA<sub>B</sub> receptor(s) comprise individual domains thereof, as well as smaller polypeptides derived from the domains. Preferably, smaller polypeptides derived from the GABA<sub>B</sub> receptor(s) according to the invention define a single feature which is characteristic of the GABA<sub>B</sub> receptor(s). Fragments may in theory be almost any size, as long as they retain one feature of the GABA<sub>B</sub> receptor(s). Preferably, fragments will be between 5 and 600 amino acids in length. Longer fragments are regarded as truncations of the full-length GABA<sub>B</sub> receptor(s) and generally encompassed by the term "GABA<sub>B</sub> receptor(s)". Preferably, said fragments retain the functional activity of the GABA<sub>B</sub> receptor(s). Such fragments may be produced by persons skilled in the art, using conventional techniques, by removing amino acid residues from the GABA<sub>B</sub> receptor proteins of the invention which are not essential for a particular functional aspect of the GABA<sub>B</sub> receptor proteins. Determination of functional aspects of a GABA<sub>B</sub> receptor protein may be made employing pharmacological or electrophysiological assays as herein described, and particularly by assays which monitor the ability of the GABA<sub>B</sub> receptor protein to bind GABA or a GABA mimic, or to couple to G proteins.

Derivatives of the GABA<sub>B</sub> receptor(s) also comprise mutants thereof, which may contain amino acid deletions, additions or substitutions, subject to the requirement to maintain at least one feature characteristic of the GABA<sub>B</sub> receptor(s). Thus, conservative amino acid substitutions may be made substantially without altering the nature of the GABA<sub>B</sub> receptor(s). Substitutions and further deletions may moreover be made to the fragments of GABA<sub>B</sub> receptor proteins comprised by the invention. GABA<sub>B</sub> receptor protein mutants may be produced from a DNA encoding a GABA<sub>B</sub> receptor protein which has been subjected to *in vitro* mutagenesis resulting e.g. in an addition, exchange and/or deletion of one or more amino acid encoding triplets. For example, substitutional, deletional or insertional variants of the GABA<sub>B</sub> receptor(s) can be prepared by recombinant methods and

Preferably, therefore, the activation of GABA<sub>B</sub> receptor proteins according to the invention is specifically inhibited by CGP64213 and CGP71872. Examples of specific inhibition by these compounds are set out hereinbelow.

As used herein, the term "GABA<sub>B</sub> receptor(s)" refers to the proteins whose sequences are substantially those set forth in SEQ ID Nos. 2 and 8, while the term "GABA<sub>B</sub> receptor proteins" includes derivatives and variants such as e.g. splice variants thereof which are related structurally and/or functionally to the GABA<sub>B</sub> receptor(s). Preferred GABA<sub>B</sub> receptor proteins according to the invention are e.g. those set forth in SEQ ID Nos. 4 and 6, and share at least one common structural determinant with the GABA<sub>B</sub> receptors having the amino acid sequences set forth in SEQ ID Nos. 2 and 8, respectively. "Common structural determinant" means that the derivative in question comprises at least one structural feature of the GABA<sub>B</sub> receptors set out in SEQ ID Nos. 2 and 8. Structural features include possession of an epitope or antigenic site that is capable of cross-reacting with antibodies raised against a naturally occurring or denatured GABA<sub>B</sub> receptor polypeptide or fragment thereof, possession of amino acid sequence identity with the GABA<sub>B</sub> receptor(s) and features having common a structure/function relationship. Thus the GABA<sub>B</sub> receptor proteins as provided by the present invention include amino acid mutants, glycosylation variants and other covalent derivatives of the GABA<sub>B</sub> receptor(s) which retain the physiological and/or physical properties of the GABA<sub>B</sub> receptor(s).

Further included within the scope of the term "GABA<sub>B</sub> receptor proteins" are naturally occurring variants of the GABA<sub>B</sub> receptor(s) found within a particular species, preferably a mammal. Such a variant may be encoded by a related gene of the same gene family, by an allelic variant of a particular gene, or represent an alternative splicing variant of the GABA<sub>B</sub> receptor gene. Variants according to the invention have the same basic function as the GABA<sub>B</sub> receptor(s), but may possess divergent characteristics consistent with their nature as variants. For example, it is expected that the GABA<sub>B</sub> receptors are members of a family of GABA<sub>B</sub> receptor proteins, the isolation and characterisation of which is enabled for the first time by the present invention. Different members of the GABA<sub>B</sub> receptor family may be expected to have different activity profiles, possibly according to differences in their tissue-specific localisation and role in modulating neuronal signalling.

Moreover, the present invention enables the isolation and characterisation of further GABA<sub>B</sub> receptors, GABA<sub>B</sub> receptor proteins and GABA<sub>B</sub> receptor protein-encoding nucleic acids from any species, including man. The provision of sequence data enables the person skilled in the art to apply standard hybridisation methodology, as is known in the art and set

out by way of example hereinbelow, to isolate any desired GABA<sub>B</sub> receptor-encoding nucleic acid.

The invention further comprises derivatives of the GABA<sub>B</sub> receptor(s), which retain at least one common structural determinant of the GABA<sub>B</sub> receptor(s). For example, derivatives include molecules wherein the protein of the invention is covalently modified by substitution, chemical, enzymatic, or other appropriate means with a moiety other than a naturally occurring amino acid. Such a moiety may be a detectable moiety such as an enzyme or a radioisotope.

Derivatives which retain common structural determinants can be fragments of the GABA<sub>B</sub> receptor(s). Fragments of the GABA<sub>B</sub> receptor(s) comprise individual domains thereof, as well as smaller polypeptides derived from the domains. Preferably, smaller polypeptides derived from the GABA<sub>B</sub> receptor(s) according to the invention define a single feature which is characteristic of the GABA<sub>B</sub> receptor(s). Fragments may in theory be almost any size, as long as they retain one feature of the GABA<sub>B</sub> receptor(s). Preferably, fragments will be between 5 and 600 amino acids in length. Longer fragments are regarded as truncations of the full-length GABA<sub>B</sub> receptor(s) and generally encompassed by the term "GABA<sub>B</sub> receptor(s)". Preferably, said fragments retain the functional activity of the GABA<sub>B</sub> receptor(s). Such fragments may be produced by persons skilled in the art, using conventional techniques, by removing amino acid residues from the GABA<sub>B</sub> receptor proteins of the invention which are not essential for a particular functional aspect of the GABA<sub>B</sub> receptor proteins. Determination of functional aspects of a GABA<sub>B</sub> receptor protein may be made employing pharmacological or electrophysiological assays as herein described, and particularly by assays which monitor the ability of the GABA<sub>B</sub> receptor protein to bind GABA or a GABA mimic, or to couple to G proteins.

Derivatives of the GABA<sub>B</sub> receptor(s) also comprise mutants thereof, which may contain amino acid deletions, additions or substitutions, subject to the requirement to maintain at least one feature characteristic of the GABA<sub>B</sub> receptor(s). Thus, conservative amino acid substitutions may be made substantially without altering the nature of the GABA<sub>B</sub> receptor(s). Substitutions and further deletions may moreover be made to the fragments of GABA<sub>B</sub> receptor proteins comprised by the invention. GABA<sub>B</sub> receptor protein mutants may be produced from a DNA encoding a GABA<sub>B</sub> receptor protein which has been subjected to *in vitro* mutagenesis resulting e.g. in an addition, exchange and/or deletion of one or more amino acid encoding triplets. For example, substitutional, deletional or insertional variants of the GABA<sub>B</sub> receptor(s) can be prepared by recombinant methods and

screened for immuno- or physiological crossreactivity with the native forms of the GABA<sub>B</sub> receptor(s).

Mutations may be performed by any method known to those of skill in the art. Preferred, however, is site-directed mutagenesis of a nucleic acid sequence encoding the polypeptide of interest. A number of methods for site-directed mutagenesis are known in the art, from methods employing single-stranded phage such as M13 to PCR-based techniques (see "PCR Protocols: A guide to methods and applications", M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (eds.). Academic Press, New York, 1990). Preferably, the commercially available Altered Site II Mutagenesis System (Promega) may be employed, according to the directions given by the manufacturer.

The fragments, mutants and other derivatives of the GABA<sub>B</sub> receptor(s) preferably retain substantial homology with the GABA<sub>B</sub> receptor(s). As used herein, "homology" means that the two entities share sufficient characteristics for the skilled person to determine that they are similar in origin and function. Preferably, homology is used to refer to sequence identity. Thus, the derivatives of the GABA<sub>B</sub> receptor(s) preferably retain substantial sequence identity with the sequences set forth in SEQ ID Nos. 2 and 8, respectively.

"Substantial homology", where homology indicates sequence identity, means more than 30% sequence identity, preferably more than 65% sequence identity and most preferably a sequence identity of 80% or more.

According to a further aspect of the present invention, there are provided nucleic acids encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins (SEQ ID Nos. 1, 7, and 3, 5, respectively). In addition to being useful for the production of recombinant GABA<sub>B</sub> receptors and receptor proteins, these nucleic acids are also useful as probes, thus readily enabling those skilled in the art to identify and/or isolate nucleic acids encoding further members of the GABA<sub>B</sub> receptor family and variants thereof as set forth hereinbefore.

In another aspect, the invention provides nucleic acid sequences that are complementary to, or are capable of hybridising to, nucleic acid sequences encoding the GABA<sub>B</sub> receptors or receptor proteins. Preferably, such nucleic acids are capable of hybridising under high or moderate stringency, as defined hereinbelow.

Furthermore, nucleic acids according to the invention are useful in a method determining the presence of a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid, said method comprising hybridising the DNA (or RNA) encoding (or complementary to) the

- 10 -

GABA<sub>B</sub> receptor or receptor protein to test sample nucleic acid and determining the presence of the GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid.

The invention also provides a method for amplifying a nucleic acid test sample comprising priming a nucleic acid polymerase (chain) reaction with nucleic acid (DNA or RNA) encoding a GABA<sub>B</sub> receptor or receptor protein, or a nucleic acid complementary thereto.

Isolated GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acids include nucleic acids that are free from at least one contaminant nucleic acid with which they are ordinarily associated in the natural source of GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acids or in crude nucleic acid preparations, such as DNA libraries and the like. Isolated nucleic acids thus are present in other than in the form or setting in which they are found in nature. However, isolated GABA<sub>B</sub> receptor and receptor protein encoding nucleic acids include GABA<sub>B</sub> receptor- and receptor protein-specific nucleic acids in ordinarily GABA<sub>B</sub> receptor- or receptor protein-expressing cells, where the nucleic acids are in a chromosomal location different from that of natural cells or are otherwise flanked by different DNA sequences than those found in nature.

In accordance with the present invention, there are provided isolated nucleic acids, e.g. DNAs or RNAs, encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, particularly mammalian GABA<sub>B</sub> receptors and receptor proteins, such as e.g. human and rat GABA<sub>B</sub> receptors and receptor proteins, or fragments thereof. In particular, the invention provides DNA molecules encoding human and rat GABA<sub>B</sub> receptors or receptor proteins, or fragments thereof. By definition, such a DNA comprises a coding single stranded DNA, a double stranded DNA consisting of said coding DNA and complementary DNA thereto, or this complementary (single stranded) DNA itself. Exemplary nucleic acids encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins are represented in SEQ ID Nos. 1, 7, and 3, 5, respectively.

The preferred sequences encoding GABA<sub>B</sub> receptors and receptor proteins are those having substantially the same nucleotide sequence as the coding sequences in SEQ ID Nos. 1, 3, 5 and 7, with the nucleic acids having the same sequence as the coding sequences in SEQ ID Nos. 1, 3, 5 and 7 being most preferred. As used herein, nucleotide sequences which are substantially the same share at least about 90 % identity. However, in the case of splice variants having e.g. an additional exon sequence homology may be lower.

screened for immuno- or physiological crossreactivity with the native forms of the GABA<sub>B</sub> receptor(s).

Mutations may be performed by any method known to those of skill in the art. Preferred, however, is site-directed mutagenesis of a nucleic acid sequence encoding the polypeptide of interest. A number of methods for site-directed mutagenesis are known in the art, from methods employing single-stranded phage such as M13 to PCR-based techniques (see "PCR Protocols: A guide to methods and applications", M.A. Innis, D.H. Gelfand, J.J. Sninsky, T.J. White (eds.). Academic Press, New York, 1990). Preferably, the commercially available Altered Site II Mutagenesis System (Promega) may be employed, according to the directions given by the manufacturer.

The fragments, mutants and other derivatives of the GABA<sub>B</sub> receptor(s) preferably retain substantial homology with the GABA<sub>B</sub> receptor(s). As used herein, "homology" means that the two entities share sufficient characteristics for the skilled person to determine that they are similar in origin and function. Preferably, homology is used to refer to sequence identity. Thus, the derivatives of the GABA<sub>B</sub> receptor(s) preferably retain substantial sequence identity with the sequences set forth in SEQ ID Nos. 2 and 8, respectively.

"Substantial homology", where homology indicates sequence identity, means more than 30% sequence identity, preferably more than 65% sequence identity and most preferably a sequence identity of 80% or more.

According to a further aspect of the present invention, there are provided nucleic acids encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins (SEQ ID Nos. 1, 7, and 3, 5, respectively). In addition to being useful for the production of recombinant GABA<sub>B</sub> receptors and receptor proteins, these nucleic acids are also useful as probes, thus readily enabling those skilled in the art to identify and/or isolate nucleic acids encoding further members of the GABA<sub>B</sub> receptor family and variants thereof as set forth hereinbefore.

In another aspect, the invention provides nucleic acid sequences that are complementary to, or are capable of hybridising to, nucleic acid sequences encoding the GABA<sub>B</sub> receptors or receptor proteins. Preferably, such nucleic acids are capable of hybridising under high or moderate stringency, as defined hereinbelow.

Furthermore, nucleic acids according to the invention are useful in a method determining the presence of a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid, said method comprising hybridising the DNA (or RNA) encoding (or complementary to) the

- 10 -

GABA<sub>B</sub> receptor or receptor protein to test sample nucleic acid and determining the presence of the GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid.

The invention also provides a method for amplifying a nucleic acid test sample comprising priming a nucleic acid polymerase (chain) reaction with nucleic acid (DNA or RNA) encoding a GABA<sub>B</sub> receptor or receptor protein, or a nucleic acid complementary thereto.

Isolated GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acids include nucleic acids that are free from at least one contaminant nucleic acid with which they are ordinarily associated in the natural source of GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acids or in crude nucleic acid preparations, such as DNA libraries and the like. Isolated nucleic acids thus are present in other than in the form or setting in which they are found in nature. However, isolated GABA<sub>B</sub> receptor and receptor protein encoding nucleic acids include GABA<sub>B</sub> receptor- and receptor protein-specific nucleic acids in ordinarily GABA<sub>B</sub> receptor- or receptor protein-expressing cells, where the nucleic acids are in a chromosomal location different from that of natural cells or are otherwise flanked by different DNA sequences than those found in nature.

In accordance with the present invention, there are provided isolated nucleic acids, e.g. DNAs or RNAs, encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins, particularly mammalian GABA<sub>B</sub> receptors and receptor proteins, such as e.g. human and rat GABA<sub>B</sub> receptors and receptor proteins, or fragments thereof. In particular, the invention provides DNA molecules encoding human and rat GABA<sub>B</sub> receptors or receptor proteins, or fragments thereof. By definition, such a DNA comprises a coding single stranded DNA, a double stranded DNA consisting of said coding DNA and complementary DNA thereto, or this complementary (single stranded) DNA itself. Exemplary nucleic acids encoding GABA<sub>B</sub> receptors and GABA<sub>B</sub> receptor proteins are represented in SEQ ID Nos. 1, 7, and 3, 5, respectively.

The preferred sequences encoding GABA<sub>B</sub> receptors and receptor proteins are those having substantially the same nucleotide sequence as the coding sequences in SEQ ID Nos. 1, 3, 5 and 7, with the nucleic acids having the same sequence as the coding sequences in SEQ ID Nos. 1, 3, 5 and 7 being most preferred. As used herein, nucleotide sequences which are substantially the same share at least about 90 % identity. However, in the case of splice variants having e.g. an additional exon sequence homology may be lower.

- 11 -

The nucleic acids of the invention, whether used as probes or otherwise, are preferably substantially homologous to the sequences encoding the GABA<sub>B</sub> receptors or receptor proteins as shown in SEQ ID No. 1, 3, 5 and 7. The terms "substantially" and "homologous" are used as hereinbefore defined with reference to the GABA<sub>B</sub> receptor polypeptides.

Preferably, nucleic acids according to the invention are fragments of the GABA<sub>B</sub> receptor- or receptor protein-encoding sequences, or derivatives thereof as hereinbefore defined in relation to polypeptides. Fragments of the nucleic acid sequences of a few nucleotides in length, preferably 5 to 150 nucleotides in length, are especially useful as probes.

Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a GABA<sub>B</sub> receptor or receptor protein as hereinbefore defined and hybridise to the DNA sequences set forth in SEQ ID Nos. 1, 3, 5 and/or 7, or a selected fragment of said DNA sequences. Preferred are such sequences encoding GABA<sub>B</sub> receptors or receptor proteins which hybridise under high-stringency conditions to the sequences of SEQ ID Nos. 1, 3, 5 and/or 7.

Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrid which decreases approximately by 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na<sup>+</sup> at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 sodium pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, *et al.*, eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, *et al.*, eds. (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). In particular, the skilled person will understand that the stringency of hybridisation conditions may be varied by altering a number of parameters, primarily the salt concentration and the temperature, and that the conditions obtained are a result of the combined effect of all such parameters. Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

Nucleic acids according to the invention may moreover be designed to have quite different sequences from those of nucleic acids encoding GABA<sub>B</sub> receptors or receptor proteins as derived from natural sources, through exploitation of the degeneracy of the amino acid code. In most cases, a plurality of nucleotide triplets may be used to encode a given amino acid. Thus, an almost limitless number of nucleic acids which encode identical GABA<sub>B</sub> receptors or receptor proteins may be designed. Those which most differ from the sequence of the naturally occurring nucleic acid may be so different as to be unable to hybridise therewith. The invention thus specifically encompasses any nucleic acid which encodes a GABA<sub>B</sub> receptor or GABA<sub>B</sub> receptor protein as hereinbefore defined. Preferred are all nucleic acids which encode the sequences of the GABA<sub>B</sub> receptors and receptor proteins set forth in SEQ ID Nos. 2, 8, and 4, 6, respectively.

Given the guidance provided herein, the nucleic acids of the invention are obtainable according to methods well known in the art. For example, a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a genomic library or a suitable cDNA library prepared from a source believed to possess GABA<sub>B</sub> receptor or receptor protein and to express it at a detectable level.

Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidit and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the

The nucleic acids of the invention, whether used as probes or otherwise, are preferably substantially homologous to the sequences encoding the GABA<sub>B</sub> receptors or receptor proteins as shown in SEQ ID No. 1, 3, 5 and 7. The terms "substantially" and "homologous" are used as hereinbefore defined with reference to the GABA<sub>B</sub> receptor polypeptides.

Preferably, nucleic acids according to the invention are fragments of the GABA<sub>B</sub> receptor- or receptor protein-encoding sequences, or derivatives thereof as hereinbefore defined in relation to polypeptides. Fragments of the nucleic acid sequences of a few nucleotides in length, preferably 5 to 150 nucleotides in length, are especially useful as probes.

Exemplary nucleic acids can alternatively be characterised as those nucleotide sequences which encode a GABA<sub>B</sub> receptor or receptor protein as hereinbefore defined and hybridise to the DNA sequences set forth in SEQ ID Nos. 1, 3, 5 and/or 7, or a selected fragment of said DNA sequences. Preferred are such sequences encoding GABA<sub>B</sub> receptors or receptor proteins which hybridise under high-stringency conditions to the sequences of SEQ ID Nos. 1, 3, 5 and/or 7.

Stringency of hybridisation refers to conditions under which polynucleic acids hybrids are stable. Such conditions are evident to those of ordinary skill in the field. As known to those of skill in the art, the stability of hybrids is reflected in the melting temperature ( $T_m$ ) of the hybrid which decreases approximately by 1 to 1.5°C with every 1% decrease in sequence homology. In general, the stability of a hybrid is a function of sodium ion concentration and temperature. Typically, the hybridisation reaction is performed under conditions of higher stringency, followed by washes of varying stringency.

As used herein, high stringency refers to conditions that permit hybridisation of only those nucleic acid sequences that form stable hybrids in 1 M Na<sup>+</sup> at 65-68 °C. High stringency conditions can be provided, for example, by hybridisation in an aqueous solution containing 6x SSC, 5x Denhardt's, 1 % SDS (sodium dodecyl sulphate), 0.1 sodium pyrophosphate and 0.1 mg/ml denatured salmon sperm DNA as non specific competitor. Following hybridisation, high stringency washing may be done in several steps, with a final wash (about 30 min) at the hybridisation temperature in 0.2 - 0.1x SSC, 0.1 % SDS.

Moderate stringency refers to conditions equivalent to hybridisation in the above described solution but at about 60-62°C. In that case the final wash is performed at the hybridisation temperature in 1x SSC, 0.1 % SDS.

Low stringency refers to conditions equivalent to hybridisation in the above described solution at about 50-52°C. In that case, the final wash is performed at the hybridisation temperature in 2x SSC, 0.1 % SDS.

It is understood that these conditions may be adapted and duplicated using a variety of buffers, e.g. formamide-based buffers, and temperatures. Denhardt's solution and SSC are well known to those of skill in the art as are other suitable hybridisation buffers (see, e.g. Sambrook, *et al.*, eds. (1989) *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, New York or Ausubel, *et al.*, eds. (1990) *Current Protocols in Molecular Biology*, John Wiley & Sons, Inc.). In particular, the skilled person will understand that the stringency of hybridisation conditions may be varied by altering a number of parameters, primarily the salt concentration and the temperature, and that the conditions obtained are a result of the combined effect of all such parameters. Optimal hybridisation conditions have to be determined empirically, as the length and the GC content of the probe also play a role.

Nucleic acids according to the invention may moreover be designed to have quite different sequences from those of nucleic acids encoding GABA<sub>B</sub> receptors or receptor proteins as derived from natural sources, through exploitation of the degeneracy of the amino acid code. In most cases, a plurality of nucleotide triplets may be used to encode a given amino acid. Thus, an almost limitless number of nucleic acids which encode identical GABA<sub>B</sub> receptors or receptor proteins may be designed. Those which most differ from the sequence of the naturally occurring nucleic acid may be so different as to be unable to hybridise therewith. The invention thus specifically encompasses any nucleic acid which encodes a GABA<sub>B</sub> receptor or GABA<sub>B</sub> receptor protein as hereinbefore defined. Preferred are all nucleic acids which encode the sequences of the GABA<sub>B</sub> receptors and receptor proteins set forth in SEQ ID Nos. 2, 8, and 4, 6, respectively.

Given the guidance provided herein, the nucleic acids of the invention are obtainable according to methods well known in the art. For example, a DNA of the invention is obtainable by chemical synthesis, using polymerase chain reaction (PCR) or by screening a genomic library or a suitable cDNA library prepared from a source believed to possess GABA<sub>B</sub> receptor or receptor protein and to express it at a detectable level.

Chemical methods for synthesis of a nucleic acid of interest are known in the art and include triester, phosphite, phosphoramidite and H-phosphonate methods, PCR and other autoprimer methods as well as oligonucleotide synthesis on solid supports. These methods may be used if the entire nucleic acid sequence of the nucleic acid is known, or the

sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

An alternative means to isolate a gene encoding GABA<sub>B</sub> receptor or receptor protein is to use PCR technology as described e.g. in section 14 of Sambrook et al., 1989. This method requires the use of oligonucleotide probes that will hybridise to a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid.

A nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein can be isolated by screening suitable cDNA or genomic libraries under suitable hybridisation conditions with a probe, i.e. a nucleic acid disclosed herein including oligonucleotides derivable from the sequences set forth in SEQ ID Nos. 1, 3, 5 and 7. Suitable libraries are commercially available or can be prepared e.g. from cell lines, tissue samples, and the like. Libraries are screened with probes or analytical tools designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries suitable means include monoclonal or polyclonal antibodies that recognise and specifically bind to the GABA<sub>B</sub> receptor or GABA<sub>B</sub> receptor protein; oligonucleotides of about 20 to 80 bases in length that encode known or suspected GABA<sub>B</sub> receptor- or receptor protein-specific cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to oligonucleotides, cDNAs or fragments thereof that encode the same or hybridising DNA; and/or homologous genomic DNAs or fragments thereof.

Particularly preferred screening techniques include the hybridisation of a test sample of DNA (cDNA or genomic library) with a GABA<sub>B</sub> receptor- or receptor protein-specific cDNA (SEQ ID Nos. 1, 3, 5, 7) under suitable hybridisation conditions. Either the full length or fragments of the GABA<sub>B</sub> receptor- or receptor protein-specific cDNA can be used as probes. Such screening is initially carried out under low-stringency conditions. Low stringency conditions are as hereinbefore defined, but may be varied by adjusting the temperature and ionic strength of the hybridisation solution. For example, suitable conditions comprise hybridisation at a temperature between 40°C and 60°C in 0.5M NaH<sub>2</sub>PO<sub>4</sub> pH 7.2, 7% sodium dodecyl sulphate (SDS), 1% bovine serum albumin, 1mM EDTA, with a washing step at 50°C or less in 2 x standard saline citrate (SSC, 20 x SSC contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0), 0.1% SDS. Preferably, hybridisation conditions will be selected which allow the identification of nucleotide sequences having at least 40% sequence homology with respect to the probe. Similar homology screening techniques

useful for the identification and isolation of additional cDNAs and genes of the GABA<sub>B</sub>-receptor gene family are described in United States Patent Number 5,202,257, incorporated herein by reference.

After low stringency hybridisation has been used to identify cDNA or genomic clones having a substantial similarity with the probe sequence, these clones are then subjected to moderate to high stringency conditions in order to identify those clones having particularly high level of homology with respect to the probe sequence. Further examples of high stringency conditions comprise a hybridisation temperature of about 60°C to 68°C using the above mentioned hybridisation solution. Washing conditions comprise 0.5 x SSC, 0.1% SDS or less at a temperature of about 65°C or less.

In view of the identification of GABA<sub>B</sub> receptor- and receptor protein-specific cDNAs according to the invention, the compiled sequence information can be used to design a set of degenerate oligonucleotide primer sequences from the regions most conserved among members of the gene family. A mixture of such oligonucleotide primers can be used in the polymerase chain reaction (PCR) to amplify cDNAs or genomic segments from genes related to the already isolated GABA<sub>B</sub> receptor- and receptor protein-specific cDNAs.

Subsequently, these segments can serve as probes for identifying further full-length cDNA clones using high stringency hybridisation conditions. Alternatively, antibodies derived against the GABA<sub>B</sub> receptors or GABA<sub>B</sub> receptor protein provided by the present invention can be used to purify and sequence related GABA<sub>B</sub> receptors and receptor proteins also recognised by the antibodies.

Screening of libraries in order to isolate nucleic acids according to the invention may moreover be performed by expression screening. Such methodology is known to those skilled in the art, for example as set out in Sambrook *et al.* (Op. Cit.), but essentially comprises the incorporation of nucleic acid clones into expression vectors which are then screened using a ligand specific for the desired protein product. GABA<sub>B</sub> receptor- or receptor protein-specific ligands may be antibodies, as described hereinbelow, or specific GABA antagonists or agonists. Especially preferred are compounds such as CGP 64213, described hereinbelow.

- As used herein, an oligonucleotide probe is preferably a single-stranded DNA or RNA that has a sequence of nucleotides that includes between 10 and 50, preferably between 15 and 30 and most preferably at least about 20 contiguous bases that are the same as (or the complement of) an equivalent or greater number of contiguous bases as set forth in

- 13 -

sequence of the nucleic acid complementary to the coding strand is available. Alternatively, if the target amino acid sequence is known, one may infer potential nucleic acid sequences using known and preferred coding residues for each amino acid residue.

An alternative means to isolate a gene encoding GABA<sub>B</sub> receptor or receptor protein is to use PCR technology as described e.g. in section 14 of Sambrook et al., 1989. This method requires the use of oligonucleotide probes that will hybridise to a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid.

A nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein can be isolated by screening suitable cDNA or genomic libraries under suitable hybridisation conditions with a probe, i.e. a nucleic acid disclosed herein including oligonucleotides derivable from the sequences set forth in SEQ ID Nos. 1, 3, 5 and 7. Suitable libraries are commercially available or can be prepared e.g. from cell lines, tissue samples, and the like. Libraries are screened with probes or analytical tools designed to identify the gene of interest or the protein encoded by it. For cDNA expression libraries suitable means include monoclonal or polyclonal antibodies that recognise and specifically bind to the GABA<sub>B</sub> receptor or GABA<sub>B</sub> receptor protein; oligonucleotides of about 20 to 80 bases in length that encode known or suspected GABA<sub>B</sub> receptor- or receptor protein-specific cDNA from the same or different species; and/or complementary or homologous cDNAs or fragments thereof that encode the same or a hybridising gene. Appropriate probes for screening genomic DNA libraries include, but are not limited to oligonucleotides, cDNAs or fragments thereof that encode the same or hybridising DNA; and/or homologous genomic DNAs or fragments thereof.

Particularly preferred screening techniques include the hybridisation of a test sample of DNA (cDNA or genomic library) with a GABA<sub>B</sub> receptor- or receptor protein-specific cDNA (SEQ ID Nos. 1, 3, 5, 7) under suitable hybridisation conditions. Either the full length or fragments of the GABA<sub>B</sub> receptor- or receptor protein-specific cDNA can be used as probes. Such screening is initially carried out under low-stringency conditions. Low stringency conditions are as hereinbefore defined, but may be varied by adjusting the temperature and ionic strength of the hybridisation solution. For example, suitable conditions comprise hybridisation at a temperature between 40°C and 60°C in 0.5M NaH<sub>2</sub>PO<sub>4</sub> pH 7.2, 7% sodium dodecyl sulphate (SDS), 1% bovine serum albumin, 1mM EDTA, with a washing step at 50°C or less in 2 x standard saline citrate (SSC, 20 x SSC contains 3M sodium chloride, 0.3M sodium citrate, pH 7.0), 0.1% SDS. Preferably, hybridisation conditions will be selected which allow the identification of nucleotide sequences having at least 40% sequence homology with respect to the probe. Similar homology screening techniques

useful for the identification and isolation of additional cDNAs and genes of the GABA<sub>B</sub>-receptor gene family are described in United States Patent Number 5,202,257, incorporated herein by reference.

After low stringency hybridisation has been used to identify cDNA or genomic clones having a substantial similarity with the probe sequence, these clones are then subjected to moderate to high stringency conditions in order to identify those clones having particularly high level of homology with respect to the probe sequence. Further examples of high stringency conditions comprise a hybridisation temperature of about 60°C to 68°C using the above mentioned hybridisation solution. Washing conditions comprise 0.5 x SSC, 0.1% SDS or less at a temperature of about 65°C or less.

In view of the identification of GABA<sub>B</sub> receptor- and receptor protein-specific cDNAs according to the invention, the compiled sequence information can be used to design a set of degenerate oligonucleotide primer sequences from the regions most conserved among members of the gene family. A mixture of such oligonucleotide primers can be used in the polymerase chain reaction (PCR) to amplify cDNAs or genomic segments from genes related to the already isolated GABA<sub>B</sub> receptor- and receptor protein-specific cDNAs.

Subsequently, these segments can serve as probes for identifying further full-length cDNA clones using high stringency hybridisation conditions. Alternatively, antibodies derived against the GABA<sub>B</sub> receptors or GABA<sub>B</sub> receptor protein provided by the present invention can be used to purify and sequence related GABA<sub>B</sub> receptors and receptor proteins also recognised by the antibodies.

Screening of libraries in order to isolate nucleic acids according to the invention may moreover be performed by expression screening. Such methodology is known to those skilled in the art, for example as set out in Sambrook *et al.* (Op. Cit.), but essentially comprises the incorporation of nucleic acid clones into expression vectors which are then screened using a ligand specific for the desired protein product. GABA<sub>B</sub> receptor- or receptor protein-specific ligands may be antibodies, as described hereinbelow, or specific GABA antagonists or agonists. Especially preferred are compounds such as CGP 64213, described hereinbelow.

- As used herein, an oligonucleotide probe is preferably a single-stranded DNA or RNA that has a sequence of nucleotides that includes between 10 and 50, preferably between 15 and 30 and most preferably at least about 20 contiguous bases that are the same as (or the complement of) an equivalent or greater number of contiguous bases as set forth in

SEQ ID Nos. 1, 3, 5 and 7. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimised. The nucleotide sequences are usually based on conserved or highly homologous nucleotide sequences or regions of the GABA<sub>B</sub> receptor or receptor protein. The nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.

Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. For example, either the full-length cDNA clones disclosed herein or fragments thereof can be used as probes. Preferably, nucleic acid probes of the invention are labelled with suitable label means for ready detection upon hybridisation. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating  $\alpha^{32}\text{P}$  dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labelled with  $\gamma^{32}\text{P}$ -labelled ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling, fluorescent labelling with suitable fluorophores and biotinylation.

After screening the library, for example with a portion of DNA including substantially the entire GABA<sub>B</sub> receptor- or receptor protein-encoding sequence or a suitable oligonucleotide based on a portion of said DNA, positive clones are identified by detecting a hybridisation signal; the identified clones are characterised by restriction enzyme mapping and/or DNA sequence analysis, and then examined, for example by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete GABA<sub>B</sub> receptor or receptor protein (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein.

In order to detect any abnormality of endogenous GABA<sub>B</sub> receptor or receptor protein, genetic screening may be carried out using the nucleotide sequences of the invention as

hybridisation probes. Also, based on the nucleic acid sequences provided herein antisense-type therapeutic agents may be designed. In particular reference thereto, it is to be noted that antisense oligonucleotides are based on oligonucleotide probes as hereinbefore defined, and included within the definition thereof. Such oligonucleotides, especially but not only when intended for use as antisense therapeutic agents, may comprise modifications to the oligonucleotide, for example by incorporation of unnatural nucleotide analogues and modifications to natural oligonucleotides. For example, the oligonucleotides may encompass an altered backbone, for example in the form of a phosphorothioate, modifications such as 2'-O-Methyl modifications, or may be in the form of peptide nucleic acids.

It is envisaged that the nucleic acids of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a GABA<sub>B</sub> receptor or receptor protein mutant that has an amino acid sequence differing from the GABA<sub>B</sub> receptor or receptor protein sequences as disclosed herein or as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.

In still another aspect of the invention, the nucleic acids are DNA molecules and further comprise a replicable vector comprising the nucleic acid encoding the GABA<sub>B</sub> receptor or receptor protein operably linked to control sequences recognised by a host transformed by the vector. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles is a routine matter for the person of ordinary skill in the art and is described, for example, in Sambrook *et al.*, (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press. Many vectors are available, and selection of appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include, but are not limited to, one or more of the following: an origin of replication,

SEQ ID Nos. 1, 3, 5 and 7. The nucleic acid sequences selected as probes should be of sufficient length and sufficiently unambiguous so that false positive results are minimised. The nucleotide sequences are usually based on conserved or highly homologous nucleotide sequences or regions of the GABA<sub>B</sub> receptor or receptor protein. The nucleic acids used as probes may be degenerate at one or more positions. The use of degenerate oligonucleotides may be of particular importance where a library is screened from a species in which preferential codon usage in that species is not known.

Preferred regions from which to construct probes include 5' and/or 3' coding sequences, sequences predicted to encode ligand binding sites, and the like. For example, either the full-length cDNA clones disclosed herein or fragments thereof can be used as probes. Preferably, nucleic acid probes of the invention are labelled with suitable label means for ready detection upon hybridisation. For example, a suitable label means is a radiolabel. The preferred method of labelling a DNA fragment is by incorporating  $\alpha^{32}\text{P}$  dATP with the Klenow fragment of DNA polymerase in a random priming reaction, as is well known in the art. Oligonucleotides are usually end-labelled with  $\gamma^{32}\text{P}$ -labelled ATP and polynucleotide kinase. However, other methods (e.g. non-radioactive) may also be used to label the fragment or oligonucleotide, including e.g. enzyme labelling, fluorescent labelling with suitable fluorophores and biotinylation.

After screening the library, for example with a portion of DNA including substantially the entire GABA<sub>B</sub> receptor- or receptor protein-encoding sequence or a suitable oligonucleotide based on a portion of said DNA, positive clones are identified by detecting a hybridisation signal; the identified clones are characterised by restriction enzyme mapping and/or DNA sequence analysis, and then examined, for example by comparison with the sequences set forth herein, to ascertain whether they include DNA encoding a complete GABA<sub>B</sub> receptor or receptor protein (i.e., if they include translation initiation and termination codons). If the selected clones are incomplete, they may be used to rescreen the same or a different library to obtain overlapping clones. If the library is genomic, then the overlapping clones may include exons and introns. If the library is a cDNA library, then the overlapping clones will include an open reading frame. In both instances, complete clones may be identified by comparison with the DNAs and deduced amino acid sequences provided herein.

In order to detect any abnormality of endogenous GABA<sub>B</sub> receptor or receptor protein, genetic screening may be carried out using the nucleotide sequences of the invention as

hybridisation probes. Also, based on the nucleic acid sequences provided herein antisense-type therapeutic agents may be designed. In particular reference thereto, it is to be noted that antisense oligonucleotides are based on oligonucleotide probes as hereinbefore defined, and included within the definition thereof. Such oligonucleotides, especially but not only when intended for use as antisense therapeutic agents, may comprise modifications to the oligonucleotide, for example by incorporation of unnatural nucleotide analogues and modifications to natural oligonucleotides. For example, the oligonucleotides may encompass an altered backbone, for example in the form of a phosphorothioate, modifications such as 2'-O-Methyl modifications, or may be in the form of peptide nucleic acids.

It is envisaged that the nucleic acids of the invention can be readily modified by nucleotide substitution, nucleotide deletion, nucleotide insertion or inversion of a nucleotide stretch, and any combination thereof. Such mutants can be used e.g. to produce a GABA<sub>B</sub> receptor or receptor protein mutant that has an amino acid sequence differing from the GABA<sub>B</sub> receptor or receptor protein sequences as disclosed herein or as found in nature. Mutagenesis may be predetermined (site-specific) or random. A mutation which is not a silent mutation must not place sequences out of reading frames and preferably will not create complementary regions that could hybridise to produce secondary mRNA structure such as loops or hairpins.

In still another aspect of the invention, the nucleic acids are DNA molecules and further comprise a replicable vector comprising the nucleic acid encoding the GABA<sub>B</sub> receptor or receptor protein operably linked to control sequences recognised by a host transformed by the vector. As used herein, vector (or plasmid) refers to discrete elements that are used to introduce heterologous DNA into cells for either expression or replication thereof. Selection and use of such vehicles is a routine matter for the person of ordinary skill in the art and is described, for example, in Sambrook et al., (1989) Molecular Cloning: A Laboratory Manual, Second Edition, Cold Spring Harbor Laboratory Press. Many vectors are available, and selection of appropriate vector will depend on the intended use of the vector, i.e. whether it is to be used for DNA amplification or for DNA expression, the size of the DNA to be inserted into the vector, and the host cell to be transformed with the vector. Each vector contains various components depending on its function (amplification of DNA or expression of DNA) and the host cell for which it is compatible. The vector components generally include, but are not limited to, one or more of the following: an origin of replication,

one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence.

Advantageously, a eukaryotic expression vector encoding a GABA<sub>B</sub> receptor or receptor protein will comprise a locus control region (LCR). LCRs are capable of directing high-level integration site independent expression of transgenes integrated into host cell chromatin, which is of importance especially where the GABA<sub>B</sub> receptor or receptor protein gene is to be expressed in the context of a permanently-transfected eukaryotic cell line in which chromosomal integration of the vector has occurred, in vectors designed for gene therapy applications or in transgenic animals.

Suitable vectors for expression in eukaryotic host cells, including yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms, will also contain sequences necessary for the termination of transcription and for stabilising the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs.

Furthermore the invention provides host cells transformed with such a vector and a method of using a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein according to the invention to produce such a GABA<sub>B</sub> receptor or receptor protein, comprising expressing a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid in a culture of the transformed host cells and, if desired, recovering the GABA<sub>B</sub> receptor or receptor protein from the host cell culture. In accordance with another embodiment of the present invention, there are provided cells containing the above-described nucleic acids. Such host cells such as prokaryote, yeast and higher eukaryote cells may be used for replicating DNA and producing GABA<sub>B</sub> receptor or receptor protein. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, such as E. coli, e.g. E. coli K-12 strains DH5a, MC1061/P3 and HB101, or Bacilli. Further hosts suitable for GABA<sub>B</sub> receptor protein encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. *Saccharomyces cerevisiae*. Higher eukaryotic cells include insect and vertebrate cells, particularly mammalian cells. In recent years propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are epithelial or fibroblastic cell lines such as Chinese hamster ovary (CHO) cells, COS cells, NIH 3T3 cells, HeLa cells or HEK293 cells. The host cells referred to in this disclosure comprise cells in *in vitro* culture as well as cells that are within a host animal.

DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art, such as those detailed in Sambrook *et al.*, Op. Cit., or Ausubel *et al.*, (1990) Current Protocols in Molecular Biology, John Wiley & Sons, Inc.

The polypeptides according to the invention can advantageously be expressed in insect cell systems, including whole insects. Insect cell lines suitable for use in the method of the invention include, in principle, any lepidopteran cell which is capable of being transformed with an expression vector and expressing heterologous proteins encoded thereby. In particular, use of the Sf cell lines, such as the *Spodoptera frugiperda* cell line IPBL-SF-21 AE (Vaughn *et al.*, (1977) *In Vitro*, **13**, 213-217) is preferred. The derivative cell line Sf9 is particularly preferred. However, other cell lines, such as *Trichoplusia ni* 368 (Kurstack and Marmorosch, (1976) Invertebrate Tissue Culture Applications in Medicine, Biology and Agriculture. Academic Press, New York, USA) may be employed. These cell lines, as well as other insect cell lines suitable for use in the invention, are commercially available (e.g. from Stratagene, La Jolla, CA, USA).

Expression vectors suitable for use in the invention include all vectors which are capable of expressing foreign proteins in insect cell lines. In general, vectors which are useful in mammalian and other eukaryotic cells are also applicable to insect cell culture. Baculovirus vectors, specifically intended for insect cell culture, are especially preferred and are widely obtainable commercially (e.g. from Invitrogen and Clontech). Other virus vectors capable of infecting insect cells are known, such as Sindbis virus (Hahn *et al.*, (1992) PNAS (USA) **89**, 2679-2683). The baculovirus vector of choice (reviewed by Miller (1988) Ann. Rev. Microbiol. **42**, 177-199) is *Autographa californica* multiple nuclear polyhedrosis virus, AcMNPV.

Nucleic acids and/or proteins according to the invention may be used in methods for screening compounds or mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptors, and thus potential pharmacological agents. For example, cells transformed with a gene encoding a GABA<sub>B</sub> receptor or receptor protein can be used in a cell-based screening assay, in which the response of the cell to the agents being tested is monitored. The response may be in the form of the activation of a reporter gene, a measurable pharmacological or electrophysiological change, or the like. Alternatively, purified GABA<sub>B</sub> receptors or receptor proteins according to the invention can be used in *in vitro* assays to screen for modulators of GABA<sub>B</sub> receptor activity.

one or more marker genes, an enhancer element, a promoter, a transcription termination sequence and a signal sequence.

Advantageously, a eukaryotic expression vector encoding a GABA<sub>B</sub> receptor or receptor protein will comprise a locus control region (LCR). LCRs are capable of directing high-level integration site independent expression of transgenes integrated into host cell chromatin, which is of importance especially where the GABA<sub>B</sub> receptor or receptor protein gene is to be expressed in the context of a permanently-transfected eukaryotic cell line in which chromosomal integration of the vector has occurred, in vectors designed for gene therapy applications or in transgenic animals.

Suitable vectors for expression in eukaryotic host cells, including yeast, fungi, insect, plant, animal, human, or nucleated cells from other multicellular organisms, will also contain sequences necessary for the termination of transcription and for stabilising the mRNA. Such sequences are commonly available from the 5' and 3' untranslated regions of eukaryotic or viral DNAs or cDNAs.

Furthermore the invention provides host cells transformed with such a vector and a method of using a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein according to the invention to produce such a GABA<sub>B</sub> receptor or receptor protein, comprising expressing a GABA<sub>B</sub> receptor- or receptor protein-specific nucleic acid in a culture of the transformed host cells and, if desired, recovering the GABA<sub>B</sub> receptor or receptor protein from the host cell culture. In accordance with another embodiment of the present invention, there are provided cells containing the above-described nucleic acids. Such host cells such as prokaryote, yeast and higher eukaryote cells may be used for replicating DNA and producing GABA<sub>B</sub> receptor or receptor protein. Suitable prokaryotes include eubacteria, such as Gram-negative or Gram-positive organisms, such as E. coli, e.g. E. coli K-12 strains DH5a, MC1061/P3 and HB101, or Bacilli. Further hosts suitable for GABA<sub>B</sub> receptor protein encoding vectors include eukaryotic microbes such as filamentous fungi or yeast, e.g. *Saccharomyces cerevisiae*. Higher eukaryotic cells include insect and vertebrate cells, particularly mammalian cells. In recent years propagation of vertebrate cells in culture (tissue culture) has become a routine procedure. Examples of useful mammalian host cell lines are epithelial or fibroblastic cell lines such as Chinese hamster ovary (CHO) cells, COS cells, NIH 3T3 cells, HeLa cells or HEK293 cells. The host cells referred to in this disclosure comprise cells in *in vitro* culture as well as cells that are within a host animal.

DNA may be stably incorporated into cells or may be transiently expressed using methods known in the art, such as those detailed in Sambrook *et al.*, Op. Cit., or Ausubel *et al.*, (1990) Current Protocols in Molecular Biology, John Wiley & Sons, Inc.

The polypeptides according to the invention can advantageously be expressed in insect cell systems, including whole insects. Insect cell lines suitable for use in the method of the invention include, in principle, any lepidopteran cell which is capable of being transformed with an expression vector and expressing heterologous proteins encoded thereby. In particular, use of the Sf cell lines, such as the *Spodoptera frugiperda* cell line IPBL-SF-21 AE (Vaughn *et al.*, (1977) *In Vitro*, **13**, 213-217) is preferred. The derivative cell line Sf9 is particularly preferred. However, other cell lines, such as *Trichoplusia ni* 368 (Kurstack and Marmorosch, (1976) *Invertebrate Tissue Culture Applications in Medicine, Biology and Agriculture*. Academic Press, New York, USA) may be employed. These cell lines, as well as other insect cell lines suitable for use in the invention, are commercially available (e.g. from Stratagene, La Jolla, CA, USA).

Expression vectors suitable for use in the invention include all vectors which are capable of expressing foreign proteins in insect cell lines. In general, vectors which are useful in mammalian and other eukaryotic cells are also applicable to insect cell culture. Baculovirus vectors, specifically intended for insect cell culture, are especially preferred and are widely obtainable commercially (e.g. from Invitrogen and Clontech). Other virus vectors capable of infecting insect cells are known, such as Sindbis virus (Hahn *et al.*, (1992) *PNAS (USA)* **89**, 2679-2683). The baculovirus vector of choice (reviewed by Miller (1988) *Ann. Rev. Microbiol.* **42**, 177-199) is *Autographa californica* multiple nuclear polyhedrosis virus, AcMNPV.

Nucleic acids and/or proteins according to the invention may be used in methods for screening compounds of mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptors, and thus potential pharmacological agents. For example, cells transformed with a gene encoding a GABA<sub>B</sub> receptor or receptor protein can be used in a cell-based screening assay, in which the response of the cell to the agents being tested is monitored. The response may be in the form of the activation of a reporter gene, a measurable pharmacological or electrophysiological change, or the like. Alternatively, purified GABA<sub>B</sub> receptors or receptor proteins according to the invention can be used in *in vitro* assays to screen for modulators of GABA<sub>B</sub> receptor activity.

Likewise, compounds which are capable of modulating the expression of the GABA<sub>B</sub> receptor genes, thus regulating GABA<sub>B</sub> receptor activity, can be screened for using an expression system in which a test gene (which may be one of the GABA<sub>B</sub> receptor genes itself) is operably linked to the control sequences normally associated with the GABA<sub>B</sub> receptor gene.

The invention moreover includes compounds identified by such screening assays and the use of such compounds for the treatment of conditions which are susceptible to treatment by GABA<sub>B</sub> receptor modulation as exemplified hereinbefore.

In accordance with yet another embodiment of the present invention, there are provided antibodies specifically recognising and binding to one or more of the GABA<sub>B</sub> receptors or receptor proteins of the invention. For example, such antibodies can be generated against the GABA<sub>B</sub> receptors having the amino acid sequences set forth in SEQ ID Nos. 2 and 8. Alternatively, GABA<sub>B</sub> receptor proteins as set forth in SEQ ID Nos. 4 and 6 or GABA<sub>B</sub> receptor protein fragments (which may also be synthesised by *in vitro* methods) are fused (by recombinant expression or an *in vitro* peptidyl bond) to an immunogenic polypeptide and this fusion polypeptide, in turn, is used to raise antibodies against a GABA<sub>B</sub> receptor protein epitope.

Anti-GABA<sub>B</sub> receptor or receptor protein antibodies may be recovered from the serum of immunised animals. Monoclonal antibodies may be prepared from cells from immunised animals in the conventional manner.

The antibodies of the invention are useful for studying GABA<sub>B</sub> receptor protein localisation, screening of an expression library to identify nucleic acids encoding GABA<sub>B</sub> receptors or receptor proteins or the structure of functional domains, as well as for the purification of GABA<sub>B</sub> receptors or receptor proteins, and the like.

Antibodies according to the invention may be whole antibodies of natural class s, such as IgE and IgM antibodies, but are preferably IgG antibodies. Moreover, the invention includes antibody fragments, such as Fab, F(ab')<sub>2</sub>, Fv and ScFv. Small fragments, such Fv and ScFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution.

The antibodies according to the invention may be used in diagnostic and therapeutic applications. Accordingly, they may be armed antibodies comprising an effector protein such as a toxin or a label. Especially preferred are labels which allow the imaging of the distribution of the antibody *in vivo*. Such labels may be radioactive labels or radioopaque labels, such as metal particles, which are readily visualisable within an organism. Moreover,

they may be fluorescent labels or other labels which are visualisable on tissue samples removed from organisms.

Recombinant DNA technology may be used to improve the antibodies of the invention. Thus, chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimised by humanising the antibodies by CDR grafting [see European Patent Application 0 239 400 (Winter)] and, optionally, framework modification [see EP 0 239 400 and Riechmann *et al.*, *Nature* 332, 323-327, 1988].

Antibodies according to the invention may be obtained from animal serum, or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

Therefore, the present invention includes a process for the production of an antibody according to the invention comprising culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding said protein, and isolating said protein.

The invention further concerns hybridoma cells secreting the monoclonal antibodies of the invention. The preferred hybridoma cells of the invention are genetically stable, secrete monoclonal antibodies of the invention of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.

The invention also concerns a process for the preparation of a hybridoma cell line secreting monoclonal antibodies directed to a GABA<sub>B</sub> receptor or receptor protein, characterised in that a suitable mammal, for example a Balb/c mouse, is immunised with purified GABA<sub>B</sub> receptor or receptor protein, an antigenic carrier containing purified GABA<sub>B</sub> receptor or receptor protein or with cells bearing GABA<sub>B</sub> receptor or receptor protein, antibody-producing cells of the immunised mammal are fused with cells of a suitable myeloma cell line, the hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example spleen cells of Balb/c mice immunised with cells bearing GABA<sub>B</sub> receptor or receptor protein are fused with cells of the myeloma cell line PA1 or the myeloma cell line Sp2/0-Ag14, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are cloned.

Likewise, compounds which are capable of modulating the expression of the GABA<sub>B</sub> receptor genes, thus regulating GABA<sub>B</sub> receptor activity, can be screened for using an expression system in which a test gene (which may be one of the GABA<sub>B</sub> receptor genes itself) is operably linked to the control sequences normally associated with the GABA<sub>B</sub> receptor gene.

The invention moreover includes compounds identified by such screening assays and the use of such compounds for the treatment of conditions which are susceptible to treatment by GABA<sub>B</sub> receptor modulation as exemplified hereinbefore.

In accordance with yet another embodiment of the present invention, there are provided antibodies specifically recognising and binding to one or more of the GABA<sub>B</sub> receptors or receptor proteins of the invention. For example, such antibodies can be generated against the GABA<sub>B</sub> receptors having the amino acid sequences set forth in SEQ ID Nos. 2 and 8. Alternatively, GABA<sub>B</sub> receptor proteins as set forth in SEQ ID Nos. 4 and 6 or GABA<sub>B</sub> receptor protein fragments (which may also be synthesised by *in vitro* methods) are fused (by recombinant expression or an *in vitro* peptidyl bond) to an immunogenic polypeptide and this fusion polypeptide, in turn, is used to raise antibodies against a GABA<sub>B</sub> receptor protein epitope.

Anti-GABA<sub>B</sub> receptor or receptor protein antibodies may be recovered from the serum of immunised animals. Monoclonal antibodies may be prepared from cells from immunised animals in the conventional manner.

The antibodies of the invention are useful for studying GABA<sub>B</sub> receptor protein localisation, screening of an expression library to identify nucleic acids encoding GABA<sub>B</sub> receptors or receptor proteins or the structure of functional domains, as well as for the purification of GABA<sub>B</sub> receptors or receptor proteins, and the like.

Antibodies according to the invention may be whole antibodies of natural classes, such as IgE and IgM antibodies, but are preferably IgG antibodies. Moreover, the invention includes antibody fragments, such as Fab, F(ab')<sub>2</sub>, Fv and ScFv. Small fragments, such Fv and ScFv, possess advantageous properties for diagnostic and therapeutic applications on account of their small size and consequent superior tissue distribution.

The antibodies according to the invention may be used in diagnostic and therapeutic applications. Accordingly, they may be altered antibodies comprising an effector protein such as a toxin or a label. Especially preferred are labels which allow the imaging of the distribution of the antibody *in vivo*. Such labels may be radioactive labels or radioopaque labels, such as metal particles, which are readily visualisable within an organism. Moreover,

they may be fluorescent labels or other labels which are visualisable on tissue samples removed from organisms.

Recombinant DNA technology may be used to improve the antibodies of the invention. Thus, chimeric antibodies may be constructed in order to decrease the immunogenicity thereof in diagnostic or therapeutic applications. Moreover, immunogenicity may be minimised by humanising the antibodies by CDR grafting [see European Patent Application 0 239 400 (Winter)] and, optionally, framework modification [see EP 0 239 400 and Riechmann *et al.*, *Nature* 332, 323-327, 1988].

Antibodies according to the invention may be obtained from animal serum, or, in the case of monoclonal antibodies or fragments thereof, produced in cell culture. Recombinant DNA technology may be used to produce the antibodies according to established procedure, in bacterial or preferably mammalian cell culture. The selected cell culture system preferably secretes the antibody product.

Therefore, the present invention includes a process for the production of an antibody according to the invention comprising culturing a host, e.g. *E. coli* or a mammalian cell, which has been transformed with a hybrid vector comprising an expression cassette comprising a promoter operably linked to a first DNA sequence encoding a signal peptide linked in the proper reading frame to a second DNA sequence encoding said protein, and isolating said protein.

The invention further concerns hybridoma cells secreting the monoclonal antibodies of the invention. The preferred hybridoma cells of the invention are genetically stable, secrete monoclonal antibodies of the invention of the desired specificity and can be activated from deep-frozen cultures by thawing and recloning.

The invention also concerns a process for the preparation of a hybridoma cell line secreting monoclonal antibodies directed to a GABA<sub>B</sub> receptor or receptor protein, characterised in that a suitable mammal, for example a Balb/c mouse, is immunised with purified GABA<sub>B</sub> receptor or receptor protein, an antigenic carrier containing purified GABA<sub>B</sub> receptor or receptor protein or with cells bearing GABA<sub>B</sub> receptor or receptor protein, antibody-producing cells of the immunised mammal are fused with cells of a suitable myeloma cell line, the hybrid cells obtained in the fusion are cloned, and cell clones secreting the desired antibodies are selected. For example spleen cells of Balb/c mice immunised with cells bearing GABA<sub>B</sub> receptor or receptor protein are fused with cells of the myeloma cell line PA1 or the myeloma cell line Sp2/0-Ag14, the obtained hybrid cells are screened for secretion of the desired antibodies, and positive hybridoma cells are cloned.

The invention also concerns recombinant DNAs comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to the extracellular domain of GABA<sub>B</sub> receptor or receptor protein as described hereinbefore. By definition such DNAs comprise coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

The invention also provides a transgenic non-human mammal which has been modified to modulate the expression of endogenous GABA<sub>B</sub> receptor or receptor protein. Preferably, the transgenic non-human mammal is a transgenic mouse. For example, therefore, a transgenic mouse may be designed in which GABA<sub>B</sub> receptor or receptor protein production is greatly reduced or eliminated, according to procedures established in the art (Mansour *et al.*, *Nature* **336**, 348-352, 1988). Alternatively, the transgenic mouse of the invention may express elevated levels of GABA<sub>B</sub> receptor or receptor protein, or may be subject to regulation of GABA<sub>B</sub> receptor or receptor protein expression in a developmentally or tissue-specific manner, or via control by exogenous agents. Study of such an animal provides insights into the importance of the GABA<sub>B</sub> receptors and receptor proteins *in vivo*.

The invention is further described hereinbelow, for the purposes of illustration only, in the following Examples.

### Example 1

#### Synthesis of ligand CGP64213

The radioligand [<sup>125</sup>I]CGP 64213, which is used to visualise GABA<sub>B</sub> receptors expressed in COS cells, is synthesised according to Scheme 1, using the following reagents and conditions:

(1) NaH, THF, rt, 3 h; 5-bromovaleronitrile, rt, 16 h; (2) Raney nickel, 4% NH<sub>3</sub> in EtOH, 45° C, 16 h; (3) *N*-ethoxy-carbonylphthalimide, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5 h; (4) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 17 h; (5) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 17 h; (*R*)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub> THF, 80° C, 17 h; HOAC, MeOH, rt, 17 h; (6) *t*-Pr<sub>2</sub>EtN, EtOH, 80° C, 7 d; (7) LiOH, EtOH, H<sub>2</sub>O (1:1), 100° C, 17 h; MeOH, H<sub>3</sub>PO<sub>4</sub>; (8) conc. HCl, 100° C, 17 h; (9) *t*-Pr<sub>2</sub>EtN, DMF, rt, 72 h; (10) Na<sup>125</sup>I, phosphate buffer pH 7.4, H<sub>2</sub>O<sub>2</sub>, cat. lactoperoxidase, 30 min, RP-HPLC.

Ethyl (1,1-diethoxyethyl)phosphinate **1**, prepared according to Froestl, W., *et al.* *J. Med. Chem.* (1995), **38**, 3297-3312, from phosphinic acid and triethylorthoacetate under catalysed by boron trifluoride diethyl etherate, is condensed with 5-bromovaleronitrile to give the oily cyano-derivative **2** (bp 164° C at 0.13 mbar), which is hydrogenated over Raney nickel in ethanol containing 4% of ammonia to give primary amine **3** (bp 150-160° C at 10<sup>-4</sup> mbar; Kugelrohr bath temperature). The amino-group in **3** is protected as pthalimide to give **4**, which is now deprotected at the phosphinic acid moiety under very mild conditions to give monosubstituted phosphinic acid ester **5**. On reaction with trimethylchlorosilane the pentavalent phosphinate ester **5** is converted into a very reactive silylated phosphonite, which reacts readily with (*R*)-epichlorohydrin under zinc chloride catalysis to produce chlorohydrin **7**. Condensation with 1-(*R*)-(+)-(3-cyanophenyl)-ethylamine **8**, which itself is prepared via resolution of racemic (3-cyano-phenyl)-ethylamine with *N*-acetyl-*L*-leucine to separate 1-(*S*)-(+)-(3-cyanophenyl)-ethylamine (according to Pickard et al., *J. Amer. Chem. Soc.* (1990) **112**, 5741-5747) and treatment of the remaining mother liquors with (-)-camphanic acid followed by three crystallisations, gives the aromatic nitrile-ester **9**, which is hydrolysed to the *meta*-benzoic acid derivative **10** with lithium hydroxide. Concomitant hydrolysis of the ethyl phosphinate ester occurs. The pthalimide protecting group is removed by boiling with concentrated hydrochlorid acid overnight to give the key intermediate CGP 57604A([3-[1-(*R*)-[[3-(5-aminopenty)-hydroxyphosphinyl]-2-(*S*)-hydroxypropyl]amino]-ethyl]-benzoic acid hydrochloride). This is reacted with commercially available *N*-hydroxysuccinimidyl-3-(4-hydroxyphenyl)-propionate **11** in DMF using Hünig's base to give intermediate **12**, which is iodinated with sodium iodide (125 isotope) using hydroperoxide and catalytic amounts of lactoperoxidase to give the radioactive ligand [<sup>125</sup>I]CGP 64213.

The invention also concerns recombinant DNAs comprising an insert coding for a heavy chain variable domain and/or for a light chain variable domain of antibodies directed to the extracellular domain of GABA<sub>B</sub> receptor or receptor protein as described hereinbefore. By definition such DNAs comprise coding single stranded DNAs, double stranded DNAs consisting of said coding DNAs and of complementary DNAs thereto, or these complementary (single stranded) DNAs themselves.

The invention also provides a transgenic non-human mammal which has been modified to modulate the expression of endogenous GABA<sub>B</sub> receptor or receptor protein. Preferably, the transgenic non-human mammal is a transgenic mouse. For example, therefore, a transgenic mouse may be designed in which GABA<sub>B</sub> receptor or receptor protein production is greatly reduced or eliminated, according to procedures established in the art (Mansour *et al.*, *Nature* **336**, 348-352, 1988). Alternatively, the transgenic mouse of the invention may express elevated levels of GABA<sub>B</sub> receptor or receptor protein, or may be subject to regulation of GABA<sub>B</sub> receptor or receptor protein expression in a developmentally or tissue-specific manner, or via control by exogenous agents. Study of such an animal provides insights into the importance of the GABA<sub>B</sub> receptors and receptor proteins *in vivo*.

The invention is further described hereinbelow, for the purposes of illustration only, in the following Examples.

### Example 1

#### Synthesis of ligand CGP64213


The radioligand [<sup>125</sup>I]CGP 64213, which is used to visualise GABA<sub>B</sub> receptors expressed in COS cells, is synthesised according to Scheme 1, using the following reagents and conditions:

(1) NaH, THF, rt, 3 h; 5-bromovaleronitrile, rt, 16 h; (2) Raney nickel, 4% NH<sub>3</sub> in EtOH, 45° C, 16 h; (3) *N*-ethoxy-carbonylphtalimide, Na<sub>2</sub>CO<sub>3</sub>, H<sub>2</sub>O, CH<sub>2</sub>Cl<sub>2</sub>, rt, 5h; (4) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 17 h; (5) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 17 h; (*R*)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub> THF, 80° C, 17 h; HOAC, MeOH, rt, 17 h; (6) *t*-Pr<sub>2</sub>EtN, EtOH, 80° C, 7 d; (7) LiOH, EtOH, H<sub>2</sub>O (1:1), 100° C, 17 h; MeOH, H<sub>3</sub>PO<sub>4</sub>; (8) conc. HCl, 100° C, 17 h; (9) *t*-Pr<sub>2</sub>EtN, DMF, rt, 72 h; (10) Na<sup>125</sup>I, phosphate buffer pH 7.4, H<sub>2</sub>O<sub>2</sub>, cat. lactoperoxidase, 30 min, RP-HPLC.

Ethyl (1,1-diethoxyethyl)phosphinate **1**, prepared according to Froestl, W., et al. *J. Med. Chem.* (1995), **38**, 3297-3312, from phosphinic acid and triethylorthoacetate under catalysed by boron trifluoride diethyl etherate, is condensed with 5-bromo-*valeronitrile* to give the oily cyano-derivative **2** (bp 164° C at 0.13 mbar), which is hydrogenated over Raney nickel in ethanol containing 4% of ammonia to give primary amine **3** (bp 150-160° C at 10<sup>-4</sup> mbar; Kugelrohr bath temperature). The amino-group in **3** is protected as pthalimide to give **4**, which is now deprotected at the phosphinic acid moiety under very mild conditions to give monosubstituted phosphinic acid ester **5**. On reaction with trimethylchlorosilane the pentavalent phosphinate ester **5** is converted into a very reactive silylated phosphonite, which reacts readily with (*R*)-epichlorohydrin under zinc chloride catalysis to produce chlorohydrin **7**. Condensation with 1-(*R*)-(+)-(3-cyanophenyl)-ethylamine **8**, which itself is prepared via resolution of racemic (3-cyano-phenyl)-ethylamine with *N*-acetyl-*L*-leucine to separate 1-(*S*)-(+)-(3-cyanophenyl)-ethylamine (according to Pickard et al., *J. Amer. Chem. Soc.* (1990) **112**, 5741-5747) and treatment of the remaining mother liquors with (-)-camphanic acid followed by three crystallisations, gives the aromatic nitrile-ester **9**, which is hydrolysed to the *meta*-benzoic acid derivative **10** with lithium hydroxide. Concomitant hydrolysis of the ethyl phosphinate ester occurs. The pthalimide protecting group is removed by boiling with concentrated hydrochlorid acid overnight to give the key intermediate CGP 57604A([3-[1-(*R*)-[(3-(5-aminopenty)-hydroxyphosphinyl]-2-(*S*)-hydroxypropyl]amino]-ethyl]-benzoic acid hydrochloride). This is reacted with commercially available *N*-hydroxysuccinimidyl-3-(4-hydroxyphenyl)-propionate **11** in DMF using Hünig's base to give intermediate **12**, which is iodinated with sodium iodide (125 isotope) using hydroperoxide and catalytic amounts of lactoperoxidase to give the radioactive ligand [<sup>125</sup>I]CGP 64213.


- 23 -

Scheme 1



Unlabelled CGP 64213 is prepared in a slightly different way: 3-(4-hydroxy-5-iodophenyl propionic acid 13 is prepared by iodination of 3-(4-hydroxy-phenyl)propionic acid according to Runeberg, J., *Acta Chem. Scand.* (1958), 12, 188-91. *N*-hydroxy-succinimidyl-3-(4-hydroxy-5-iodophenyl)propionate 14 (mp: 191-4° C) is prepared according to Scheme 2 in 73% yield. Condensation of CGP 57604A (Scheme 1) with 14 using Hünig's base in DMF at room temperature for 72 hours proceeded as reaction 9 of Scheme 1 to give non radioactive CGP 64213 (mp: 170-5° C, crystallised from acetone) in a yield of 53%.

**Scheme 2<sup>a</sup>**



<sup>a</sup> Reagents and conditions: *N*-hydroxysuccinimide, DCC, dioxane, rt, 16 h.


#### Characterisation of radioligand [<sup>125</sup>I]CGP 64213:

##### *Preparation of synaptic membranes from rat cerebral cortex*


Twenty male rats [Tif: RAI f (SPF)] of about 200 g body weight are used. The animals are decapitated, the brains removed, the cerebral cortices dissected and homogenised in 10 volumes of ice-cold 0.32 M sucrose, containing MgCl<sub>2</sub> (1 mM) and K<sub>2</sub>HPO<sub>4</sub> (1 mM), with a glass/Teflon homogeniser. The membranes are centrifuged at 1000 × g for 15 min, the pellet resuspended and the centrifugation repeated. The supernatants are pooled and centrifuged at 20000 × g for 15 min. The pellet is osmotically shocked by resuspension in 10 volumes H<sub>2</sub>O and kept on ice for 30 min. The suspension is centrifuged at 39000 × g, resuspended in Krebs-Henseleit buffer (20 mM Tris, pH 7.4, 118 mM NaCl, 5.6 mM glucose, 1.2 mM KH<sub>2</sub>PO<sub>4</sub>, 1.2 mM MgSO<sub>4</sub>, 4.7 mM KCl, 1.8 mM CaCl<sub>2</sub>), and kept for 2 days at -20°C. The membranes are thawed at room temperature, washed three times with Krebs-Henseleit buffer by centrifugation at 20000 × g for 15 min, left overnight at 4°C and washed again three times. The final pellet is resuspended with a glass/Teflon homogenise in 20 ml of the same buffer. 2 ml aliquots are frozen and stored in liquid nitrogen. Just before use membranes are thawed quickly in a water bath at 37°C and again washed by centrifugation at 20000 × g for 15 min with the same buffer three times.

- 23 -

Scheme 1



Unlabelled CGP 64213 is prepared in a slightly different way: 3-(4-hydroxy-5-iodophenyl propionic acid 13 is prepared by iodination of 3-(4-hydroxy-phenyl)propionic acid according to Runeberg, J., *Acta Chem. Scand.* (1958), 12, 188-91. *N*-hydroxy-succinimidyl-3-(4-hydroxy-5-iodophenyl)propionate 14 (mp: 191-4° C) is prepared according to Scheme 2 in 73% yield. Condensation of CGP 57604A (Scheme 1) with 14 using Hünig's base in DMF at room temperature for 72 hours proceeded as reaction 9 of Scheme 1 to give non radioactive CGP 64213 (mp: 170-5° C, crystallised from acetone) in a yield of 53%.

Scheme 2<sup>a</sup>

<sup>a</sup> Reagents and conditions: *N*-hydroxysuccinimide, DCC, dioxane, rt, 16 h.

#### Characterisation of radioligand [<sup>125</sup>I]CGP 64213:

##### *Preparation of synaptic membranes from rat cerebral cortex*

Twenty male rats [Tif: RAI f (SPF)] of about 200 g body weight are used. The animals are decapitated, the brains removed, the cerebral cortices dissected and homogenised in 10 volumes of ice-cold 0.32 M sucrose, containing MgCl<sub>2</sub> (1 mM) and K<sub>2</sub>HPO<sub>4</sub> (1 mM), with a glass/Teflon homogeniser. The membranes are centrifuged at 1000 × g for 15 min, the pellet resuspended and the centrifugation repeated. The supernatants are pooled and centrifuged at 20000 × g for 15 min. The pellet is osmotically shocked by resuspension in 10 volumes H<sub>2</sub>O and kept on ice for 30 min. The suspension is centrifuged at 39000 × g, resuspended in Krebs-Henseleit buffer (20mM Tris, pH 7.4, 118mM NaCl, 5.6mM glucose, 1.2mM KH<sub>2</sub>PO<sub>4</sub>, 1.2mM MgSO<sub>4</sub>, 4.7mM KCl, 1.8mM CaCl<sub>2</sub>), and kept for 2 days at -20°C. The membranes are thawed at room temperature, washed three times with Krebs-Henseleit buffer by centrifugation at 20000 × g for 15 min, left overnight at 4°C and washed again three times. The final pellet is resuspended with a glass/Teflon homogenise in 20 ml of the same buffer. 2 ml aliquots are frozen and stored in liquid nitrogen. Just before use membranes are thawed quickly in a water bath at 37°C and again washed by centrifugation at 20000 × g for 15 min with the same buffer three times.

*Binding assay and characterisation of radioligand*


Incubation with [<sup>125</sup>I]CGP 64213, specific radioactivity for fresh material 2000 Ci/mmol, is performed in 0.2 ml Krebs-Henseleit-Tris buffer, pH 7.4, at 20°C for 90 min with 50µg cortex membrane protein as substrate. The incubation is terminated by filtration through GF/B Whatman glass fibre filters. Nonspecific binding is defined by 10<sup>-6</sup> M CGP 54626A and is 5% of total binding at a concentration of 2 nM. In saturation experiments with increasing concentrations of [<sup>125</sup>I]CGP 64213 and with nonlinear least square fitting a dissociation constant K<sub>D</sub> of 2.66 nM is determined. In inhibition studies at a concentration of 0.1 nM [<sup>125</sup>I]CGP 64213, L-baclofen showed an inhibition constant K<sub>i</sub> of 442 nM and the antagonist CGP 54626 A a K<sub>i</sub> of 2.5 nM in good agreement with K<sub>i</sub>'s obtained with other GABA<sub>B</sub> receptor antagonist radioligands. Unlabelled CGP 64213 is found to be inactive at a concentration of 1 µM in assays for GABA<sub>A</sub>, benzodiazepine, kainate, AMPA, NMDA receptors, for the strychnine independent binding site at NMDA receptors, muscarinic cholinergic, α<sub>1</sub>- and α<sub>2</sub>- adrenergic, β-adrenergic, 5HT<sub>1</sub>, 5HT<sub>2</sub>, 5HT<sub>3</sub>, histamine<sub>1</sub>, histamine<sub>2</sub>, adenosine, μ- opiate and substance P receptors. The compound is therefore selective for GABA<sub>B</sub> receptors. At a concentration of 0.1 nM of [<sup>125</sup>I]CGP 64213 association and dissociation kinetics are measured. The halftime of association is 20 min at 20°C and the halftime of dissociation 40 min. The halftime of dissociation is increased to 4 hours by reduction of the temperature to 4°C. This slow off rate and the high specific radioactivity of [<sup>125</sup>I]CGP 64213 allows autoradiographic studies of receptor binding in COS cells as expression systems for GABA<sub>B</sub> receptors.

**Example 2****Preparation of photoaffinity ligand**

The photoaffinity ligand [<sup>125</sup>I]CGP 71872, which is used to tag GABA<sub>B</sub> receptors from rat cortex membranes and recombinant GABA<sub>B</sub> receptors expressed in COS cells is synthesised according to Scheme 3: Commercially available *N*-hydroxy-succinimidyl-4-azido-salicylate **15** is condensed with CGP 57604A to give intermediate **16**, which is iodinated with sodium iodide 125 isotope using chloramine T to give an approximately 1:1 mixture of the 5-iodo derivative [<sup>125</sup>I]CGP 71872 and the 3-iodo-derivative [<sup>125</sup>I]CGP 72565. They are separated via reverse phase HPLC on a Vydac 218TP54 column (retention times: 16.4 and 17.4 minutes, respectively). Reagents and conditions are as follows:


- 26 -

(1) CGP 57604A (Scheme 1), *i*-Pr<sub>2</sub>EtN, DMF, rt, 70 h; (2) Na<sup>125</sup>I, chloramine T, 0.01 N NaOH, rt, 1 h; RP-HPLC.

**Scheme 3**

Unlabelled CGP 71872 is prepared in a different way: *N*-hydroxy-succinimidyl-4-azido-5-iodo-salicylate 17 is prepared via iodination of 4-azidosalicylic acid and subsequent condensation with *N*-hydroxy-succinimide (Scheme 4). Condensation of 17 with CGP 57604A (see Scheme 1, reaction 9) proceeded in 57 % yield to give non radioactive CGP 71872 (mp: >190° C dec.).

Reagents and conditions as follows: (1) (1) NaI, 2N NaOH, chloramine T, rt, 88 h; (2) *N*-hydroxysuccinimide, DCC, dioxane, rt, 16 h;

**Scheme 4**

*Binding assay and characterisation of radioligand*

Incubation with [<sup>125</sup>I]CGP 64213, specific radioactivity for fresh material 2000 Ci/mmol, is performed in 0.2 ml Krebs-Henseleit-Tris buffer, pH 7.4, at 20°C for 90 min with 50µg cortex membrane protein as substrate. The incubation is terminated by filtration through GF/B Whatman glass fibre filters. Nonspecific binding is defined by 10<sup>-6</sup> M CGP 54626A and is 5% of total binding at a concentration of 2 nM. In saturation experiments with increasing concentrations of [<sup>125</sup>I]CGP 64213 and with nonlinear least square fitting a dissociation constant K<sub>D</sub> of 2.66 nM is determined. In inhibition studies at a concentration of 0.1 nM [<sup>125</sup>I]CGP 64213, L-baclofen showed an inhibition constant K<sub>i</sub> of 442 nM and the antagonist CGP 54626 A a K<sub>i</sub> of 2.5 nM in good agreement with K<sub>i</sub>'s obtained with other GABA<sub>B</sub> receptor antagonist radioligands. Unlabelled CGP 64213 is found to be inactive at a concentration of 1 µM in assays for GABA<sub>A</sub>, benzodiazepine, kainate, AMPA, NMDA receptors, for the strychnine independent binding site at NMDA receptors, muscarinic cholinergic, α<sub>1</sub>- and α<sub>2</sub>- adrenergic, β-adrenergic, 5HT<sub>1</sub>, 5HT<sub>2</sub>, 5HT<sub>3</sub>, histamine<sub>1</sub>, histamine<sub>2</sub>, adenosine, μ- opiate and substance P receptors. The compound is therefore selective for GABA<sub>B</sub> receptors. At a concentration of 0.1 nM of [<sup>125</sup>I]CGP 64213 association and dissociation kinetics are measured. The halftime of association is 20 min at 20°C and the halftime of dissociation 40 min. The halftime of dissociation is increased to 4 hours by reduction of the temperature to 4°C. This slow off rate and the high specific radioactivity of [<sup>125</sup>I]CGP 64213 allows autoradiographic studies of receptor binding in COS cells as expression systems for GABA<sub>B</sub> receptors.


**Example 2****Preparation of photoaffinity ligand**

The photoaffinity ligand [<sup>125</sup>I]CGP 71872, which is used to tag GABA<sub>B</sub> receptors from rat cortex membranes and recombinant GABA<sub>B</sub> receptors expressed in COS cells is synthesised according to Scheme 3: Commercially available *N*-hydroxy-succinimidyl-4-azido-salicylate **15** is condensed with CGP 57604A to give intermediate **16**, which is iodinated with sodium iodide <sup>125</sup>I isotope using chloramine T to give an approximately 1:1 mixture of the 5-iodo derivative [<sup>125</sup>I]CGP 71872 and the 3-iodo-derivative [<sup>125</sup>I]CGP 72565. They are separated via reverse phase HPLC on a Vydac 218TP54 column (retention times: 16.4 and 17.4 minutes, respectively). Reagents and conditions are as follows:

- 26 -

(1) CGP 57604A (Scheme 1),  $\text{t-Pr}_2\text{EtN}$ , DMF, rt, 70 h; (2)  $\text{Na}^{125}\text{I}$ , chloramine T, 0.01 N NaOH, rt, 1 h; RP-HPLC.


**Scheme 3**



Unlabelled CGP 71872 is prepared in a different way: *N*-hydroxy-succinimidyl-4-azido-5-iodo-salicylate 17 is prepared via iodination of 4-azidosalicylic acid and subsequent condensation with *N*-hydroxy-succinimide (Scheme 4). Condensation of 17 with CGP 57604A (see Scheme 1, reaction 9) proceeded in 57 % yield to give non radioactive CGP 71872 (mp: >190° C dec.).

Reagents and conditions as follows: (1) (1)  $\text{NaI}$ , 2N  $\text{NaOH}$ , chloramine T, rt, 88 h; (2) *N*-hydroxysuccinimide, DCC, dioxane, rt, 16 h;

**Scheme 4**



- 27 -

### Characterisation of ph t affinity ligand [<sup>125</sup>I]CGP 71872:

#### *Binding assay and characterisation of ligand*

Rat cortex membranes as described for the [<sup>125</sup>I]CGP 64213 assay are used as substrates. Incubation with [<sup>125</sup>I]CGP 71872, specific radioactivity of fresh material 2000Ci/mmol, is performed in 0.2 ml Krebs-Henseleit buffer, pH 7.4, at 20°C for 90 min with 50 µg membrane protein as substrate. The incubation is terminated by filtration through GF/C Whatman glass fibre filters. Nonspecific binding is defined by 10<sup>-6</sup> M CGP 54626 A and is 5% of total binding at a concentration of 2 nM of [<sup>125</sup>I]CGP 71872. In saturation experiments with increasing concentrations of [<sup>125</sup>I]CGP 71872, and nonlinear least square fitting a dissociation constant K<sub>D</sub> of 3.1 nM is calculated. L-baclofen showed in inhibition experiments a K<sub>i</sub> of 340 nM and the antagonist CGP 54 626 A showed a K<sub>i</sub> of 3.1 nM. Unlabelled CGP 64213 is found to be inactive at a concentration of 1 µM in the same receptor assays as described for [<sup>125</sup>I]CGP 64213 and is, therefore, also selective for GABA<sub>B</sub> receptors. At a concentration of 2 nM and at 20°C, the halftime for association is 5 min, the halftime of dissociation 10 min. The dissociation time at 8°C is much longer. Only 25% of radioligand dissociates after 120 min.

#### *Photoaffinity labelling of membranes*

Membranes from rat cerebral cortex and from COS1 cells transiently transfected with GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b rat-cDNA, respectively, suspended in Krebs-Henseleit-Tris buffer, pH 7.3, at a concentration of 4 mg protein/ml, are incubated in the dark with 0.6 nM [<sup>125</sup>I] CGP 71872 for one hour at room temperature. The incubation is terminated by centrifugation at 20 000 x g for 10 min at 4°C. This step removed free unbound photoaffinity label. Under these conditions about 50% of the total radioactivity used bound to the receptors. The pellet is resuspended at a concentration of 4mg protein/ml in a polyethylene vial and illuminated with UV light (365 nm) for 3 min (24 W). The suspension is centrifuged at 20 000 x g for 10 min and resuspended at a concentration of 8mg/ml protein in buffer. When the labelling is performed in the presence of excess unlabelled GABA<sub>B</sub> receptor antagonist (10<sup>-6</sup> M CGP 54626A), no radioactivity is bound to the membranes. The labelled membranes could be stored at -80°C. The results are shown in Figures 1a and 1b.

Additionally, [<sup>125</sup>I]CGP71872 photoaffinity labelling of cortex, cerebellum and spinal cord cell membranes is analysed as outlined above and reveals that the two GABA<sub>B</sub> protein variants R1a and R1b are differentially expressed in the nervous system. In cerebellum the

100K protein is predominant over the 130K protein, whereas in spinal cord the 130K protein is more prevalent. In cortex tissue both proteins appear equally abundant. No proteins are labelled in tissues such as liver and kidney which are expected to lack GABA<sub>B</sub> receptors and therefore have been used as controls (see Figure 4a).

Furthermore, native GABA<sub>B</sub> receptors are photoaffinity-labelled in the presence of various competitor substances indicated in Figure 4b. Neither the GABA<sub>A</sub> selective ligands muscimol and bicuculline nor the GABA<sub>C</sub> receptor agonist *cis*-aminocrotonic acid (CACA) or the inhibitor of the GABA uptake system, SK&F89976A (Zuiderwijk, M., Veenstra, E., Lopes Da Silva, F. H. & Ghijssen, W. E. J. M. Effects of uptake carrier blockers SK&F89976-A and L-trans-PDC on in vivo release of amino acids in rat hippocampus. *Eur. J. Pharmacol.* 307, 275-282 (1996)), compete significantly for radioligand binding. In contrast, the GABA<sub>B</sub> receptor agonists GABA, APPA (3-aminopropyl-phosphinic acid) and L-baclofen compete with [<sup>125</sup>I]CGP71872 for binding. As another known criterion, L-baclofen competes more potently than D-baclofen. The GABA<sub>B</sub> receptor antagonists CGP54626A, CGP35348 and the non-radioactive photoaffinity ligand are also effective displacers of [<sup>125</sup>I]CGP71872 at native receptors. For all ligands tested, there is no visible difference in the displacement of [<sup>125</sup>I]CGP71872 at the 130K and 100K proteins, indicating a qualitatively similar binding pharmacology for the two receptors.

Native GABA<sub>B</sub> receptors are N-glycosylated, as shown by the reduction in molecular weight to 110K and 90K, respectively, after cleavage with N-glycosidase F (Fig. 4c). No significant shift in molecular weight is detected after enzymatic treatment with O-glycosidase (Fig. 4c). Photoaffinity-labelled proteins of 130K and 100K are detectable in tissues from all vertebrate species analysed, including zebrafish (Fig. 4d), indicating that the two proteins and their antagonist binding site are highly conserved. The avian GABA<sub>B</sub> receptor proteins exhibit molecular weights slightly higher than in other species, possibly reflecting differences in glycosylation and/or RNA splicing. No binding of the photoaffinity ligand to any protein can be detected in the fruitfly *Drosophila melanogaster* and the nematode *Haemonchus concordus*.

### Example 3

#### Synthesis of the GABA<sub>B</sub> antagonist ligand CGP 54626A:

The ligand used for displacement experiments, CGP 54626A, is synthesised according to Scheme 5:

**Characterisation of photoaffinity ligand [<sup>125</sup>I]CGP 71872:*****Binding assay and characterisation of ligand***

Rat cortex membranes as described for the [<sup>125</sup>I]CGP 64213 assay are used as substrates. Incubation with [<sup>125</sup>I]CGP 71872, specific radioactivity of fresh material 2000Ci/mmol, is performed in 0.2 ml Krebs-Henseleit buffer, pH 7.4, at 20°C for 90 min with 50 µg membrane protein as substrate. The incubation is terminated by filtration through GF/C Whatman glass fibre filters. Nonspecific binding is defined by 10<sup>-6</sup> M CGP 54626 A and is 5% of total binding at a concentration of 2 nM of [<sup>125</sup>I]CGP 71872. In saturation experiments with increasing concentrations of [<sup>125</sup>I]CGP 71872, and nonlinear least square fitting a dissociation constant K<sub>D</sub> of 3.1 nM is calculated. L-baclofen showed in inhibition experiments a K<sub>i</sub> of 340 nM and the antagonist CGP 54 626 A showed a K<sub>i</sub> of 3.1 nM. Unlabelled CGP 64213 is found to be inactive at a concentration of 1 µM in the same receptor assays as described for [<sup>125</sup>I]CGP 64213 and is, therefore, also selective for GABA<sub>B</sub> receptors. At a concentration of 2 nM and at 20°C, the halftime for association is 5 min, the halftime of dissociation 10 min. The dissociation time at 8°C is much longer. Only 25% of radioligand dissociates after 120 min.

***Photoaffinity labelling of membranes***

Membranes from rat cerebral cortex and from COS1 cells transiently transfected with GABA<sub>B</sub>R1a and GABA<sub>B</sub>R1b rat-cDNA, respectively, suspended in Krebs-Henseleit-Tris buffer, pH 7.3; at a concentration of 4 mg protein/ml, are incubated in the dark with 0.6 nM [<sup>125</sup>I] CGP 71872 for one hour at room temperature. The incubation is terminated by centrifugation at 20 000 x g for 10 min at 4°C. This step removed free unbound photoaffinity label. Under these conditions about 50% of the total radioactivity used bound to the receptors. The pellet is resuspended at a concentration of 4 mg protein/ml in a polyethylene vial and illuminated with UV light (365 nm) for 3 min (24 W). The suspension is centrifuged at 20 000 x g for 10 min and resuspended at a concentration of 8 mg/ml protein in buffer. When the labelling is performed in the presence of excess unlabelled GABA<sub>B</sub> receptor antagonist (10<sup>-6</sup> M CGP 54626A), no radioactivity is bound to the membranes. The labelled membranes could be stored at -80°C. The results are shown in Figures 1a and 1b.

Additionally, [<sup>125</sup>I]CGP71872 photoaffinity labelling of cortex, cerebellum and spinal cord cell membranes is analysed as outlined above and reveals that the two GABA<sub>B</sub> protein variants R1a and R1b are differentially expressed in the nervous system. In cerebellum the

100K protein is predominant over the 130K protein, whereas in spinal cord the 130K protein is more prevalent. In cortex tissue both proteins appear equally abundant. No proteins are labelled in tissues such as liver and kidney which are expected to lack GABA<sub>B</sub> receptors and therefore have been used as controls (see Figure 4a).

Furthermore, native GABA<sub>B</sub> receptors are photoaffinity-labelled in the presence of various competitor substances indicated in Figure 4b. Neither the GABA<sub>A</sub> selective ligands muscimol and bicuculline nor the GABA<sub>C</sub> receptor agonist *cis*-aminocrotonic acid (CACA) or the inhibitor of the GABA uptake system, SK&F89976A (Zuiderwijk, M., Veenstra, E., Lop s Da Silva, F. H. & Ghijssen, W. E. J. M. Effects of uptake carrier blockers SK&F89976-A and L-trans-PDC on in vivo release of amino acids in rat hippocampus. *Eur. J. Pharmacol.* 307, 275-282 (1996)), compete significantly for radioligand binding. In contrast, the GABA<sub>B</sub> receptor agonists GABA, APPA (3-aminopropyl-phosphinic acid) and L-baclofen compete with [<sup>125</sup>I]CGP71872 for binding. As another known criterion, L-baclofen competes more potently than D-baclofen. The GABA<sub>B</sub> receptor antagonists CGP54626A, CGP35348 and the non-radioactive photoaffinity ligand are also effective displacers of [<sup>125</sup>I]CGP71872 at native receptors. For all ligands tested, there is no visible difference in the displacement of [<sup>125</sup>I]CGP71872 at the 130K and 100K proteins, indicating a qualitatively similar binding pharmacology for the two receptors.


Native GABA<sub>B</sub> receptors are N-glycosylated, as shown by the reduction in molecular weight to 110K and 90K, respectively, after cleavage with N-glycosidase F (Fig. 4c). No significant shift in molecular weight is detected after enzymatic treatment with O-glycosidase (Fig. 4c). Photoaffinity-labelled proteins of 130K and 100K are detectable in tissues from all vertebrate species analysed, including zebrafish (Fig. 4d), indicating that the two proteins and their antagonist binding site are highly conserved. The avian GABA<sub>B</sub> receptor proteins exhibit molecular weights slightly higher than in other species, possibly reflecting differences in glycosylation and/or RNA splicing. No binding of the photoaffinity ligand to any protein can be detected in the fruitfly *Drosophila melanogaster* and the nematode *Haemonchus concordus*.

### Example 3:

#### Synthesis of the GABA<sub>B</sub> antagonist ligand CGP 54626A:

The ligand used for displacement experiments, CGP 54626A, is synthesised according to Scheme 5:

- 29 -

Scheme 5<sup>a</sup>

<sup>a</sup> Reagents and conditions: (1) NaH, THF, rt, 3 h; bromomethylcyclohexane, reflux, 24 h; (2) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 24 h; (3) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 24 h; (*R*)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub> THF, 80° C, 17 h; HOAc, MeOH, rt, 17 h; (4) *i*-Pr<sub>2</sub>EtN, EtOH, 80° C, 7 d; (5) conc. HCl, 100° C, 24 h.


Ethyl (1,1-diethoxyethyl)phosphinate 1, prepared according to Froestl et al., *J. Med. Chem.* (1995), 38, 3297-3312, from phosphinic acid and triethylorthoacetate catalysed by boron trifluoride diethyletherate, is condensed with bromomethylcyclohexane to give the oily derivative 18 (bp 85° C at 6 × 10<sup>-4</sup> mbar), which is deprotected at the phosphinic acid moiety under very mild conditions to give monosubstituted phosphinic acid ester 19 (bp 50° C at 3 × 10<sup>-4</sup> mbar). On reaction with trimethylchlorosilane the penta-valent phosphinate ester 19 is converted into a very reactive trivalent ethyl phosphonite, which reacted rapidly with (*R*)-epichlorohydrin 6 when catalysed by zinc chloride to produce chlorohydrin 20. Condensation with 1-(*S*)-(−)-(3,4-dichlorophenyl)-ethylamine 21, prepared via resolution of racemic 1-(3,4-dichlorophenyl)-ethylamine with (+)-mandelic acid according to Mickel, EP 543780 A2, gave the corresponding secondary amine 22 as a 1:1 mixture of

- 30 -

diastereoisomers, which is hydrolysed by boiling with concentrated hydrochloric acid to give CGP 54626A.


$[^3\text{H}]$ CGP54626A is prepared in an analogous way (Scheme 6) by condensation of ethyl (1,1-diethoxyethyl)phosphinate 1 with 3,4-dehydro-cylohexylmethylbromide (prepared according to Yadav and Fallis, (1991) *Can. J. Chem.* 69, 779-789), preparation of the corresponding 3,4-dehydroderivative of CGP 54626A, i.e. CGP 54951A, which is tritiated under very carefully controlled conditions to yield  $[^3\text{H}]$ CGP54626A. The compound is the first GABA<sub>B</sub> receptor antagonist radioligand which was characterised by Bittiger *et al.*, *Pharmacol. Commun.* (1992), 2, 23.

Scheme 6<sup>a</sup>



<sup>a</sup> Reagents and conditions: (1) NaH, THF, rt, 3 h; 3-4-dehydrobromo-methylcyclohexane, reflux, 24 h; (2) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 24 h; (3) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 24 h; (R)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub> THF, 80° C, 17 h; HOAc, MeOH, rt, 17 h; (4) *i*-Pr<sub>2</sub>EtN, EtOH, 80° C, 4 d; (5) LiOH, EtOH, H<sub>2</sub>O, 100° C, 17 h; HCl, MeOH, rt, 1 h; (6) <sup>3</sup>H<sub>2</sub>, 5% Pd/C, HCl, MeOH, pH = 1, rt, 15 min, prep. TLC.

- 29 -

Scheme 5<sup>a</sup>


<sup>a</sup> Reagents and conditions: (1) NaH, THF, rt, 3 h; bromomethylcyclohexane, reflux, 24 h; (2) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 24 h; (3) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 24 h; (R)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub>, THF, 80° C, 17 h; HOAc, MeOH, rt, 17 h; (4) i-Pr<sub>2</sub>EtN, EtOH, 80° C, 7 d; (5) conc. HCl, 100° C, 24 h.

Ethyl (1,1-diethoxyethyl)phosphinate 1, prepared according to Froestl et al., *J. Med. Chem.* (1995), 38, 3297-3312, from phosphinic acid and triethylorthoacetate catalysed by boron trifluoride diethyletherate, is condensed with bromomethylcyclohexane to give the oily derivative 18 (bp 85° C at 6 × 10<sup>-4</sup> mbar), which is deprotected at the phosphinic acid moiety under very mild conditions to give monosubstituted phosphinic acid ester 19 (bp 50° C at 3 × 10<sup>-4</sup> mbar). On reaction with trimethylchlorosilane the penta-valent phosphinate ester 19 is converted into a very reactive trivalent ethyl phosphonite, which reacted rapidly with (R)-epichlorohydrin 6 when catalysed by zinc chloride to produce chlorohydrin 20. Condensation with 1-(S)-(−)-(3,4-dichlorophenyl)-ethylamine 21, prepared via resolution of racemic 1-(3,4-dichlorophenyl)-ethylamine with (+)-mandelic acid according to Mickel, EP 543780 A2, gave the corresponding secondary amine 22 as a 1:1 mixture of

- 30 -

diastereoisomers, which is hydrolysed by boiling with concentrated hydrochloric acid to give CGP 54626A.

$[^3\text{H}]$ CGP54626A is prepared in an analogous way (Scheme 6) by condensation of ethyl (1,1-diethoxyethyl)phosphinate 1 with 3,4-dehydro-cylohexylmethylbromide (prepared according to Yadav and Fallis, (1991) *Can. J. Chem.* 69, 779-789), preparation of the corresponding 3,4-dehydroderivative of CGP 54626A, i.e. CGP 54951A, which is tritiated under very carefully controlled conditions to yield  $[^3\text{H}]$ CGP54626A. The compound is the first GABA<sub>B</sub> receptor antagonist radioligand which was characterised by Bittiger *et al.*, *Pharmacol. Commun.* (1992), 2, 23.

Scheme 6<sup>a</sup>

<sup>a</sup> Reagents and conditions: (1) NaH, THF, rt, 3 h; 3-4-dehydrobromo-methylcyclohexane, reflux, 24 h; (2) Me<sub>3</sub>SiCl, EtOH, CH<sub>2</sub>Cl<sub>2</sub> (1:9), rt, 24 h; (3) Me<sub>3</sub>SiCl, Et<sub>3</sub>N, THF, rt, 24 h; (R)-epichlorohydrin, 10 mol% ZnCl<sub>2</sub> THF, 80° C, 17 h; HOAc, MeOH, rt, 17 h; (4) i-Pr<sub>2</sub>EtN, EtOH, 80° C, 4 d; (5) LiOH, EtOH, H<sub>2</sub>O, 100° C, 17 h; HCl, MeOH, rt, 1 h; (6) <sup>3</sup>H<sub>2</sub>, 5% Pd/C, HCl, MeOH, pH = 1, rt, 15 min, prep. TLC.

**Example 4****Proof of functional activity of CGP 64213 and CGP 71872 as GABA<sub>A</sub> receptor antagonists by in vitro electrophysiological measurements.**

Experiments are performed on 400 µm thick hippocampal slices obtained either from female Wistar COB rats (3-4 weeks old) or male rats Tif: RAI f (SPF) using standard techniques. In brief, rats are cervically dislocated prior to decapitation. The brain minus cerebellum is removed rapidly and placed in ice-cold artificial cerebrospinal fluid (ACSF). The hippocampus is carefully isolated and, using either a tissue chopper (Sorvall®) or a vibroslicer (Campden), transverse 400 µm thick slices are cut. The CA3 region of each slice is removed via a scalpel cut. This procedure is performed to eliminate changes in network function that can occur due to epileptiform bursting in area CA3. The resultant CA3-ectomized slices are placed on a nylon mesh at the interface of a warmed (32°C), perfusing (1-2 ml·min<sup>-1</sup>) ACSF and an oxygen-enriched (95% O<sub>2</sub>, 5% CO<sub>2</sub>), humidified atmosphere. The standard perfusion medium comprised (mM): NaCl, 124; KCl, 3; NaHCO<sub>3</sub>, 26; NaH<sub>2</sub>PO<sub>4</sub>, 1.25; CaCl<sub>2</sub>, 2; MgSO<sub>4</sub>, 1; D-glucose, 10; and is bubbled with 95% O<sub>2</sub>, 5% CO<sub>2</sub>. An Axoprobe or an Axoclamp-2 amplifier (Axon Instruments, Foster City, CA, USA) is used in bridge mode to make extracellular recordings from either *stratum radiatum* or *stratum oriens* using 4 M NaCl-filled microelectrodes (2 - 5 MΩ). Intracellular recordings are made using 2 M potassium methylsulphate filled microelectrodes (60-100 MΩ). Digitised records are stored on the hard disk of an IBM-compatible PC for off-line analysis. Bipolar stimulating electrodes, made from 55 µm diameter insulated nickel-chromium wire, are positioned in *stratum radiatum* close to the recording electrode placed in either *stratum radiatum* or *stratum oriens*, to provide orthodromic monosynaptic activation of CA1 neurones (Davies et al. (1990) *Journal of Physiology* 424: 513). In every experiment stimuli comprise square-wave pulses (20-200 µs; 5-30 V) delivered homosynaptically at a fixed intensity. All drugs are administered via the perfusion medium. Data are presented as means ± standard error of the mean (S.E.M.) and statistical significance is assessed using Students t-tests. n values refer to the number of times a particular experiment is performed, each in a different slice taken from a different rat.

**GABA<sub>B</sub> autoreceptors**

Paired-pulse widening of field EPSPs is used to monitor the effects of CGP 71872 and CGP 64213 on GABA<sub>B</sub> autoreceptors. Paired-pulse widening occurs when two stimuli

are delivered at 5-10 Hz (interstimulus interval 100 - 200 ms); a stimulation protocol that does not release sufficient GABA to activate GABA<sub>B</sub> heteroreceptors which would, in any case, cause a depression rather than a facilitation of the second field EPSP. This phenomenon is also independent of postsynaptic GABA<sub>B</sub> receptors (Nathan *et al.* (1991) *Exp. Brain Res.* 84(3) 529-537). It is, however, occluded by blocking GABA<sub>A</sub> receptor-mediated IPSPs and is inhibited by GABA<sub>B</sub> receptor antagonists at concentrations that are required to block GABA<sub>B</sub> autoreceptors (Nathan *et al.* (1990), *Brain Research* 531: 55-65). (Note that these concentrations are 3-10 fold higher than those necessary to block postsynaptic GABA<sub>B</sub> receptors on both pyramidal neurones and inhibitory interneurones so ruling out an effect at these receptors). Paired-pulse widening of field EPSPs (fEPSPs) is a sensitive measure of GABA<sub>B</sub> autoreceptor activity. There is no precedent for any compound being effective in this test system and not in other assays of GABA<sub>B</sub> autoreceptor activity e.g., paired-pulse or (-)-baclofen-induced depression of IPSCs.

Paired-pulse stimulation at an interstimulus interval of 200 ms caused a consistent widening of the second EPSP relative to the first EPSP. Thus, the area under the curve of the second fEPSP is 247 ± 17 % (in the CGP 64213 series of experiments) and 241 ± 21 % (in the CGP 71872 series of experiments) of the first fEPSP, respectively. In the presence of CGP 64213 (0.3 µM; n = 5) and CGP 71872 (1 µM; n = 3) this paired-pulse widening of EPSPs is abolished indicating the effectiveness of these compounds as antagonists of GABA<sub>B</sub> autoreceptors.

#### *GABA<sub>B</sub> heteroreceptors*

The effect of CGP 71872 on the depression of field EPSPs induced by bath application of (-)-baclofen is used as an assay for the effect of this compound on GABA<sub>B</sub> heteroreceptors located on glutamate afferent terminals. Although, under these conditions, (-)-baclofen will activate other populations of GABA<sub>B</sub> receptors (e.g., GABA<sub>B</sub> autoreceptors and postsynaptic GABA<sub>B</sub> receptors), in addition to GABA<sub>B</sub> heteroreceptors, activation of these receptors would tend to increase the size of the field EPSP rather than decrease it. As such, this method is a reasonable measure of activity at GABA<sub>B</sub> heteroreceptors. This method provides a more reliable and a quantitatively more repeatable method for activating GABA<sub>B</sub> heteroreceptors than that used by Isaacson *et al.* (1993) *Neuron* 332: 156-158, as it does not rely on physiologically released GABA to activate the heteroreceptors. This latter method is inherently variable due to the different concentrations of synaptically released

**Example 4****Proof of functional activity of CGP 64213 and CGP 71872 as GABA<sub>B</sub> receptor antagonists by in vitro electrophysiological measurements.**

Experiments are performed on 400 µm thick hippocampal slices obtained either from female Wistar COB rats (3-4 weeks old) or male rats Tif: RAI f (SPF) using standard techniques. In brief, rats are cervically dislocated prior to decapitation. The brain minus cerebellum is removed rapidly and placed in ice-cold artificial cerebrospinal fluid (ACSF). The hippocampus is carefully isolated and, using either a tissue chopper (Sorvall®) or a vibroslicer (Campden), transverse 400 µm thick slices are cut. The CA3 region of each slice is removed via a scalpel cut. This procedure is performed to eliminate changes in network function that can occur due to epileptiform bursting in area CA3. The resultant CA3-ectomized slices are placed on a nylon mesh at the interface of a warmed (32°C), perfusing (1-2 ml·min<sup>-1</sup>) ACSF and an oxygen-enriched (95% O<sub>2</sub>, 5% CO<sub>2</sub>), humidified atmosphere. The standard perfusion medium comprised (mM): NaCl, 124; KCl, 3; NaHCO<sub>3</sub>, 26; NaH<sub>2</sub>PO<sub>4</sub>, 1.25; CaCl<sub>2</sub>, 2; MgSO<sub>4</sub>, 1; D-glucose, 10; and is bubbled with 95% O<sub>2</sub>, 5% CO<sub>2</sub>. An Axoprobe or an Axoclamp-2 amplifier (Axon Instruments, Foster City, CA, USA) is used in bridge mode to make extracellular recordings from either *stratum radiatum* or *stratum oriens* using 4 M NaCl-filled microelectrodes (2 - 5 MΩ). Intracellular recordings are made using 2 M potassium methylsulphate filled microelectrodes (60-100 MΩ). Digitised records are stored on the hard disk of an IBM-compatible PC for off-line analysis. Bipolar stimulating electrodes, made from 55 µm diameter insulated nickel-chromium wire, are positioned in *stratum radiatum* close to the recording electrode placed in either *stratum radiatum* or *stratum oriens*, to provide orthodromic monosynaptic activation of CA1 neurones (Davies et al. (1990) *Journal of Physiology* 424: 513). In every experiment stimuli comprise square-wave pulses (20-200 µs; 5-30 V) delivered homosynaptically at a fixed intensity. All drugs are administered via the perfusion medium. Data are presented as means ± standard error of the mean (S.E.M.) and statistical significance is assessed using Students t-tests. n values refer to the number of times a particular experiment is performed, each in a different slice taken from a different rat.

**GABA<sub>B</sub> autoreceptors**

Paired-pulse widening of field EPSPs is used to monitor the effects of CGP 71872 and CGP 64213 on GABA<sub>B</sub> autoreceptors. Paired-pulse widening occurs when two stimuli

are delivered at 5-10 Hz (interstimulus interval 100 - 200 ms); a stimulation protocol that does not release sufficient GABA to activate GABA<sub>B</sub> heteroreceptors which would, in any case, cause a depression rather than a facilitation of the second field EPSP. This phenomenon is also independent of postsynaptic GABA<sub>B</sub> receptors (Nathan *et al.* (1991) *Exp. Brain Res.* 84(3) 529-537). It is, however, occluded by blocking GABA<sub>A</sub> receptor-mediated IPSPs and is inhibited by GABA<sub>B</sub> receptor antagonists at concentrations that are required to block GABA<sub>B</sub> autoreceptors (Nathan *et al.* (1990), *Brain Research* 531: 55-65). (Note that these concentrations are 3-10 fold higher than those necessary to block postsynaptic GABA<sub>B</sub> receptors on both pyramidal neurones and inhibitory interneurones so ruling out an effect at these receptors). Paired-pulse widening of field EPSPs (fEPSPs) is a sensitive measure of GABA<sub>B</sub> autoreceptor activity. There is no precedent for any compound being effective in this test system and not in other assays of GABA<sub>B</sub> autoreceptor activity e.g., paired-pulse or (-)-baclofen-induced depression of IPSCs.

Paired-pulse stimulation at an interstimulus interval of 200 ms caused a consistent widening of the second EPSP relative to the first EPSP. Thus, the area under the curve of the second fEPSP is 247 ± 17 % (in the CGP 64213 series of experiments) and 241 ± 21 % (in the CGP 71872 series of experiments) of the first fEPSP, respectively. In the presence of CGP 64213 (0.3 μM; n = 5) and CGP 71872 (1 μM; n = 3) this paired-pulse widening of EPSPs is abolished indicating the effectiveness of these compounds as antagonists of GABA<sub>B</sub> autoreceptors.

#### *GABA<sub>B</sub> heteroreceptors*

The effect of CGP 71872 on the depression of field EPSPs induced by bath application of (-)-baclofen is used as an assay for the effect of this compound on GABA<sub>B</sub> heteroreceptors located on glutamate afferent terminals. Although, under these conditions, (-)-baclofen will activate other populations of GABA<sub>B</sub> receptors (e.g., GABA<sub>B</sub> autoreceptors and postsynaptic GABA<sub>B</sub> receptors), in addition to GABA<sub>B</sub> heteroreceptors, activation of these receptors would tend to increase the size of the field EPSP rather than decrease it. As such, this method is a reasonable measure of activity at GABA<sub>B</sub> heteroreceptors. This method provides a more reliable and a quantitatively more repeatable method for activating GABA<sub>B</sub> heteroreceptors than that used by Isaacson *et al.* (1993) *Neuron* 332: 156-158, as it does not rely on physiologically released GABA to activate the heteroreceptors. This latter method is inherently variable due to the different concentrations of synaptically released

GABA to which heteroreceptors are exposed in different preparations; a parameter that depends upon the level of GABA released, the distance between the release site and heteroreceptor, and the efficiency of GABA uptake sites. It is important to note, however, that, to date, no discrepancy between the results obtained using these two methods to study GABA<sub>B</sub> heteroreceptors has been documented for any compound tested.

(-)-Baclofen (10 µM) had no significant effect on the presynaptic fibre volley of the field EPSP (100 ± 1% of control;  $P>0.05$ ), recorded in *stratum radiatum*, but depressed the field EPSP slope and peak amplitude by 65 ± 6% and 76 ± 9%, respectively ( $n = 10$ ). Maximum depression is obtained after a 5-10 min perfusion and persisted at this level for the duration of the agonist application. Addition of CGP 71872 (1 µM) to the perfusion medium reversed the depression in every experiment in which it is tested ( $n = 6$ ;  $P<0.05$ ). Similar results are obtained for field EPSPs recorded in *stratum oriens* ( $n = 3$ ). In brain slices CGP 71872 had no significant effect on the peak amplitude, slope or presynaptic fibre volley of field EPSPs recorded in *stratum radiatum* ( $n = 4$ ;  $P>0.05$ ) or *oriens* ( $n = 3$ ).

#### *Postsynaptic GABA<sub>B</sub> receptors*

The effect of CGP 71872 on the pharmacologically isolated late IPSP is used as a test system to evaluate the effect of CGP 71872 on postsynaptic GABA<sub>B</sub> receptors located on CA1 pyramidal neurones. There is a substantial literature (Froestl et al. (1995) Op. Cit.; Jarolimek et al. (1993) *Neurosci. Lett.* **154**: 31-34; Olpe et al. (1990) *Clin. Neuropharmacol.* **13 Suppl. 2**; 396; McCormick, (1990) *J.Neurophysiol.* **62/5**: 1018; Lambert et al., (1989) *Neurosci. Lett.* **107**: 125-128; Soltesz et al., (1989) *Brain Research* **479**: 49-55; Mueller and Misgeld, (1989) *Neurosci. Lett.* **102**: 229-234; Dutar and Nicoll, (1988) *Nature* **322**: 156-8; Karlsson, Pozza and Olpe, (1988) *Eur. J. Pharmacol.* **148**: 485-486) which indicates that this IPSP is mediated by the synaptic activation of GABA<sub>B</sub> receptors. In addition, this method has been used many times in the past and the data generated have always been consistent with that generated for antagonism of (-)-baclofen-induced hyperpolarisations; an approach that has also been adopted as an assay for activity at postsynaptic GABA<sub>B</sub> receptors.

The effect of CGP 71872 is tested on a monosynaptically activated GABA<sub>B</sub> receptor-mediated late IPSP isolated using a combination of the ionotropic excitatory amino acid antagonists D-2-amino-5-phosphonopentanoate (AP5; 50µM) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 µM) and the GABA<sub>A</sub> receptor antagonist picrotoxin

(50 $\mu$ M). In all neurones tested CGP 71872 (1  $\mu$ M) abolished the late IPSP ( $n = 6$ ) indicating that this compound is an antagonist of postsynaptic GABA<sub>B</sub> receptors.

### Example 5

#### cDNA library construction

RNA is purified from cortex and cerebellum of 7 day old rats according to Chomczynski, P. & Sacchi, N. (1987) *Anal. Biochem.* 162, 156-159. Poly A(+) RNA is enriched by two passages over an oligo (dT) column (Boehringer Mannheim) as described (Maniatis, T., Fritsch, E.F. & Sambrook, J. (1982) *Molecular cloning: A laboratory manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY). Oligo (dT) primed double stranded cDNA is synthesised from 5  $\mu$ g of poly A(+) RNA using a commercial cDNA synthesis system (Amersham). The reverse transcriptase supplied with the kit is replaced by the RNaseH(-) Superscript II reverse transcriptase (Gibco BRL). The cDNA solution is concentrated on Centricon-100 devices (Amicon), preabsorbed with tRNA, to a final volume of 100 $\mu$ l. Small cDNAs are removed by passage through a Chromaspin-1000 column (Clontech). BstXI adaptors (Invitrogen) are added using T4 DNA ligase (Boehringer Mannheim) and the cDNAs are size-fractionated on an agarose gel. cDNAs with sizes larger than 2kb are purified (Qiaex, Qiagen) and ligated into the BstXI sites of the expression vector pcDNA1 (Invitrogen). An aliquot of the ligation mixture is transformed (BioRad Gene Pulser II) into electrocompetent MC1061/P3 E.coli cells. The complexity of the library is estimated to be  $2 \times 10^6$  independent clones. The average insert size deduced from the analysis of 48 clones is 2.9kb (sizes ranging from 2.0kb to 6.6kb).

Plasmids for the transfections of COS1 cells are isolated from bacterial colonies obtained after the initial round of cDNA transformation. Briefly, an aliquot of the cDNA library is transformed into electrocompetent MC1061/P3 E.coli cells and titrated by plating on agar plates. The cDNA library is divided into pools of approximately 2'000 colonies that are plated on 9cm agar plates and grown overnight at 37°C. The bacteria are scraped off the plates and plasmid DNA is prepared using ion exchange columns (Qiawell, Qiagen).

- 33 -

GABA to which heteroreceptors are exposed in different preparations; a parameter that depends upon the level of GABA released, the distance between the release site and heteroreceptor, and the efficiency of GABA uptake sites. It is important to note, however, that, to date, no discrepancy between the results obtained using these two methods to study GABA<sub>B</sub> heteroreceptors has been documented for any compound tested.

(-)-Baclofen (10 µM) had no significant effect on the presynaptic fibre volley of the field EPSP (100 ± 1% of control;  $P>0.05$ ), recorded in *stratum radiatum*, but depressed the field EPSP slope and peak amplitude by 65 ± 6% and 76 ± 9%, respectively ( $n = 10$ ). Maximum depression is obtained after a 5-10 min perfusion and persisted at this level for the duration of the agonist application. Addition of CGP 71872 (1 µM) to the perfusion medium reversed the depression in every experiment in which it is tested ( $n = 6$ ;  $P<0.05$ ). Similar results are obtained for field EPSPs recorded in *stratum oriens* ( $n = 3$ ). In brain slices CGP 71872 had no significant effect on the peak amplitude, slope or presynaptic fibre volley of field EPSPs recorded in *stratum radiatum* ( $n = 4$ ;  $P>0.05$ ) or *oriens* ( $n = 3$ ).

#### *Postsynaptic GABA<sub>B</sub> receptors*

The effect of CGP 71872 on the pharmacologically isolated late IPSP is used as a test system to evaluate the effect of CGP 71872 on postsynaptic GABA<sub>B</sub> receptors located on CA1 pyramidal neurones. There is a substantial literature (Froestl et al. (1995) Op. Cit.; Jarolimek et al. (1993) *Neurosci. Lett.* **154**: 31-34; Olpe et al. (1990) *Clin. Neuropharmacol.* **13 Suppl. 2**: 396; McCormick, (1990) *J. Neurophysiol.* **62/5**: 1018; Lambert et al., (1989) *Neurosci. Lett.* **107**: 125-128; Soltesz et al., (1989) *Brain Research* **479**: 49-55; Mueller and Misgeld, (1989) *Neurosci. Lett.* **102**: 229-234; Dutar and Nicoll, (1988) *Nature* **322**: 156-8; Karlsson, Pozza and Olpe, (1988) *Eur. J. Pharmacol.* **148**: 485-486) which indicates that this IPSP is mediated by the synaptic activation of GABA<sub>B</sub> receptors. In addition, this method has been used many times in the past and the data generated have always been consistent with that generated for antagonism of (-)-baclofen-induced hyperpolarisations; an approach that has also been adopted as an assay for activity at postsynaptic GABA<sub>B</sub> receptors.

The effect of CGP 71872 is tested on a monosynaptically activated GABA<sub>B</sub> receptor-mediated late IPSP isolated using a combination of the ionotropic excitatory amino acid antagonists D-2-amino-5-phosphonopentanoate (AP5; 50µM) and 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX; 20 µM) and the GABA<sub>A</sub> receptor antagonist picrotoxin

(50 $\mu$ M). In all neurones tested CGP 71872 (1  $\mu$ M) abolished the late IPSP ( $n = 6$ ) indicating that this compound is an antagonist of postsynaptic GABA<sub>A</sub> receptors.

### Example 5

#### cDNA library construction

RNA is purified from cortex and cerebellum of 7 day old rats according to Chomczynski, P. & Sacchi, N. (1987) *Anal. Biochem.* 162, 156-159. Poly A(+) RNA is enriched by two passages over an oligo (dT) column (Boehringer Mannheim) as described (Maniatis, T., Fritsch, E.F. & Sambrook, J. (1982) *Molecular cloning: A laboratory manual* (Cold Spring Harbor Lab., Cold Spring Harbor, NY). Oligo (dT) primed double stranded cDNA is synthesised from 5  $\mu$ g of poly A(+) RNA using a commercial cDNA synthesis system (Amersham). The reverse transcriptase supplied with the kit is replaced by the RNaseH(-) Superscript II reverse transcriptase (Gibco BRL). The cDNA solution is concentrated on Centricon-100 devices (Amicon), preabsorbed with tRNA, to a final volume of 100 $\mu$ l. Small cDNAs are removed by passage through a Chromaspin-1000 column (Clontech). BstXI adaptors (Invitrogen) are added using T4 DNA ligase (Boehringer Mannheim) and the cDNAs are size-fractionated on an agarose gel. cDNAs with sizes larger than 2kb are purified (Qiaex, Qiagen) and ligated into the BstXI sites of the expression vector pcDNA1 (Invitrogen). An aliquot of the ligation mixture is transformed (BioRad Gene Pulser II) into electrocompetent MC1061/P3 E.coli cells. The complexity of the library is estimated to be  $2 \times 10^6$  independent clones. The average insert size deduced from the analysis of 48 clones is 2.9kb (sizes ranging from 2.0kb to 6.6kb).

Plasmids for the transfections of COS1 cells are isolated from bacterial colonies obtained after the initial round of cDNA transformation. Briefly, an aliquot of the cDNA library is transformed into electrocompetent MC1061/P3 E.coli cells and titrated by plating on agar plates. The cDNA library is divided into pools of approximately 2'000 colonies that are plated on 9cm agar plates and grown overnight at 37°C. The bacteria are scraped off the plates and plasmid DNA is prepared using ion exchange columns (Qiawell, Qiagen).

- 35 -

### **Example 6**

#### **Transfection of COS cells with cDNA**

COS1 cells are obtained from the American Type Culture Collection (ATCC) and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 15µg/ml gentamycin (Gibco BRL) in a humidified atmosphere with 5% CO<sub>2</sub>.

Plasmid DNA from pools of independent bacterial colonies are introduced into COS1 cells using a modification of the standard DEAE-dextran transfection procedure. Briefly, one day before transfection 7.5 x 10<sup>5</sup> cells are seeded per 9cm dish. The next day the medium is removed and the cells are incubated 15 min in 10ml of phosphate buffered saline (PBS tablets, Gibco BRL). Afterwards, PBS is removed and 4ml of 1mg/ml DEAE-dextran (Pharmacia) in PBS is added to the dish. After 9 min incubation at room temperature the cells are washed twice with 5ml of PBS each. The PBS is aspirated and 4µg plasmid DNA (derived from pools of 2'000 independent bacterial colonies) in 540µl PBS is added to the dish and the cells incubated with the DNA for 30 min at 37°C with occasional rocking. Subsequently 4ml of DMEM medium containing 10% NU-serum (Collaborative Research) and 80µM chloroquine (Sigma) is added. After 4 hrs incubation at 37°C the medium is removed and the cells are incubated 2 min in 10% (vol/vol) dimethyl sulfoxide (Merck) in PBS. The cells are rinsed with PBS, cell culture medium is added to the culture dishes and the cells are grown for an additional 2 to 3 days.

### **Example 7**

#### **Identification of GABA<sub>B</sub> receptor clone by ligand binding assay**

Pools of cDNAs (2000 independent clones each) are analysed for GABA<sub>B</sub> receptor expression, after transient transfection into COS1 cells, using a radioligand binding assay with iodinated CGP64213 (specific activity 2'000 Ci/mmol).

Culture dishes with transfected COS1 cells are placed on ice and washed twice with 5ml each of ice-cold Krebs-Henseleit-Tris buffer (20mM Tris-Cl pH 7.4, 118mM NaCl, 5.6mM glucose, 1.2mM KH<sub>2</sub>PO<sub>4</sub>, 1.2mM MgSO<sub>4</sub>, 4.7mM KCl, 1.8mM CaCl<sub>2</sub>). Afterwards the cells are incubated with 0.2nM of <sup>125</sup>I-CGP 64213 in Krebs-Tris buffer (1ml solution per 9cm dish). After 80 min incubation at room temperature the dishes are cooled on ice and washed twice for 5 min with 5ml of ice-cold Krebs-Tris buffer. Subsequently the dishes are

air dried using a fan and the walls of the plates are removed. For autoradiography, the bottom of the plates are exposed, together with intensifying screens, to Kodak X-OMAT AR films for 2 to 3 weeks at -80°C.

A total of 640,000 independent clones (320 individual pools) from the above mentioned cDNA library are screened. One pool yields a positive signal in the ligand binding assay. The plasmid DNA from this pool is re-transformed into electrocompetent MC1061/P3 cells. 10 plasmid pools from 500 colonies each are prepared, two of which rescreened positive in the binding assay. After 4 subsequent rounds of subdivisions of one of the two pools (SIB selection; McCormick, M. (1987) *Methods Enzymol.* 151, 445-449) a single cDNA clone containing a 4376bp insert is identified. This first cDNA clone identified, originally referred to as F4, is designated GABA<sub>B</sub>R1a (SEQ ID No. 1). This cDNA clone encompasses a large open reading frame coding for a putative protein of 960 amino acids with a calculated molecular weight of 108kDa (SEQ ID No.2). According to von Heijne (von Heijne, G. (1986) *Nucl. Acids. Res.* 14, 4683-4691) the first 16 amino acids encode with high probability a signal peptide that is absent in the mature protein. The calculated molecular weight of the predicted mature protein is 106kDa. Hydrophobicity analysis of the putative protein with the algorithm of Kyte and Doolittle (1982) *J. Mol. Biol.* 157, 105-132, using sequence analysis programs from the University of Wisconsin Genetics Computer Group (Devereux, et al., (1984) *Nucl. Acids. Res.* 12, 387-395) predicts, as expected for a cell surface receptor coupled to G-proteins, several membrane spanning regions. Putative N-glycosylation sites are found at amino acid positions 7, 67, 392, 423, 465, 485, 497 and 614 of the predicted mature protein as set forth in SEQ ID No. 2.

### Example 8

#### Assay of cloned GABA<sub>B</sub> receptor

In order to isolate membranes containing the cloned GABA<sub>B</sub> receptor, culture dishes containing GABA<sub>B</sub> receptor-expressing COS cells are washed twice with Krebs-Henseleit-Tris buffer. Afterwards the cells are scraped off the dishes, homogenised in a glass-glass homogeniser and centrifuged for 30 min at 4°C at 40'000 g. The homogenisation and centrifugation step is repeated once. The pellet is resuspended in buffer and stored in liquid nitrogen until further analysis.

**Example 6****Transfection of COS cells with cDNA**

COS1 cells are obtained from the American Type Culture Collection (ATCC) and grown in Dulbecco's modified Eagle medium (DMEM) supplemented with 10% fetal calf serum (FCS) and 15 $\mu$ g/ml gentamycin (Gibco BRL) in a humidified atmosphere with 5% CO<sub>2</sub>.

Plasmid DNA from pools of independent bacterial colonies are introduced into COS1 cells using a modification of the standard DEAE-dextran transfection procedure. Briefly, one day before transfection 7.5 x 10<sup>5</sup> cells are seeded per 9cm dish. The next day the medium is removed and the cells are incubated 15 min in 10ml of phosphate buffered saline (PBS tablets, Gibco BRL). Afterwards, PBS is removed and 4ml of 1mg/ml DEAE-dextran (Pharmacia) in PBS is added to the dish. After 9 min incubation at room temperature the cells are washed twice with 5ml of PBS each. The PBS is aspirated and 4 $\mu$ g plasmid DNA (derived from pools of 2'000 independent bacterial colonies) in 540 $\mu$ l PBS is added to the dish and the cells incubated with the DNA for 30 min at 37°C with occasional rocking. Subsequently 4ml of DMEM medium containing 10% NU-serum (Collaborative Research) and 80 $\mu$ M chloroquine (Sigma) is added. After 4 hrs incubation at 37°C the medium is removed and the cells are incubated 2 min in 10% (vol/vol) dimethyl sulfoxide (Merck) in PBS. The cells are rinsed with PBS, cell culture medium is added to the culture dishes and the cells are grown for an additional 2 to 3 days.

**Example 7****Identification of GABA<sub>B</sub> receptor clone by ligand binding assay**

Pools of cDNAs (2000 independent clones each) are analysed for GABA<sub>B</sub> receptor expression, after transient transfection into COS1 cells, using a radioligand binding assay with iodinated CGP64213 (specific activity 2'000 Ci/mmol).

Culture dishes with transfected COS1 cells are placed on ice and washed twice with 5ml each of ice-cold Krebs-Henseleit-Tris buffer (20mM Tris-Cl pH 7.4, 118mM NaCl, 5.6mM glucose, 1.2mM KH<sub>2</sub>PO<sub>4</sub>, 1.2mM MgSO<sub>4</sub>, 4.7mM KCl, 1.8mM CaCl<sub>2</sub>). Afterwards the cells are incubated with 0.2nM of <sup>125</sup>I-CGP 64213 in Krebs-Tris buffer (1ml solution per 9cm dish). After 80 min incubation at room temperature the dishes are cooled on ice and washed twice for 5 min with 5ml of ice-cold Krebs-Tris buffer. Subsequently the dishes are

air dried using a fan and the walls of the plates are removed. For autoradiography, the bottom of the plates are exposed, together with intensifying screens, to Kodak X-OMAT AR films for 2 to 3 weeks at -80°C.

A total of 640,000 independent clones (320 individual pools) from the above mentioned cDNA library are screened. One pool yields a positive signal in the ligand binding assay. The plasmid DNA from this pool is re-transformed into electrocompetent MC1061/P3 cells. 10 plasmid pools from 500 colonies each are prepared, two of which rescreened positive in the binding assay. After 4 subsequent rounds of subdivisions of one of the two pools (SIB selection; McCormick, M. (1987) *Methods Enzymol.* **151**, 445-449) a single cDNA clone containing a 4376bp insert is identified. This first cDNA clone identified, originally referred to as F4, is designated GABA<sub>B</sub>R1a (SEQ ID No. 1). This cDNA clone encompasses a large open reading frame coding for a putative protein of 960 amino acids with a calculated molecular weight of 108kDa (SEQ ID No.2). According to von Heijne (von Heijne, G. (1986) *Nucl. Acids. Res.* **14**, 4683-4691) the first 16 amino acids encode with high probability a signal peptide that is absent in the mature protein. The calculated molecular weight of the predicted mature protein is 106kDa. Hydrophobicity analysis of the putative protein with the algorithm of Kyte and Doolittle (1982) *J. Mol. Biol.* **157**, 105-132, using sequence analysis programs from the University of Wisconsin Genetics Computer Group (Devereux, et al., (1984) *Nucl. Acids. Res.* **12**, 387-395) predicts, as expected for a cell surface receptor coupled to G-proteins, several membrane spanning regions. Putative N-glycosylation sites are found at amino acid positions 7, 67, 392, 423, 465, 485, 497 and 614 of the predicted mature protein as set forth in SEQ ID No. 2.

### Example 8

#### Assay of cloned GABA<sub>B</sub> receptor

In order to isolate membranes containing the cloned GABA<sub>B</sub> receptor, culture dishes containing GABA<sub>B</sub> receptor-expressing COS cells are washed twice with Krebs-Henseleit-Tris buffer. Afterwards the cells are scraped off the dishes, homogenised in a glass-glass homogeniser and centrifuged for 30 min at 4°C at 40'000 g. The homogenisation and centrifugation step is repeated once. The pellet is resuspended in buffer and stored in liquid nitrogen until further analysis.

Membranes from COS1 cells transfected with the GABA<sub>B</sub> receptor cDNA (membranes derived in a similar manner from brain tissue are used for reference) are suspended in Krebs-Henseleit-Tris buffer at a concentration of approximately 1mg/ml. The membranes are then incubated in the dark with 0.6nM <sup>125</sup>I-CGP 71872 for one hour at room temperature. In control experiments 1μM of unlabeled CGP 54626A, a GABA<sub>B</sub> receptor specific antagonist, is included. The incubation is terminated by centrifugation at 20'000 g for 10 min at 4°C. The pellet is washed once in buffer to remove unbound from bound photoaffinity label. The pellet is resuspended in buffer and illuminated with UV light (365nm, 24W) for 3 min. The suspension is again centrifuged (20 min, 40'000 g). The pellet is washed in buffer, dissolved in SDS sample buffer and separated on a 6% SDS gel according to Laemmli, U.K (1970) *Nature* 227, 680-685. The gel is dried and, together with intensifying screens, exposed to Dupont Reflection NEF-495 X-ray films overnight. The protein expressed from the 4'376bp cDNA clone has an apparent molecular mass of about 120kDa (Figure 1). The apparent molecular weight of the recombinant GABA<sub>B</sub> receptor is estimated from gel mobility relative to those of SDS-PAGE standards (BioRad).

The binding pharmacology of the GABA<sub>B</sub>R1a receptor expressed in COS1 cells is compared with the binding pharmacology of native GABA<sub>B</sub> receptors in rat cerebral cortex membranes. To that aim, the binding characteristics of the radioligand [<sup>125</sup>I]CGP 64213 and the inhibition of this binding by selected GABA<sub>B</sub> receptor antagonists and agonists are compared. The dissociation constant K<sub>D</sub> for the GABA<sub>B</sub>R1a receptor expressed in COS cells is determined to be 1.85 nM. The K<sub>D</sub> of GABA<sub>B</sub> receptors expressed in cortex membranes is determined to be 2.7 nM and thus is similar to the value obtained for the recombinant receptor. The IC<sub>50</sub> values (Table 1) and the slopes of the inhibition curves (Figure 2) for the GABA<sub>B</sub> receptor antagonists CGP 54626A (Froestl *et al.*, (1992) *Pharmacol. Communications* 2, 52-56), CGP 71872, CGP 64213 and CGP 35348 (Froestl *et al.*, 1992) are very similar for recombinant and native receptors. The rank order of affinity for the agonists GABA, L-baclofen and CGP 27492 (aminophosphinic acid, APPA) is identical at recombinant and native receptors, however the agonist affinity is always significantly lower at the recombinant GABA<sub>B</sub>R1a receptor (Figure 3, Table 1). It is known that GTP or its stable analogue Gpp(NH)p reduce the affinity of agonists at native GABA<sub>B</sub> receptors by decoupling the receptors from their G-proteins (Hill *et al.*, (1984) *J.Neurochem.* 42, 652-657). Therefore, the lower affinity of agonists at the recombinant receptor may reflect the fact that in COS cells the G-proteins that normally couple to GABA<sub>B</sub> receptors in brain cells

are not available. We have determined that for rat cortex GABA<sub>B</sub> receptors the IC<sub>50</sub> value of L-baclofen is shifted from 170 nM to 10 µM in the presence of 300 µM Gpp(NH)p. Thus decoupling G-proteins from native GABA<sub>B</sub> receptors results in an IC<sub>50</sub> value comparable to the 34 µM obtained for the recombinant GABA<sub>B</sub>R1a receptor expressed in COS cells. In conclusion, the recombinant GABA<sub>B</sub>R1a receptor shows similar binding pharmacology as native GABA<sub>B</sub> receptors from rat cortex.

Table 1. BINDING PHARMACOLOGY OF NATIVE AND RECOMBINANT GABA<sub>B</sub> RECEPATORS

Inhibition of [<sup>125</sup>I]CGP 64213 binding by GABA<sub>B</sub> receptor antagonists and agonists

ANTAGONISTS	<i>Rat cerebral cortex</i>	<i>COS1 cells</i>
	IC <sub>50</sub> (µM)	IC <sub>50</sub> (µM)
CGP 54626A	0.0019	0.0016
CGP 64213	0.0014	0.0022
CGP 71872	0.0021	0.0038
CGP 35348	9.3	20.0

**AGONISTS**

GABA	0.13	23.9
L-baclofen	0.17	34.0
CGP 27492 (APPA)	0.018	2.6
CGP 47656 (partial agonist)	0.28	12.3

Membranes from COS1 cells transfected with the GABA<sub>B</sub> receptor cDNA (membranes derived in a similar manner from brain tissue are used for reference) are suspended in Krebs-Henseleit-Tris buffer at a concentration of approximately 1mg/ml. The membranes are then incubated in the dark with 0.6nM <sup>125</sup>I-CGP 71872 for one hour at room temperature. In control experiments 1μM of unlabeled CGP 54626A, a GABA<sub>B</sub> receptor specific antagonist, is included. The incubation is terminated by centrifugation at 20'000 g for 10 min at 4°C. The pellet is washed once in buffer to remove unbound from bound photoaffinity label. The pellet is resuspended in buffer and illuminated with UV light (365nm, 24W) for 3 min. The suspension is again centrifuged (20 min, 40'000 g). The pellet is washed in buffer, dissolved in SDS sample buffer and separated on a 6% SDS gel according to Laemmli, U.K (1970) *Nature* 227, 680-685. The gel is dried and, together with intensifying screens, exposed to Dupont Reflection NEF-495 X-ray films overnight. The protein expressed from the 4'376bp cDNA clone has an apparent molecular mass of about 120kDa (Figure 1). The apparent molecular weight of the recombinant GABA<sub>B</sub> receptor is estimated from gel mobility relative to those of SDS-PAGE standards (BioRad).

The binding pharmacology of the GABA<sub>B</sub>R1a receptor expressed in COS1 cells is compared with the binding pharmacology of native GABA<sub>B</sub> receptors in rat cerebral cortex membranes. To that aim, the binding characteristics of the radioligand [<sup>125</sup>I]CGP 64213 and the inhibition of this binding by selected GABA<sub>B</sub> receptor antagonists and agonists are compared. The dissociation constant K<sub>D</sub> for the GABA<sub>B</sub>R1a receptor expressed in COS cells is determined to be 1.85 nM. The K<sub>D</sub> of GABA<sub>B</sub> receptors expressed in cortex membranes is determined to be 2.7 nM and thus is similar to the value obtained for the recombinant receptor. The IC<sub>50</sub> values (Table 1) and the slopes of the inhibition curves (Figure 2) for the GABA<sub>B</sub> receptor antagonists CGP 54626A (Froestl *et al.*, (1992) *Pharmacol. Communications* 2, 52-56), CGP 71872, CGP 64213 and CGP 35348 (Froestl *et al.*, 1992) are very similar for recombinant and native receptors. The rank order of affinity for the agonists GABA, L-baclofen and CGP 27492 (aminophosphinic acid, APPA) is identical at recombinant and native receptors, however the agonist affinity is always significantly lower at the recombinant GABA<sub>B</sub>R1a receptor (Figure 3, Table 1). It is known that GTP or its stable analogue Gpp(NH)p reduce the affinity of agonists at native GABA<sub>B</sub> receptors by decoupling the receptors from their G-proteins (Hill *et al.*, (1984) *J.Neurochem.* 42, 652-657). Therefore, the lower affinity of agonists at the recombinant receptor may reflect the fact that in COS cells the G-proteins that normally couple to GABA<sub>B</sub> receptors in brain cells

are not available. We have determined that for rat cortex GABA<sub>B</sub> receptors the IC<sub>50</sub> value of L-baclofen is shifted from 170 nM to 10 µM in the presence of 300 µM Gpp(NH)p. Thus decoupling G-proteins from native GABA<sub>B</sub> receptors results in an IC<sub>50</sub> value comparable to the 34 µM obtained for the recombinant GABA<sub>B</sub>R1a receptor expressed in COS cells. In conclusion, the recombinant GABA<sub>B</sub>R1a receptor shows similar binding pharmacology as native GABA<sub>B</sub> receptors from rat cortex.

**Table 1. BINDING PHARMACOLOGY OF NATIVE AND RECOMBINANT GABA<sub>B</sub> RECEPTORS**

Inhibition of [<sup>125</sup>I]CGP 64213 binding by GABA<sub>B</sub> receptor antagonists and agonists

<b>ANTAGONISTS</b>	<i>Rat cerebral cortex</i>	<i>COS1 cells</i>
	IC <sub>50</sub> (µM)	IC <sub>50</sub> (µM)
CGP 54626A	0.0019	0.0016
CGP 64213	0.0014	0.0022
CGP 71872	0.0021	0.0038
CGP 35348	9.3	20.0

**AGONISTS**

GABA	0.13	23.9
L-baclofen	0.17	34.0
CGP 27492 (APPA)	0.018	2.6
CGP 47656 (partial agonist)	0.28	12.3

**Example 9****Use of the GABA<sub>B</sub>R1a receptor cDNA to clone related genes**

The rat GABA<sub>B</sub>R1a-receptor cDNA isolated (SEQ ID No. 1) is useful as a probe to identify and isolate additional cDNAs, genes and proteins of the GABA<sub>B</sub>-receptor gene family. It is also useful to identify and isolate cDNAs, genes and proteins of the GABA<sub>B</sub>-receptor gene family in other species, such as for example humans.

In order to isolate a further rat clone (referred to as GABA<sub>B</sub>R1b) and human GABA<sub>B</sub> receptor clones, the abovementioned rat library and a human fetal brain cDNA library (Clontech, Palo Alto, cat. No. HL3025s) are cross-hybridised with the GABA<sub>B</sub>R1a cDNA under suitable hybridisation conditions. The human library is an unidirectional oligo (dT)-primed library consisting of  $1.2 \times 10^6$  independent cDNA clones inserted into the expression vector pcDNAI. The method of screening a plasmid library by colony hybridisation is described in Sambrook et al. (1989). The hybridisation probe used is a  $^{32}\text{P}$ -labelled 1.3kb Pvull/Scal fragment corresponding to bases 1931 to 3264 of the GABA<sub>B</sub>R1a cDNA (SEQ ID No. 1). Hybridisation is in 0.5M NaH<sub>2</sub>PO<sub>4</sub> (pH 7.2), 7% SDS, 1mM EDTA at 60°C overnight. Subsequent wash steps are for one hour at a final stringency of 0.5 x SSC, 0.1% SDS at 55 °C (rat library) or 2 x SSC, 0.1% SDS at 50°C (human library). Kodak X OMAT AR films are exposed to the membranes overnight at -80°C with intensifying screens. The X-ray films are aligned to the agar plates with the bacterial colonies and colonies containing cross-hybridising cDNA clones are isolated. The bacteria are replated on agar dishes and the colony hybridisation screen is repeated twice. The individual colonies obtained are further analysed by Southern blot hybridisation. Selected cDNA clones are analysed by sequencing and a 2.9 kb cDNA for rat GABA<sub>B</sub>R1b characterised (see SEQ ID No. 5). This cDNA encodes a protein of 844 amino acids (see SEQ ID No. 6). The mature GABA<sub>B</sub>R1b differs from the former GABA<sub>B</sub>R1a in that the N-terminal 147 amino acid residues are replaced by 18 different residues. Presumably, these two GABA<sub>B</sub> receptor variants are derived from the same gene by alternative splicing. Those clones which are positive in screening the human library are also analysed by sequencing and reveal one clone termed GABA<sub>B</sub>R1a/b (see SEQ ID No. 3) with a partial sequence encoding a receptor protein of 793 amino acid residues (see SEQ ID No. 4), as well as another clone termed GABA<sub>B</sub>R1b human (see SEQ ID No. 7) which represents a full-length cDNA encoding a human GABA<sub>B</sub> receptor having 844 amino acids (see SEQ ID No. 8).

**Example 10****GABA<sub>B</sub> receptors stably expressed in HEK293 cells negatively couple to adenylate cyclase**

GABA<sub>B</sub> receptors are described to inhibit adenylate cyclase activity, stimulate phospholipase A<sub>2</sub>, activate K<sup>+</sup>-channels, inactivate voltage-dependent Ca<sup>2+</sup>-channels and to modulate inositol phospholipid hydrolysis. As GABA<sub>B</sub>R1a and -b have identical sequence in all domains predicted to be intracellular they are expected to be able to couple to the same effector systems. Using rat cortical slice preparations, L-baclofen has been shown to reduce forskolin-stimulated cAMP accumulation by about 40 percent. The ability of GABA<sub>B</sub>R1a stably expressed in HEK293 cells to reduce forskolin-stimulated cAMP accumulation is analysed (Fig. 5). We chose concentrations of forskolin and L-baclofen that should produce a maximal effect. Forskolin stimulates cAMP levels in HEK293 cells to more than ten times over the basal level. Stimulation of recombinantly expressed GABA<sub>B</sub> receptors by co-addition of 300 µM L-baclofen reduces forskolin stimulated cAMP accumulation by approximately 30 percent. This inhibition is antagonised by CGP54626A, a GABA<sub>B</sub> receptor antagonist. The modulation of adenylate cyclase activity by GABA<sub>B</sub>R1a is sensitive to pertussis toxin, indicating that in HEK293 cells, which are deficient in G<sub>o</sub>, GABA<sub>B</sub>R1a couples to G<sub>i</sub>. As a control, L-baclofen does not inhibit forskolin-stimulated cAMP formation in untransfected HEK293 cells (Fig. 5).

**Deposition Data**

The GABA<sub>B</sub> receptor clone GABA<sub>B</sub>R1a derived from rat was deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany, with an effective deposition date of 17th May 1996 under the accession number DSM 10689.

The GABA<sub>B</sub> receptor clones GABA<sub>B</sub>R1b derived from rat as well as GABA<sub>B</sub>R1b derived from human sources were deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany, with an effective deposition date of 21th February 1997 under the accession numbers DSM 11422 and 11421, respectively.

**Example 9****Use of the GABA<sub>B</sub>R1a receptor cDNA to clone related genes**

The rat GABA<sub>B</sub>R1a-receptor cDNA isolated (SEQ ID No. 1) is useful as a probe to identify and isolate additional cDNAs, genes and proteins of the GABA<sub>B</sub>-receptor gene family. It is also useful to identify and isolate cDNAs, genes and proteins of the GABA<sub>B</sub>-receptor gene family in other species, such as for example humans.

In order to isolate a further rat clone (referred to as GABA<sub>B</sub>R1b) and human GABA<sub>B</sub> receptor clones, the abovementioned rat library and a human fetal brain cDNA library (Clontech, Palo Alto, cat. No. HL3025s) are cross-hybridised with the GABA<sub>B</sub>R1a cDNA under suitable hybridisation conditions. The human library is an unidirectional oligo (dT)-primed library consisting of  $1.2 \times 10^8$  independent cDNA clones inserted into the expression vector pcDNA1. The method of screening a plasmid library by colony hybridisation is described in Sambrook et al. (1989). The hybridisation probe used is a  $^{32}\text{P}$ -labelled 1.3kb Pvull/Scal fragment corresponding to bases 1931 to 3264 of the GABA<sub>B</sub>R1a cDNA (SEQ ID No. 1). Hybridisation is in 0.5M NaH<sub>2</sub>PO<sub>4</sub> (pH 7.2), 7% SDS, 1mM EDTA at 60°C overnight. Subsequent wash steps are for one hour at a final stringency of 0.5 x SSC, 0.1% SDS at 55 °C (rat library) or 2 x SSC, 0.1% SDS at 50°C (human library). Kodak X OMAT AR films are exposed to the membranes overnight at -80°C with intensifying screens. The X-ray films are aligned to the agar plates with the bacterial colonies and colonies containing cross-hybridising cDNA clones are isolated. The bacteria are replated on agar dishes and the colony hybridisation screen is repeated twice. The individual colonies obtained are further analysed by Southern blot hybridisation. Selected cDNA clones are analysed by sequencing and a 2,9 kb cDNA for rat GABA<sub>B</sub>R1b characterised (see SEQ ID No. 5). This cDNA encodes a protein of 844 amino acids (see SEQ ID No. 6). The mature GABA<sub>B</sub>R1b differs from the former GABA<sub>B</sub>R1a in that the N-terminal 147 amino acid residues are replaced by 18 different residues. Presumably, these two GABA<sub>B</sub> receptor variants are derived from the same gene by alternative splicing. Those clones which are positive in screening the human library are also analysed by sequencing and reveal one clone termed GABA<sub>B</sub>R1a/b (see SEQ ID No. 3) with a partial sequence encoding a receptor protein of 793 amino acid residues (see SEQ ID No. 4), as well as another clone termed GABA<sub>B</sub>R1b human (see SEQ ID No. 7) which represents a full-length cDNA encoding a human GABA<sub>B</sub> receptor having 844 amino acids (see SEQ ID No. 8).

**Example 10****GABA<sub>B</sub> receptors stably expressed in HEK293 cells negatively couple to adenylate cyclase**

GABA<sub>B</sub> receptors are described to inhibit adenylate cyclase activity, stimulate phospholipase A<sub>2</sub>, activate K<sup>+</sup>-channels, inactivate voltage-dependent Ca<sup>2+</sup>-channels and to modulate inositol phospholipid hydrolysis. As GABA<sub>B</sub>R1a and -b have identical sequence in all domains predicted to be intracellular they are expected to be able to couple to the same effector systems. Using rat cortical slice preparations, L-baclofen has been shown to reduce forskolin-stimulated cAMP accumulation by about 40 percent. The ability of GABA<sub>B</sub>R1a stably expressed in HEK293 cells to reduce forskolin-stimulated cAMP accumulation is analysed (Fig. 5). We chose concentrations of forskolin and L-baclofen that should produce a maximal effect. Forskolin stimulates cAMP levels in HEK293 cells to more than ten times over the basal level. Stimulation of recombinantly expressed GABA<sub>B</sub> receptors by co-addition of 300 µM L-baclofen reduces forskolin stimulated cAMP accumulation by approximately 30 percent. This inhibition is antagonised by CGP54626A, a GABA<sub>B</sub> receptor antagonist. The modulation of adenylate cyclase activity by GABA<sub>B</sub>R1a is sensitive to pertussis toxin, indicating that in HEK293 cells, which are deficient in G<sub>O</sub>, GABA<sub>B</sub>R1a couples to G<sub>i</sub>. As a control, L-baclofen does not inhibit forskolin-stimulated cAMP formation in untransfected HEK293 cells (Fig. 5).

**Deposition Data**

The GABA<sub>B</sub> receptor clone GABA<sub>B</sub>R1a derived from rat was deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany, with an effective deposition date of 17th May 1996 under the accession number DSM 10689.

The GABA<sub>B</sub> receptor clones GABA<sub>B</sub>R1b derived from rat as well as GABA<sub>B</sub>R1b derived from human sources were deposited under the Budapest Treaty at the Deutsche Sammlung von Microorganismen und Zellkulturen GmbH (DSMZ), Mascheroder Weg 1b, D-38124 Braunschweig, Germany, with an effective deposition date of 21th February 1997 under the accession numbers DSM 11422 and 11421, respectively.

- 41 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: NOVARTIS AG
- (B) STREET: SCHWARZWALDALLEE
- (C) CITY: Basel
- (E) COUNTRY: Switzerland
- (F) POSTAL CODE (ZIP): 4002
- (G) TELEPHONE: +41 61 696 11 11
- (H) TELEFAX: +41 61 696 79 76
- (I) TELEX: 962 991

(ii) TITLE OF INVENTION: Novel Receptors

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4376 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

- 42 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: *Rattus norvegicus*

(vii) IMMEDIATE SOURCE:

(B) CLONE: GABAR<sub>1</sub>a rat

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 182..3061

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide

(B) LOCATION: 182..3061

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTGGGGTTTG CGGGTAGCGA TCGAGAAAGGG GAGAGACCCC GGCCAGGCAG GAGCCTGGAT	60
TCCTGTGGAA GAAGAACAGG GGGAGGGGAA GCTGGAGGAC CGGGAGGGAG AACGGGGAGC	120
CGCGGCCGGG CCTGGGGCCT TGAGGCCCGG GGAGAGCCGC GGAGCAGGAC CGGCCGCCGA	180
G ATG CTG CTG CTG CTG GTG CCT CTC TTC CTC CGC CCC CTG GGC	226
Met Leu Leu Leu Leu Leu Val Pro Leu Phe Leu Arg Pro Leu Gly	
1                   5                   10                   15	
GCT GGC GGG GCG CAG ACC CCC AAC GCC ACC TCG GAA GGT TGC CAG ATT	274
Ala Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile	
20                   25                   30	
ATA CAT CCG CCC TGG GAA GGT GGC ATC AGG TAC CGT GGC TTG ACT CGC	322
Ile His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg	
35                   40                   45	

- 41 -

SEQUENCE LISTING

(1) GENERAL INFORMATION:

(i) APPLICANT:

- (A) NAME: NOVARTIS AG
- (B) STREET: SCHWARZWALDALLEE
- (C) CITY: Basel
- (E) COUNTRY: Switzerland
- (F) POSTAL CODE (ZIP): 4002
- (G) TELEPHONE: +41 61 696 11 11
- (H) TELEFAX: +41 61 696 79 76
- (I) TELEX: 962 991

(ii) TITLE OF INVENTION: Novel Receptors

(iii) NUMBER OF SEQUENCES: 8

(iv) COMPUTER READABLE FORM:

- (A) MEDIUM TYPE: Floppy disk
- (B) COMPUTER: IBM PC compatible
- (C) OPERATING SYSTEM: PC-DOS/MS-DOS
- (D) SOFTWARE: PatentIn Release #1.0, Version #1.30 (EPO)

(2) INFORMATION FOR SEQ ID NO: 1:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 4376 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

- 42 -

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

(A) ORGANISM: Rattus norvegicus

(vii) IMMEDIATE SOURCE:

(B) CLONE: GABAR<sub>1a</sub> rat

(ix) FEATURE:

(A) NAME/KEY: CDS

(B) LOCATION: 182..3061

(ix) FEATURE:

(A) NAME/KEY: mat\_peptide

(B) LOCATION: 182..3061

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 1:

GTGGGGTTTG CGGGTAGCGA TCGAGAAAGGG GAGAGACCCC GGCCAGGCAG GAGCCTGGAT	60
TCCTGTGGAA GAAGAACAGG GGGAGGGGAA CCTGGAGGAC CGGGAGGGAG AACGGGGAGC	120
CGCGGCCGGG CCTGGGGCCT TGAGGCCCGG GGAGAGCCGC GGAGCAGGAC CGGCCGCCGA	180
G ATG CTG CTG CTG CTG GTG CCT CTC TTC CTC CGC CCC CTG GGC	226
Met Leu Leu Leu Leu Leu Val Pro Leu Phe Leu Arg Pro Leu Gly	
1 5 10 15	15
GCT GGC GGG GCG CAG ACC CCC AAC GCC ACC TCG GAA GGT TGC CAG ATT	274
Ala Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile	
20 25 30	30
ATA CAT CCG CCC TGG GAA GGT GGC ATC AGG TAC CGT GGC TTG ACT CGC	322
Ile His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg	
35 40 45	45

- 43 -

GAC CAG GTG AAG GCC ATC AAC TTC CTG CCT GTG GAC TAT GAG ATC GAA			370
Asp Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu			
50	55	60	
TAT GTG TGC CGA GGG GAG CGC GAG GTG GTG GGG CCC AAG GTG CGC AAA			418
Tyr Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys			
65	70	75	
TGC CTG GCC AAC GGC TCC TGG ACG GAT ATG GAC ACA CCC AGC CGC TGT			466
Cys Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys			
80	85	90	95
GTC CGA ATC TGC TCC AAG TCT TAT TTG ACC CTG GAA AAT GGG AAG GTT			514
Val Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val			
100	105	110	
TTC CTG ACG GGT GGG GAC CTC CCA GCT CTG GAT GGA GCC CGG GTG GAG			562
Phe Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Glu			
115	120	125	
TTC CGA TGT GAC CCC GAC TTC CAT CTG GTG GGC AGC TCC CGG AGC GTC			610
Phe Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Val			
130	135	140	
TGT AGT CAG GGC CAG TGG AGC ACC CCC AAG CCC CAC TGC CAG GTG AAT			658
Cys Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn			
145	150	155	
CGA ACG CCA CAC TCA GAA CGG CGT GCA GTA TAC ATC GGG GCG CTG TTT			706
Arg Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe			
160	165	170	175
CCC ATG AGC GGG GGC TGG CCG GGG GGC CAG GCC TGC CAG CCC GCG GTG			754
Pro Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val			
180	185	190	

- 44 -

GAG ATG GCG CTG GAG GAC GTT AAC AGC CGC AGA GAC ATC CTG CCG GAC			802
Glu Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp			
195	200	205	
TAC GAG CTC AAG CTT ATC CAC CAC GAC AGC AAG TGT GAC CCA GGG CAA			850
Tyr Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln			
210	215	220	
GCC ACC AAG TAC TTG TAC GAA CTA CTC TAC AAT GAC CCC ATC AAG ATC			898
Ala Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile			
225	230	235	
ATT CTC ATG CCT GGC TGT AGT TCT GTC TCC ACA CTT GTA GCT GAG GCT			946
Ile Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala			
240	245	250	255
GCC CGG ATG TGG AAC CTT ATT GTG CTC TCA TAT GGC TCC AGT TCA CCA			994
Ala Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro			
260	265	270	
GCC TTG TCA AAC CGA CAG CGG TTT CCC ACG TTC TTC CCG ACG CAT CCA			1042
Ala Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro			
275	280	285	
TCC GCC ACA CTC CAC AAT CCC ACC CGG GTG AAA CTC TTC GAA AAG TGG			1090
Ser Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp			
290	295	300	
GGC TGG AAG AAG ATC GCT ACC ATC CAA CAG ACC ACC GAG GTC TTC ACC			1138
Gly Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr			
305	310	315	
TCA ACG CTG GAT GAC CTG GAG GAG CGA GTG AAA GAG GCT GGG ATC GAG			1186
Ser Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu			
320	325	330	335

- 43 -

GAC CAG GTG AAG GCC ATC AAC TTC CTG CCT GTG GAC TAT GAG ATC GAA			370
Asp Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu			
50	55	60	
TAT GTG TGC CGA GGG GAG CGC GAG GTG GTG GGG CCC AAG GTG CGC AAA			418
Tyr Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys			
65	70	75	
TGC CTG GCC AAC GGC TCC TGG ACG GAT ATG GAC ACA CCC AGC CGC TGT			466
Cys Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys			
80	85	90	95
GTC CGA ATC TGC TCC AAG TCT TAT TTG ACC CTG GAA AAT GGG AAG GTT			514
Val Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val			
100	105	110	
TTC CTG ACG GGT GGG GAC CTC CCA GCT CTG GAT GGA GCC CGG GTG GAG			562
Phe Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Glu			
115	120	125	
TTC CGA TGT GAC CCC GAC TTC CAT CTG GTG GGC AGC TCC CGG AGC GTC			610
Phe Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Val			
130	135	140	
TGT AGT CAG GGC CAG TGG AGC ACC CCC AAG CCC CAC TGC CAG GTG AAT			658
Cys Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn			
145	150	155	
CGA ACG CCA CAC TCA GAA CGG CGT GCA GTA TAC ATC GGG GCG CTG TTT			706
Arg Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe			
160	165	170	175
CCC ATG AGC GGG GGC TGG CCG GGG GGC CAG GCC TGC CAG CCC GCG GTG			754
Pro Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val			
180	185	190	

- 44 -

GAG ATG GCG CTG GAG GAC GTT AAC AGC CGC AGA GAC ATC CTG CCG GAC			802
Glu Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp			
195	200	205	
TAC GAG CTC AAG CTT ATC CAC CAC GAC AGC AAG TGT GAC CCA GGG CAA			850
Tyr Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln			
210	215	220	
GCC ACC AAG TAC TTG TAC GAA CTA CTC TAC AAT GAC CCC ATC AAG ATC			898
Ala Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile			
225	230	235	
ATT CTC ATG CCT GGC TGT AGT TCT GTC TCC ACA CTT GTA GCT GAG GCT			946
Ile Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala			
240	245	250	255
GCC CGG ATG TGG AAC CTT ATT GTG CTC TCA TAT GGC TCC AGT TCA CCA			994
Ala Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro			
260	265	270	
GCC TTG TCA AAC CGA CAG CGG TTT CCC ACG TTC TTC CGG ACG CAT CCA			1042
Ala Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro			
275	280	285	
TCC GCC ACA CTC CAC AAT CCC ACC CGG GTG AAA CTC TTC GAA AAG TGG			1090
Ser Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp			
290	295	300	
GGC TGG AAG AAG ATC GCT ACC ATC CAA CAG ACC ACC GAG GTC TTC ACC			1138
Gly Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr			
305	310	315	
TCA ACG CTG GAT GAC CTG GAG GAG CGA GTG AAA GAG GCT GGG ATC GAG			1186
Ser Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu			
320	325	330	335

- 45 -

ATC ACT TTC CGA CAG AGT TTC TCG GAT CCA GCT GTG CCT GTT AAA			1234
Ile Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys			
340	345	350	
AAC CTG AAG CGT CAA GAT GCT CGA ATC ATC GTG GGA CTT TTC TAT GAG			1282
Asn Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu			
355	360	365	
ACG GAA GCC CGG AAA GTT TTT TGT GAG GTC TAT AAG GAA AGG CTC TTT			1330
Thr Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe			
370	375	380	
GGG AAG AAG TAC GTC TGG TTC CTC ATC GGG TGG TAT GCT GAC AAC TGG			1378
Gly Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp			
385	390	395	
TTC AAG ACC TAT GAC CCG TCA ATC AAT TGT ACA GTG GAA GAA ATG ACC			1426
Phe Lys Thr Tyr Asp Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr			
400	405	410	415
GAG GCG GTG GAG GGC CAC ATC ACC ACG GAG ATT GTC ATG CTG AAC CCT			1474
Glu Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro			
420	425	430	
GCC AAC ACC CGA AGC ATT TCC AAC ATG ACG TCA CAG GAA TTT GTG GAG			1522
Ala Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu			
435	440	445	
AAA CTA ACC AAG CGG CTG AAA AGA CAC CCC GAG GAG ACT GGA GGC TTC			1570
Lys Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe			
450	455	460	
CAG GAG GCA CCA CTG GCC TAT GAT GCT ATC TGG GCC TTG GCT TTG GCC			1618
Gln Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala			
465	470	475	

- 46 -

TTG AAC AAG ACG TCT GGA GGA GGT GGT CGT TCC GGC GTG CGC CTG GAG Leu Asn Lys Thr Ser Gly Gly Gly Arg Ser Gly Val Arg Leu Glu 480                   485                   490                   495	1666
GAC TTT AAC TAC AAC AAC CAG ACC ATT ACA GAC CAG ATC TAC CGG GCC Asp Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala 500                   505                   510	1714
ATG AAC TCC TCC TCC TTT GAG GGC GTT TCT GGC CAT GTG GTC TTT GAT Met Asn Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp 515                   520                   525	1762
GCC AGC GGC TCC CGG ATG GCA TGG ACA CTT ATC GAG CAG CTA CAG GGC Ala Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly 530                   535                   540	1810
GGC AGC TAC AAG AAG ATC GGC TAC TAC GAC AGC ACC AAG GAT GAT CTT Gly Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu 545                   550                   555	1858
TCC TGG TCC AAA ACG GAC AAG TGG ATT GGA GGG TCT CCC CCA GCT GAC Ser Trp Ser Lys Thr Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp 560                   565                   570                   575	1906
CAG ACC TTG GTC ATC AAG ACA TTC CGT TTC CTG TCT CAG AAA CTC TTT Gln Thr Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe 580                   585                   590	1954
ATC TCC GTC TCA GTT CTC TCC AGC CTG GGC ATT GTT CTT GCT GTT GTC Ile Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val 595                   600                   605	2002
TGT CTG TCC TTT AAC ATC TAC AAC TCC CAC GTT CGT TAT ATC CAG AAC Cys Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn 610                   615                   620	2050

- 45 -

ATC ACT TTC CGA CAG AGT TTC TCG GAT CCA GCT GTG CCT GTT AAA Ile Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys 340			1234	
AAC CTG AAG CGT CAA GAT GCT CGA ATC ATC GTG GGA CTT TTC TAT GAG Asn Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu 355	360	365	1282	
ACG GAA GCC CGG AAA GTT TTT TGT GAG GTC TAT AAG GAA AGG CTC TTT Thr Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe 370	375	380	1330	
GGG AAG AAG TAC GTC TGG TTC CTC ATC GGG TGG TAT GCT GAC AAC TGG Gly Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp 385	390	395	1378	
TTC AAG ACC TAT GAC CCG TCA ATC AAT TGT ACA GTG GAA GAA ATG ACC Phe Lys Thr Tyr Asp Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr 400	405	410	415	1426
GAG GCG GTG GAG GGC CAC ATC ACC ACG GAG ATT GTC ATG CTG AAC CCT Glu Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro 420	425	430	1474	
GCC AAC ACC CGA AGC ATT TCC AAC ATG ACG TCA CAG GAA TTT GTG GAG Ala Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu 435	440	445	1522	
AAA CTA ACC AAG CGG CTG AAA AGA CAC CCC GAG GAG ACT GGA GGC TTC Lys Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe 450	455	460	1570	
CAG GAG GCA CCA CTG GCC TAT GAT GCT ATC TGG GCC TTG GCT TTG GCC Gln Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala 465	470	475	1618	

- 46 -

TTG AAC AAG ACG TCT GGA GGA GGT CGT TCC GGC GTG CGC CTG GAG Leu Asn Lys Thr Ser Gly Gly Gly Arg Ser Gly Val Arg Leu Glu 480	485	490	495	1666
GAC TTT AAC TAC AAC AAC CAG ACC ATT ACA GAC CAG ATC TAC CGG GCC Asp Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala 500	505		510	1714
ATG AAC TCC TCC TCC TTT GAG GGC GTT TCT GGC CAT GTG GTC TTT GAT Met Asn Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp 515	520		525	1762
GCC AGC GGC TCC CGG ATG GCA TGG ACA CTT ATC GAG CAG CTA CAG GGC Ala Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly 530	535	540		1810
GGC AGC TAC AAG AAG ATC GGC TAC TAC GAC AGC ACC AAG GAT GAT CTT Gly Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu 545	550	555		1858
TCC TGG TCC AAA ACG GAC AAG TGG ATT GGA GGG TCT CCC CCA GCT GAC Ser Trp Ser Lys Thr Asp Lys Trp Ile Gly Ser Pro Pro Ala Asp 560	565	570	575	1906
CAG ACC TTG GTC ATC AAG ACA TTC CGT TTC CTG TCT CAG AAA CTC TTT Gln Thr Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe 580	585	590		1954
ATC TCC GTC TCA GTT CTC TCC AGC CTG GGC ATT GTT CTT GCT GTT GTC Ile Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val 595	600	605		2002
TGT CTG TCC TTT AAC ATC TAC AAC TCC CAC GTT CGT TAT ATC CAG AAC Cys Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn 610	615	620		2050

- 47 -

TCC CAG CCC AAC CTG AAC AAT CTG ACT GCT GTG GGC TGC TCA CTG GCA Ser Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala	625	630	635	2098	
CTG GCT GCT GTC TTC CCT CTC GGG CTG GAT GGT TAC CAC ATA GGG AGA Leu Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg	640	645	650	2146	
AGC CAG TTC CCG TTT GTC TGC CAG GCC CGC CTT TGG CTC TTG GGC TTG Ser Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu	660	665	670	2194	
GGC TTT AGT CTG GGC TAT GGC TCT ATG TTC ACC AAG ATC TGG TGG GTC Gly Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val	675	680	685	2242	
CAC ACA GTC TTC ACG AAG AAG GAG GAG AAG AAG GAG TGG AGG AAG ACC His Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr	690	695	700	2290	
CTA GAG CCC TGG AAA CTC TAT GCC ACT GTG GGC CTG CTG GTG GGC ATG Leu Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met	705	710	715	2338	
GAT GTC CTG ACT CTT GCC ATC TGG CAG ATT GTG GAC CCC TTG CAC CGA Asp Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg	720	725	730	735	2386
ACC ATT GAG ACT TTT GCC AAG GAG GAA CCA AAG GAA GAC ATC GAT GTC Thr Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val	740	745	750	2434	
TCC ATT CTG CCC CAG TTG GAG CAC TGC AGC TCC AAG AAG ATG AAT ACG Ser Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr	755	760	765	2482	

- 48 -

TGG CTT GGC ATT TTC TAT GGT TAC AAG GGG CTG CTG CTG CTG CTG GGA				2530
Trp Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly				
770	775	780		
ATC TTT CTT GCT TAC GAA ACC AAG AGC GTG TCC ACT GAA AAG ATC AAT				2578
Ile Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn				
785	790	795		
GAC CAC AGG GCC GTG GGC ATG GCT ATC TAC AAT GTC GCG GTC CTG TGT				2626
Asp His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys				
800	805	810	815	
CTC ATC ACT GCT CCT GTG ACC ATG ATC CTT TCC AGT CAG CAG GAC GCA				2674
Leu Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala				
820	825	830		
GCC TTT GCC TTT GCC TCT CTG GCC ATC GTG TTC TCT TCC TAC ATC ACT				2722
Ala Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr				
835	840	845		
CTG GTT GTG CTC TTT GTG CCC AAG ATG CGC AGG CTG ATC ACC CGA GGG				2770
Leu Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly				
850	855	860		
GAA TGG CAG TCT GAA ACG CAG GAC ACC ATG AAA ACA GGA TCA TCC ACC				2811
Glu Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr				
865	870	875		
AAC AAC AAC GAG GAA GAG AAG TCC CGA CTG TTG GAG AAG GAA AAC CGA				2866
Asn Asn Asn Glu Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg				
880	885	890	895	
GAA CTG GAA AAG ATC ATC GCT GAG AAA GAG GAG CGC GTC TCT GAA CTG				2911
Glu Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu				
900	905	910		

- 47 -

TCC CAG CCC AAC CTG AAC AAT CTG ACT GCT GTG GGC TGC TCA CTG GCA Ser Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala	625	630	635	2098	
CTG GCT GCT GTC TTC CCT CTC GGG CTG GAT GGT TAC CAC ATA GGG AGA Leu Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg	640	645	650	2146	
AGC CAG TTC CCG TTT GTC TGC CAG GCC CGC CTT TGG CTC TTG GGC TTG Ser Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu	660	665	670	2194	
GGC TTT AGT CTG GGC TAT GGC TCT ATG TTC ACC AAG ATC TGG TGG GTC Gly Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val	675	680	685	2242	
CAC ACA GTC TTC ACG AAG AAG GAG GAG AAG AAG GAG TGG AGG AAG ACC His Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr	690	695	700	2290	
CTA GAG CCC TGG AAA CTC TAT GCC ACT GTG GGC CTG CTG GTG GGC ATG Leu Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met	705	710	715	2338	
GAT GTC CTG ACT CTT GCC ATC TGG CAG ATT GTG GAC CCC TTG CAC CGA Asp Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg	720	725	730	735	2386
ACC ATT GAG ACT TTT GCC AAG GAG GAA CCA AAG GAA GAC ATC GAT GTC Thr Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val	740	745	750	2434	
TCC ATT CTG CCC CAG TTG GAG CAC TGC AGC TCC AAG AAG ATG AAT ACG Ser Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr	755	760	765	2482	

- 48 -

TGG CTT GGC ATT TTC TAT GGT TAC AAG GGG CTG CTG CTG CTG CTG GGA	2530		
Trp Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Leu Gly			
770	775	780	
ATC TTT CTT GCT TAC GAA ACC AAG AGC GTG TCC ACT GAA AAG ATC AAT	2578		
Ile Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn			
785	790	795	
GAC CAC AGG GCC GTG GGC ATG GCT ATC TAC AAT GTC GCG GTC CTG TGT	2626		
Asp His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys			
800	805	810	815
CTC ATC ACT GCT CCT GTG ACC ATG ATC CTT TCC AGT CAG CAG GAC GCA	2674		
Leu Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala			
820	825	830	
GCC TTT GCC TTT GCC TCT CTG GCC ATC GTG TTC TCT TCC TAC ATC ACT	2722		
Ala Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr			
835	840	845	
CTG GTT GTG CTC TTT GTG CCC AAG ATG CGC AGG CTG ATC ACC CGA GGG	2770		
Leu Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly			
850	855	860	
GAA TGG CAG TCT GAA ACG CAG GAC ACC ATG AAA ACA GGA TCA TCC ACC	2818		
Glu Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr			
865	870	875	
AAC AAC AAC GAG GAA GAG AAG TCC CGA CTG TTG GAG AAG GAA AAC CGA	2866		
Asn Asn Asn Glu Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg			
880	885	890	895
GAA CTG GAA AAG ATC ATC GCT GAG AAA GAG GAG CGC GTC TCT GAA CTG	2914		
Glu Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu			
900	905	910	

- 49 -

CGC CAT CAG CTC CAG TCT CGG CAG CAA CTC CGC TCA CGG CGC CAC CCC	2962
Arg His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro	
915	920
	925
CCA ACA CCC CCA GAT CCC TCT GGG GGC CTT CCC AGG GGA CCC TCT GAG	3010
Pro Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu	
930	935
	940
CCC CCT GAC CGG CTT AGC TGT GAT GGG AGT CGA GTA CAT TTG CTT TAC	3058
Pro Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr	
945	950
	955
AAG TGAGGGGGCA TGGAGAAGGA TCAAGCCAGT AGGGGAGGGA AGGGTCTGGG	3111
Lys	
960	
AAGAGGGTGG GGGCCTGGGA GGAGGGTAAG GACTCCTATC TCCAACCTGG AGAGCACACG	3171
CTCCAATCCC CCTCTTATAA ATACATGTGCG CTCTGTGCAT CTGGGGTTAT TTGGGTCTCC	3231
AGTACTCTGG GAAACAGACT GTTTTCTTTC TCCCCTATAA TTTTATATCT CCACTTACAA	3291
GGTTTTGTAA GAACCCTGCT TGGAGTTATT ATTCACTCAT GGCTCCAGAG GGGCATCTCA	3351
TTTTTCTCCG GTAGCCTGTC TTGTACAGTT ACCACAGCAA CTCCGTGCAT TTCAGCAGCA	3411
GGGGTCTTCC TACACTAGCA GGGCTCTCGC TCTCTCCATT TTTCAGCCTC AGAATCTCCT	3471
TCCATTATTTC TTCTCCTTCT ACATGTCTCC ATGGCTTCCT CTCCCAGGGG ACTCGTTCTA	3531
CACACATACA CACACACACA CACACACACA CACACACACA CACACACACA CACCCCGCAT	3591
CCTGCCCTCT CCTAGGCAGC TGCATGTGCGT CCTGTACAAA TGTGCTCGCT TCTGAGTGCT	3651
TTGTGCGGCC GTTCACTTGT GCTGTCTGCA TAAGCTGCGT CTGTGAGTGC ACGGTGGTTT	3711
GTGGGTGCGT GAAGTGGCAT GCTCCGGTAG GTGTGTATGA TGCCTTGAGC ACGCTACGCT	3771

- 50 -

GTCTCCCTCA TGTGCACGCA TTGTGTCTGC TTATGTTTA CTTGTATGCC TCTGTGTACT	3831
GTGTGTGTGT GTGTGTGTGC CCACCGGTGC GCCCCGTGTGC ATGCGTTCTGT GTTGCCTGA	3891
CTGGCTGTCT CAGCCTTCTG AGTAATTGGG ATTCCAGTTG TCTGTCTAGC TCATGTCTG	3951
TCTTCCTCCA GTAGAGCCGT GAACACCCAA CACACACAGT TAATCGGGCT CCCCCCAGTC	4011
CATGTTTCT GAGCCATCCA AAAACTCTCC TTGGCCTTAG GTTCATCTAC AAATGTTCCC	4071
TCTGTTCTTT GCTCTCGTGC GTCCACCTTC ATTCTCTTCA GTCATTTCTC AGATCTGCTG	4131
CGTCGTGGTT TCCTTCCCTT CATTATCATC GTCATTATTT TTCAGAACTT AAGGGAAAAA	4191
GAAATGGGGA CAGGTTGGAG GCTGTTCCA GTGGAATAGT GGGTGCGCGT CCTGACCAAA	4251
TGAAGGCACG GACAGATGGA CTGACGGGGC GGGAGGCCGC GTCCCTTCA CACTGTGGTG	4311
TCTCTTGGGG GGGAAAGGATC TCCCTGAATC TCAATAAAGC AGTGAACAGT AAAAAAAAAA	4371
<b>AAAAA</b>	4376

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 960 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

-- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Leu Leu Leu Leu Val Pro Leu Phe Leu Arg Pro Leu Gly Ala

1

5

10

15

- 49 -

CGC CAT CAG CTC CAG TCT CGG CAG CAA CTC CGC TCA CGG CGC CAC CCC	2962
Arg His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro	
915	920
	925
CCA ACA CCC CCA GAT CCC TCT GGG GGC CTT CCC AGG GGA CCC TCT GAG	3010
Pro Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu	
930	935
	940
CCC CCT GAC CGG CTT AGC TGT GAT GGG AGT CGA GTA CAT TTG CTT TAC	3058
Pro Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr	
945	950
	955
AAG TGAGGGGGCA TGGAGAAGGA TCAAGCCAGT AGGGGAGGGA AGGGTCTGGG	3111
Lys	
960	
AAGAGGGTGG GGGCCTGGGA GGAGGGTAAG GACTCCTATC TCCAACCTGG AGAGCACACG	3171
CTCCAATCCC CCTCTTATAA ATACATGTGCT CTCTGTGCAT CTGGGGTTAT TTGGGICTCC	3231
AGTACTCTGG GAAACAGACT GTTTTCTTTC TCCCCTATAA TTTTATATCT CCACTTCA	3291
GGTTTTGTTT GAACCCTGCT TGGAGTTATT ATTCACTCAT GGCTCCAGAG GGGCATCTCA	3351
TTTTTCTCCG GTAGCCTGTC TTGTACAGTT ACCACAGCAA CTCTGTGCAT TTCAGCAGCA	3411
GGGGTCTTCC TACACTAGCA GGGCTCTCGC TCTCTCCATT TTTCAGCCTC AGAATCTCCT	3471
TCCATTATTTC TTCTCCTTCT ACATGTCTCC ATGGCTTCCT CTCCCAGGGG ACTCGTTCTA	3531
CACACATACA CACACACACA CACACACACA CACACACACA CACACACACA CACCCCGCAT	3591
CCTGCCCTCT CCTAGGCAGC TGCATGTGCGT CCTGTACAAA TGTGCTCGCT TCTGAGTGCT	3651
TTGTGCGGCC GTTCACTTGT GCTGTCTGCA TAAGCTGCGT CTGTGAGTGC ACGGTGGTTT	3711
GTGGGTGCGT GAAGTGGCAT GCTCCGGTAG GTGTGTATGA TGCCTTGAGC ACGCTACGCT	3771

- 50 -

GTCTCCCTCA TGTGCACGCA TTGTGTCTGC TTATGTTTTA CTTGTATGCC TCTGTGTACT	3831
GTGTGTGTGT GTGTGTGTGC CCACCGGTGC GCCCCGTGTGC ATGCGTTCGT GTTGCCCTGA	3891
CTGGCTGTCT CAGCCTTCTG AGTAATTGGG ATTCCAGTTG TCTGTCTAGC TCATGTCCTG	3951
TCTTCTTCCA GTAGAGCCGT GAACACCCAA CACACACAGT TAATCGGGCT CCCCCCAGTC	4011
CATGTTTCT GAGCCATCCA AAAACTCTCC TTGGCCTTAG GTTCATCTAC AAATGTTCCC	4071
TCTGTTCTTT GCTCTCGTGC GTCCACCTTC ATTCTCTTCA GTCATTCTC AGATCTGCTG	4131
CGTCGTGGTT TCCTTTCTT CATTATCATC GTCATTATTT TTCAGAACTT AAGGGAAAAA	4191
GAAATGGGGA CAGGTTGGAG GCTGTTCCA GTGGAATAGT GGGTGGCGGT CCTGACCAAA	4251
TGAAGGCACG GACAGATGGA CTGACGGGGC GGGAGGCGGC GTCCCTTCA CACTGTGGTG	4311
TCTCTGGGG GGGAAAGGATC TCCCTGAATC TCAATAAAGC AGTGAACAGT AAAAAAAAAA	4371
<b>AAAAAA</b>	<b>4376</b>

(2) INFORMATION FOR SEQ ID NO: 2:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 960 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

-- (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 2:

Met Leu Leu Leu Leu Leu Val Pro Leu Phe Leu Arg Pro Leu Gly Ala

- 51 -

Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile Ile  
20 25 30

His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg Asp  
35 40 45

Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu Tyr  
50 55 60

Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys Cys  
65 70 75 80

Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys Val  
85 90 95

Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val Phe  
100 105 110

Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Glu Phe  
115 120 125

Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Val Cys  
130 135 140

Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn Arg  
145 150 155 160

Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro  
165 170 175

Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu  
180 185 190

Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr  
195 200 205

- 52 -

Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala  
210 215 220

Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile  
225 230 235 240

Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala  
245 250 255

Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala  
260 265 270

Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser  
275 280 285

Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly  
290 295 300

Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser  
305 310 315 320

Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile  
325 330 335

Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn  
340 345 350

Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr  
355 360 365

Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly  
370 375 380

Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe  
385 390 395 400

- 51 -

Gly Gly Ala Gln Thr Pro Asn Ala Thr Ser Glu Gly Cys Gln Ile Ile  
20 25 30

His Pro Pro Trp Glu Gly Gly Ile Arg Tyr Arg Gly Leu Thr Arg Asp  
35 40 45

Gln Val Lys Ala Ile Asn Phe Leu Pro Val Asp Tyr Glu Ile Glu Tyr  
50 55 60

Val Cys Arg Gly Glu Arg Glu Val Val Gly Pro Lys Val Arg Lys Cys  
65 70 75 80

Leu Ala Asn Gly Ser Trp Thr Asp Met Asp Thr Pro Ser Arg Cys Val  
85 90 95

Arg Ile Cys Ser Lys Ser Tyr Leu Thr Leu Glu Asn Gly Lys Val Phe  
100 105 110

Leu Thr Gly Gly Asp Leu Pro Ala Leu Asp Gly Ala Arg Val Glu Phe  
115 120 125

Arg Cys Asp Pro Asp Phe His Leu Val Gly Ser Ser Arg Ser Val Cys  
130 135 140

Ser Gln Gly Gln Trp Ser Thr Pro Lys Pro His Cys Gln Val Asn Arg  
145 150 155 160

Thr Pro His Ser Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro  
165 170 175

Met Ser Gly Gly Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu  
180 185 190

Met Ala Leu Glu Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr  
195 200 205

- 52 -

Glu Leu Lys Leu Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala  
210 215 220

Thr Lys Tyr Leu Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile  
225 230 235 240

Leu Met Pro Gly Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala  
245 250 255

Arg Met Trp Asn Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala  
260 265 270

Leu Ser Asn Arg Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser  
275 280 285

Ala Thr Leu His Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly  
290 295 300

Trp Lys Lys Ile Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser  
305 310 315 320

Thr Leu Asp Asp Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile  
325 330 335

Thr Phe Arg Gln Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn  
340 345 350

Leu Lys Arg Gln Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr  
355 360 365

Glu Ala Arg Lys Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly  
370 375 380

Lys Lys Tyr Val Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe  
385 390 395 400

- 53 -

Lys Thr Tyr Asp Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu  
405 410 415

Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala  
420 425 430

Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys  
435 440 445

Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln  
450 455 460

Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu  
465 470 475 480

Asn Lys Thr Ser Gly Gly Arg Ser Gly Val Arg Leu Glu Asp  
485 490 495

Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met  
500 505 510

Asn Ser Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala  
515 520 525

Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly  
530 535 540

Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser  
545 550 555 560

Trp Ser Lys Thr Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln  
565 570 575

Thr Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile  
580 585 590

- 54 -

Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys  
595 600 605

Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser  
610 615 620

Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu  
625 630 635 640

Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser  
645 650 655

Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly  
660 665 670

Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His  
675 680 685

Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu  
690 695 700

Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp  
705 710 715 720

Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr  
725 730 735

Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser  
740 745 750

Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp  
755 760 765

Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile  
770 775 780

- 53 -

Lys Thr Tyr Asp Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu  
405 410 415

Ala Val Glu Gly His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala  
420 425 430

Asn Thr Arg Ser Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys  
435 440 445

Leu Thr Lys Arg Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln  
450 455 460

Glu Ala Pro Leu Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu  
465 470 475 480

Asn Lys Thr Ser Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp  
485 490 495

Phe Asn Tyr Asn Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met  
500 505 510

Asn Ser Ser Ser Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala  
515 520 525

Ser Gly Ser Arg Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly  
530 535 540

Ser Tyr Lys Lys Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser  
545 550 555 560

Trp Ser Lys Thr Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln  
565 570 575

Thr Leu Val Ile Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile  
580 585 590

- 54 -

Ser Val Ser Val Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys  
595 600 605

Leu Ser Phe Asn Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser  
610 615 620

Gln Pro Asn Leu Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu  
625 630 635 640

Ala Ala Val Phe Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser  
645 650 655

Gln Phe Pro Phe Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly  
660 665 670

Phe Ser Leu Gly Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His  
675 680 685

Thr Val Phe Thr Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu  
690 695 700

Glu Pro Trp Lys Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp  
705 710 715 720

Val Leu Thr Leu Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr  
725 730 735

Ile Glu Thr Phe Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser  
740 745 750

Ile Leu Pro Gln Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp  
755 760 765

Leu Gly Ile Phe Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile  
770 775 780

- 55 -

Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp  
785                    790                    795                    800

His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu  
805                    810                    815

Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala  
820                    825                    830

Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu  
835                    840                    845

Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu  
850                    855                    860

Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn  
865                    870                    875                    880

Asn Asn Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu  
885                    890                    895

Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg  
900                    905                    910

His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro  
915                    920                    925

Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro  
930                    935                    940

Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
945                    950                    955                    960

- 56 -

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2620 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1a/b human

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2379

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 1..2379

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCA GTG TAC ATC GGG GCA CTG TTT CCC ATG AGC GGG GGC TGG CCA GGG  
Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly

- 55 -

Phe Leu Ala Tyr Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp  
785                    790                    795                    800

His Arg Ala Val Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu  
805                    810                    815

Ile Thr Ala Pro Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala  
820                    825                    830

Phe Ala Phe Ala Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu  
835                    840                    845

Val Val Leu Phe Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu  
850                    855                    860

Trp Gln Ser Glu Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn  
865                    870                    875                    880

Asn Asn Glu Glu Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu  
885                    890                    895

Leu Glu Lys Ile Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg  
900                    905                    910

His Gln Leu Gln Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro  
915                    920                    925

Thr Pro Pro Asp Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro  
930                    935                    940

Pro Asp Arg Leu Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
945                    950                    955                    960

- ..

- 56 -

(2) INFORMATION FOR SEQ ID NO: 3:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2620 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1a/b human

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 1..2379

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 1..2379

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 3:

GCA GTG TAC ATC GGG GCA CTG TTT CCC ATG AGC GGG GCC TGG CCA GGG  
Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly

48

1

5

10

15

- 57 -

GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTG AAT	96	
Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn		
20	25	30
AGC CGC AGG GAC ATC CTG CCG GAC TAT GAG CTC AAG CTC ATC CAC CAC	144	
Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His		
35	40	45
GAC AGC AAG TGT GAT CCA GGC CAA GCC ACC AAG TAC CTA TAT GAG CTG	192	
Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu		
50	55	60
CTC TAC AAC GAC CCT ATC AAG ATC ATC CTT ATG CCT GGC TGC AGC TCT	240	
Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser		
65	70	75
		80
GTC TCC ACG CTG GTG GCT GAG GCT GCT AGG ATG TGG AAC CTC ATT GTG	288	
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val		
85	90	95
CTT TCC TAT GGC TCC AGC TCA CCA GCC CTG TCA AAC CGG CAG CGT TTC	336	
Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe		
100	105	110
CCC ACT TTC TTC CGA ACG CAC CCA TCA GCC ACA CTC CAC AAC CCT ACC	384	
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr		
115	120	125
CGC GTG AAA CTC TTT GAA AAG TGG GGC TGG AAG AAG ATT GCT ACC ATC	432	
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile		
130	135	140
CAG CAG ACC ACT GAG GTC TTC ACT TCG ACT CTG GAC GAC CTG GAG GAA	480	
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu		
145	150	155
		160

- 58 -

CGA GTG AAG GAG GCT GGA ATT GAG ATT ACT TTC CGC CAG AGT TTC TTC	528
Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe	
165	170
	175
TCA GAT CCA GCT GTG CCC GTC AAA AAC CTG AAG CGC CAG GAT GCC CGA	576
Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg	
180	185
	190
ATC ATC GTG GGA CTT TTC TAT GAG ACT GAA GCC CGG AAA GTT TTT TGT	624
Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys	
195	200
	205
GAG GTG TAC AAG GAG CGT CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC	672
Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu	
210	215
	220
ATT GGG TGG TAT GCT GAC AAT TGG TTC AAG ATC TAC GAC CCT TCT ATC	720
Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile	
225	230
	235
	240
AAC TGC ACA GTG GAT GAG ATG ACT GAG GCG GTG GAG GGC CAC ATC ACA	768
Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr	
245	250
	255
ACT GAG ATT GTC ATG CTG AAT CCT GCC AAT ACC CGC AGC ATT TCC AAC	816
Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn	
260	265
	270
ATG ACA TCC CAG GAA TTT GTG GAG AAA CTA ACC AAG CGA CTG AAA AGA	864
Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg	
275	280
	285
CAC CCT GAG GAG ACA GGA GGC TTC CAG GAG GCA CCG CTG GCC TAT GAT	912
His Pro Glu Glu Thr Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp	
290	295
	300

- 57 -

GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTG AAT				96
Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn				
20	25	30		
AGC CGC AGG GAC ATC CTG CCG GAC TAT GAG CTC AAG CTC ATC CAC CAC				144
Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His				
35	40	45		
GAC AGC AAG TGT GAT CCA GCC CAA GCC ACC AAG TAC CTA TAT GAG CTG				192
Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu				
50	55	60		
CTC TAC AAC GAC CCT ATC AAG ATC ATC CTT ATG CCT GGC TGC AGC TCT				240
Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser				
65	70	75	80	
GTC TCC ACG CTG GTG GCT GAG GCT GCT AGG ATG TGG AAC CTC ATT GTG				288
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val				
85	90	95		
CTT TCC TAT GGC TCC AGC TCA CCA GCC CTG TCA AAC CGG CAG CGT TTC				336
Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe				
100	105	110		
CCC ACT TTC TTC CGA ACG CAC CCA TCA GCC ACA CTC CAC AAC CCT ACC				384
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr				
115	120	125		
CGC GTG AAA CTC TTT GAA AAG TGG GGC TGG AAG AAG ATT GCT ACC ATC				432
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile				
130	135	140		
CAG CAG ACC ACT GAG GTC TTC ACT TCG ACT CTG GAC GAC CTG GAG GAA				480
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu				
145	150	155	160	

- 58 -

CGA GTG AAG GAG GCT GGA ATT GAG ATT ACT TTC CGC CAG AGT TTC TTC  
 Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe  
 165 170 175  
 TCA GAT CCA GCT GTG CCC GTC AAA AAC CTG AAG CGC CAG GAT GCC CGA  
 Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg  
 180 185 190  
 ATC ATC GTG GGA CTT TTC TAT GAG ACT GAA GCC CGG AAA GTT TTT TGT  
 Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys  
 195 200 205  
 GAG GTG TAC AAG GAG CGT CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC  
 Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu  
 210 215 220  
 ATT GGG TGG TAT GCT GAC AAT TGG TTC AAG ATC TAC GAC CCT TCT ATC  
 Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile  
 225 230 235 240  
 AAC TGC ACA GTG GAT GAG ATG ACT GAG GCG GTG GAG GGC CAC ATC ACA  
 Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr  
 245 250 255  
 ACT GAG ATT GTC ATG CTG AAT CCT GCC AAT ACC CGC AGC ATT TCC AAC  
 Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn  
 260 265 270  
 ATG ACA TCC CAG GAA TTT GTG GAG AAA CTA ACC AAG CGA CTG AAA AGA  
 Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg  
 275 280 285  
 CAC CCT GAG GAG ACA GGA GGC TTC CAG GAG GCA CCG CTG GCC TAT GAT  
 His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp  
 290 295 300

- 59 -

GCC ATC TGG GCC TTG GCA CTG GCC CTG AAC AAG ACA TCT GGA GGA GGC Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly Gly	305	310	315	320	960
GGC CGT TCT GGT GTG CGC CTG GAG GAC TTC AAC TAC AAC AAC CAG ACC Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr	325	330	335		1008
ATT ACC GAC CAA ATC TAC CGG GCA ATG AAC TCT TCG TCC TTT GAG GGT Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly	340	345	350		1056
GTC TCT GGC CAT GTG GTG TTT GAT GCC AGC GGC TCT CGG ATG GCA TGG Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp	355	360	365		1104
ACG CTT ATC GAG CAG CTT CAG GGT GGC AGC TAC AAG AAG ATT GGC TAC Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys Ile Gly Tyr	370	375	380		1152
TAT GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACA GAT AAA TGG Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp	385	390	395	400	1200
ATT GGA GGG TCC CCC CCA GCT GAC CAG ACC CTG GTC ATC AAG ACA TTC Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe	405	410	415		1248
CGC TTC CTG TCA CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser	420	425	430		1296
CTG GGC ATT GTC CTA GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn	435	440	445		1344

- 60 -

TCA CAT GTC CGT TAT ATC CAG AAC TCA CAG CCC AAC CTG AAC AAC CTG		1392
Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu		
450	455	460
ACT GCT GTG GGC TGC TCA CTG GCT TTA GCT GCT GTC TTC CCC CTG GGG		1440
Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly		
465	470	475
480		
CTC GAT GGT TAC CAC ATT GGG AGG AAC CAG TTT CCT TTC GTC TGC CAG		1488
Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln		
485	490	495
GCC CGC CTC TGG CTC CTG GGC CTG GGC TTT AGT CTG GGC TAC GGT TCC		1536
Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser		
500	505	510
ATG TTC ACC AAG ATT TGG TGG GTC CAC ACG GTC TTC ACA AAG AAG GAA		1584
Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu		
515	520	525
GAA AAG AAG GAG TGG AGG AAG ACT CTG GAA CCC TGG AAG CTG TAT GCC		1632
Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala		
530	535	540
ACA GTG GGC CTG CTG GTG GGC ATG GAT GTC CTC ACT CTC GCC ATC TGG		1680
Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp		
545	550	555
560		
CAG ATC GTG GAC CCT CTG CAC CGG ACC ATT GAG ACA TTT GCC AAG GAG		1728
Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu		
565	570	575
GAA CCT AAG GAA GAT ATT GAC GTC TCT ATT CTG CCC CAG CTG GAG CAT		1776
Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His		
580	585	590

- 59 -

GCC ATC TGG GCC TTG GCA CTG GCC CTG AAC AAG ACA TCT GGA GGA GGC Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly Gly	305	310	315	320	960
GGC CGT TCT GGT GTG CGC CTG GAG GAC TTC AAC TAC AAC AAC CAG ACC Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr	325	330	335		1008
ATT ACC GAC CAA ATC TAC CGG GCA ATG AAC TCT TCG TCC TTT GAG GGT Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly	340	345	350		1056
GTC TCT GGC CAT GTG GTG TTT GAT GCC AGC GGC TCT CGG ATG GCA TGG Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp	355	360	365		1104
ACG CTT ATC GAG CAG CTT CAG GGT GGC AGC TAC AAG AAG ATT GGC TAC Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys Ile Gly Tyr	370	375	380		1152
TAT GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACA GAT AAA TGG Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp	385	390	395	400	1200
ATT GGA GGG TCC CCC CCA GCT GAC CAG ACC CTG GTC ATC AAG ACA TTC Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe	405	410	415		1248
CGC TTC CTG TCA CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser	420	425	430		1296
CTG GGC ATT GTC CTA GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn	435	440	445		1344

- 60 -

TCA CAT GTC CGT TAT ATC CAG AAC TCA CAG CCC AAC CTG AAC AAC CTG			1392
Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu			
450	455	460	
ACT GCT GTG GGC TGC TCA CTG GCT TTA GCT GCT GTC TTC CCC CTG GGG			1440
Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly			
465	470	475	480
CTC GAT GGT TAC CAC ATT GGG AGG AAC CAG TTT CCT TTC GTC TGC CAG			1488
Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln			
485	490	495	
GCC CGC CTC TGG CTC CTG GGC CTG GGC TTT AGT CTG GGC TAC GGT TCC			1536
Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser			
500	505	510	
ATG TTC ACC AAG ATT TGG TGG GTC CAC ACG GTC TTC ACA AAG AAG GAA			1584
Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu			
515	520	525	
GAA AAG AAG GAG TGG AGG AAG ACT CTG GAA CCC TGG AAG CTG TAT GCC			1632
Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala			
530	535	540	
ACA GTG GGC CTG CTG GTG GGC ATG GAT GTC CTC ACT CTC GCC ATC TGG			1680
Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp			
545	550	555	560
CAG ATC GTG GAC CCT CTG CAC CGG ACC ATT GAG ACA TTT GCC AAG GAG			1728
Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu			
565	570	575	
GAA CCT AAG GAA GAT ATT GAC GTC TCT ATT CTG CCC CAG CTG GAG CAT			1776
Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His			
580	585	590	

- 61 -

TGC AGC TCC AGG AAG ATG AAT ACA TGG CTT GGC ATT TTC TAT GGT TAC Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr 595	600	605	1824
AAG GGG CTG CTG CTG CTG GGA ATC TTC CTT GCT TAT GAG ACC AAG Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys 610	615	620	1872
AGT GTG TCC ACT GAG AAG ATC AAT GAT CAC CGG GCT GTG GGC ATG GCT Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala 625	630	635	1920
ATC TAC AAT GTG GCA GTC CTG TGC CTC ATC ACT GCT CCT GTC ACC ATG Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met 645	650	655	1968
ATT CTG TCC AGC CAG CAG GAT GCA GCC TTT GCC TTT GCC TCT CTT GCC Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala 660	665	670	2016
ATA GTT TTC TCC TCC TAT ATC ACT CTT GTT GTG CTC TTT GTG CCC AAG Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys 675	680	685	2064
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCG GAG GCG CAG GAC Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp 690	695	700	2112
ACC ATG AAG ACA GGG TCA TCG ACC AAC AAC AAC GAG GAG GAG AAG TCC Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser 705	710	715	2160
CGG CTG TTG GAG AAG GAG AAC CGT GAA CTG GAA AAG ATC ATT GCT GAG Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu 725	730	735	2208

- 62 -

AAA GAG GAG CGT GTC TCT GAA CTG CGC CAT CAA CTC CAG TCT CGG CAG	2256	
Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln		
740	745	750
CAG CTC CGC TCC CGG CGC CAC CCA CCG ACA CCC CCA GAA CCC TCT GGG	2304	
Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly		
755	760	765
GGC CTG CCC AGG GGA CCC CCT GAG CCC CCC GAC CGG CTT AGC TGT GAT	2352	
Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp		
770	775	780
GGG AGT CGA GTG CAT TTG CTT TAT AAG TGAGGGTAGG GTGAGGGAGG	2399	
Gly Ser Arg Val His Leu Leu Tyr Lys		
785	790	
ACAGGCCAGT AGGGGGAGGG AAAGGGAGAG GGGAAAGGGCA GGGGACTCAG GAAGCAGGGG	2459	
GTCCCCATCC CCAGCTGGGA AGAACATGCT ATCCAATCTC ATCTCTTGTA AATACATGTC	2519	
CCCCTGTGAG TTCTGGGCTG ATTTGGGTCT CTCATACTC TGGGAAACAG ACCTTTTCT	2579	
CTCTTACTGC TTCATGTAAT TTTGGAATTG CACCACACTG G	2620	

## (2) INFORMATION FOR SEQ ID NO: 4:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 793 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

## .. (ii) MOLECULE TYPE: protein

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly

- 61 -

TGC AGC TCC AGG AAG ATG AAT ACA TGG CTT GGC ATT TTC TAT GGT TAC	1824	
Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr		
595	600	605
AAG GGG CTG CTG CTG CTG GGA ATC TTC CTT GCT TAT GAG ACC AAG	1872	
Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys		
610	615	620
AGT GTG TCC ACT GAG AAG ATC AAT GAT CAC CGG GCT GTG GGC ATG GCT	1920	
Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala		
625	630	635
ATC TAC AAT GTG GCA GTC CTG TGC CTC ATC ACT GCT CCT GTC ACC ATG	1968	
Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met		
645	650	655
ATT CTG TCC AGC CAG CAG GAT GCA GCC TTT GCC TTT GCC TCT CTT GCC	2016	
Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala		
660	665	670
ATA GTT TTC TCC TCC TAT ATC ACT CTT GTT GTG CTC TTT GTG CCC AAG	2064	
Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys		
675	680	685
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCG GAG GCG CAG GAC	2112	
Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp		
690	695	700
ACC ATG AAG ACA GGG TCA TCG ACC AAC AAC AAC GAG GAG GAG AAG TCC	2160	
Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser		
705	710	715
CGG CTG TTG GAG AAG GAG AAC CGT GAA AAG ATC ATT GCT GAG	2208	
Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu		
725	730	735

- 62 -

AAA GAG GAG CGT GTC TCT GAA CTG CGC CAT CAA CTC CAG TCT CGG CAG	2256	
Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln		
740	745	750
CAG CTC CGC TCC CGG CGC CAC CCA CCG ACA CCC CCA GAA CCC TCT GGG	2304	
Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly		
755	760	765
GGC CTG CCC AGG GGA CCC CCT GAG CCC CCC GAC CGG CTT AGC TGT GAT	2352	
Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp		
770	775	780
GGG AGT CGA GTG CAT TTG CTT TAT AAG TGAGGGTAGG GTGAGGGAGG	2399	
Gly Ser Arg Val His Leu Leu Tyr Lys		
785	790	
ACAGGCCAGT AGGGGGAGGG AAAGGGAGAG GGGAAAGGGCA GGGGACTCAG GAAGCAGGGG	2459	
GTCCCCATCC CCAGCTGGGA AGAACATGCT ATCCAATCTC ATCTCTTGTA AATACATGTC		
CCCCCTGTGAG TTCTGGGCTG ATTTGGGTCT CTCATAACCTC TGGGAAACAG ACCTTTTCT	2579	
CCTCTTACTGTC TTCAATGTAAT TTGGAAATTTC CACCACACTG G		
2620		

(2) INFORMATION FOR SEQ ID NO: 4:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 793 amino acids
  - (B) TYPE: amino acid
  - (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 4:

Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly

- 63 -

Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn

20

25

30

Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His

35

40

45

Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu

50

55

60

Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser

65

70

75

80

Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val

85

90

95

Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe

100

105

110

Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr

115

120

125

Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile

130

135

140

Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu

145

150

155

160

Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe

165

170

175

Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg

180

185

190

Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys

195

200

205

- 64 -

Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu  
210 215 220

Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile  
225 230 235 240

Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr  
245 250 255

Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn  
260 265 270

Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg  
275 280 285

His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp  
290 295 300

Ala Ile Trp Ala Leu Ala Leu Ala Asn Lys Thr Ser Gly Gly Gly  
305 310 315 320

Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr  
325 330 335

Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser Phe Glu Gly  
340 345 350

Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp  
355 360 365

Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys Ile Gly Tyr  
370 375 380

Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp  
385 390 395 400

- 63 -

Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn

20

25

30

Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His

35

40

45

Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu

50

55

60

Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser

65

70

75

80

Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val

85

90

95

Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe

100

105

110

Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr

115

120

125

Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile

130

135

140

Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu

145

150

155

160

Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe

165

170

175

Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg

180

185

190

Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys

195

200

205

- 64 -

Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu

210 215 220

Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile

225 230 235 240

Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr

245 250 255

Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn

260 265 270

Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg

275 280 285

His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp

290 295 300

Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly Gly

305 310 315 320

Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr

325 330 335

Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly

340 345 350

Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp

355 360 365

Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys Ile Gly Tyr

370 375 380

Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp

385 390 395 400

- 65 -

Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe  
405 410 415

Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser  
420 425 430

Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn  
435 440 445

Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu  
450 455 460

Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly  
465 470 475 480

Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln  
485 490 495

Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser  
500 505 510

Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu  
515 520 525

Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala  
530 535 540

Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp  
545 550 555 560

Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu  
565 570 575

Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His  
580 585 590

- 66 -

Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr  
595 600 605

Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys  
610 615 620

Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala  
625 630 635 640

Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met  
645 650 655

Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala  
660 665 670

Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys  
675 680 685

Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp  
690 695 700

Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser  
705 710 715 720

Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu  
725 730 735

Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln  
740 745 750

Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly  
755 760 765

Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp  
770 775 780

- 65 -

Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe  
405 410 415

Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser  
420 425 430

Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn  
435 440 445

Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu  
450 455 460

Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly  
465 470 475 480

Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln  
485 490 495

Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser  
500 505 510

Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu  
515 520 525

Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala  
530 535 540

Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp  
545 550 555 560

Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu  
565 570 575

Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His  
580 585 590

- 66 -

Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr  
595 600 605

Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys  
610 615 620

Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala  
625 630 635 640

Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met  
645 650 655

Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala  
660 665 670

Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys  
675 680 685

Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp  
690 695 700

Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser  
705 710 715 720

Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu  
725 730 735

Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln  
740 745 750

Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly  
755 760 765

Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp  
770 775 780

Gly Ser Arg Val His Leu Leu Tyr Lys  
785 790

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2837 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Rattus norvegicus

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1b rat

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 228..2759

## (ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 228..2759

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

AACGGCCGCC AGTGTGCTGG AAAGGGAGAG TCCGCGGTGG CGGGAGCGAA CGTCTCCTGG

- 68 -

CCCTAGGAAG CCCACGTCTC TGCCTTCCCC GGGCTCTGGC CCCTCCTCCC CAATGAGACC	120		
GGGGATGGAG ACACCTCCCC GACGCCCTCC CAGAAGCCTT CCCCCAGAAGA AGTGTCCCCC	180		
CTGAGCTGCC CCCCCACCCCA AGGAGGCCGC CCCCCGCCGC CCTCGCC ATG GGC CCG	236		
	Met Gly Pro		
	1		
GGG GGA CCC TGT ACC CCA GTG GGG TGG CCG CTG CCT CTT CTG CTG GTG	284		
Gly Gly Pro Cys Thr Pro Val Gly Trp Pro Leu Pro Leu Leu Val			
5	10	15	
ATG GCG GCT GGG GTG GCT CCG GTG TGG GCC TCT CAC TCC CCT CAT CTC	332		
Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser Pro His Leu			
20	25	30	35
CCG CGG CCT CAC CCG AGG GTC CCC CCG CAC CCC TCC TCA GAA CGG CGT	380		
Pro Arg Pro His Pro Arg Val Pro Pro His Pro Ser Ser Glu Arg Arg			
40	45	50	
GCA GTA TAC ATC GGG GCG CTG TTT CCC ATG AGC GGG GGC TGG CCG GGG	428		
Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly			
55	60	65	
GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTT AAC	476		
Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn			
70	75	80	
AGC CGC AGA GAC ATC CTG CCG GAC TAC GAG CTC AAG CTT ATC CAC CAC	524		
Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His			
85	90	95	
GAC AGC AAG TGT GAC CCA GGG CAA GCC ACC AAG TAC TTG TAC GAA CTA	572		
Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu			
100	105	110	115

WO 97/46675

- 67 -

Gly Ser Arg Val His Leu Leu Tyr Lys  
785                           790

## (2) INFORMATION FOR SEQ ID NO: 5:

## (i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2837 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

## (vi) ORIGINAL SOURCE:

- (A) ORGANISM: Rattus norvegicus

## (vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1b rat

## (ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 228..2759

## (ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 228..2759

## (xi) SEQUENCE DESCRIPTION: SEQ ID NO: 5:

AACGGCCGCC AGTGTGCTGG AAAGGGAGAG TCCGGGGTGG CGGGAGCGAA CGTCTCCTGG

- 68 -

CCCTAGGAAG CCCACGTCTC TGCCTTCCCC GGGCTCTGGC CCCTCCTCCC CAATGAGACC	120		
GGGGATGGAG ACACACTCCCC GACGCCCTCC CAGAACGCTT CCCCAGAAGA AGTGTCCCC	180		
CTGAGCTGCC CCCCCACCCCA AGGAGGCCGC CCCCAGCCCC CCTCGCC ATG GGC CCG	236		
	Met Gly Pro 1		
GGG GGA CCC TGT ACC CCA GTG GGG TGG CCG CTG CCT CTT CTG CTG GTG	284		
Gly Gly Pro Cys Thr Pro Val Gly Trp Pro Leu Pro Leu Leu Val			
5	10	15	
ATG GCG GCT GGG GTG GCT CCG GTG TGG GCC TCT CAC TCC CCT CAT CTC	332		
Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser Pro His Leu			
20	25	30	35
CCG CGG CCT CAC CCG AGG GTC CCC CCG CAC CCC TCC TCA GAA CGG CGT	380		
Pro Arg Pro His Pro Arg Val Pro Pro His Pro Ser Ser Glu Arg Arg			
40	45	50	
GCA GTA TAC ATC GGG GCG CTG TTT CCC ATG AGC GGG GGC TGG CCG GGG	428		
Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly			
55	60	65	
GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTT AAC	476		
Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn			
70	75	80	
AGC CGC AGA GAC ATC CTG CCG GAC TAC GAG CTC AAG CTT ATC CAC CAC	524		
Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His			
85	90	95	
GAC AGC AAG TGT GAC CCA GGG CAA GCC ACC AAG TAC TTG TAC GAA CTA	572		
Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu			
100	105	110	115

- 69 -

CTC TAC AAT GAC CCC ATC AAG ATC ATT CTC ATG CCT GGC TGT AGT TCT			620
Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser			
120	125	130	
GTC TCC ACA CTT GTA GCT GAG GCT GCC CGG ATG TGG AAC CTT ATT GTG			668
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val			
135	140	145	
CTC TCA TAT GGC TCC AGT TCA CCA GCC TTG TCA AAC CGA CAG CGG TTT			716
Leu Ser Tyr Gly Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe			
150	155	160	
CCC ACG TTC TTC CGG ACG CAT CCA TCC GCC ACA CTC CAC AAT CCC ACC			764
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr			
165	170	175	
CGG GTG AAA CTC TTC GAA AAG TGG GGC TGG AAG AAG ATC GCT ACC ATC			812
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile			
180	185	190	195
CAA CAG ACC ACC GAG GTC TTC ACC TCA ACG CTG GAT GAC CTG GAG GAG			860
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu			
200	205	210	
CGA GTG AAA GAG GCT GGG ATC GAG ATC ACT TTC CGA CAG AGT TTC TTC			908
Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe			
215	220	225	
TCG GAT CCA GCT GTG CCT GTT AAA AAC CTG AAG CGT CAA GAT GCT CGA			956
Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg			
230	235	240	
ATC ATC GTG GGA CTT TTC TAT GAG ACG GAA GCC CGG AAA GTT TTT TGT			1004
Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys			
245	250	255	

- 70 -

GAG GTC TAT AAG GAA AGG CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu 260 265 270 275	1052
ATC GGG TGG TAT GCT GAC AAC TGG TTC AAG ACC TAT GAC CCG TCA ATC Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Thr Tyr Asp Pro Ser Ile 280 285 290	1100
AAT TGT ACA GTG GAA GAA ATG ACC GAG GCG GTG GAG GGC CAC ATC ACC Asn Cys Thr Val Glu Glu Met Thr Glu Ala Val Glu Gly His Ile Thr 295 300 305	1148
ACG GAG ATT GTC ATG CTG AAC CCT GCC AAC ACC CGA AGC ATT TCC AAC Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn 310 315 320	1196
ATG ACG TCA CAG GAA TTT GTG GAG AAA CTA ACC AAG CGG CTG AAA AGA Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg 325 330 335	1244
CAC CCC GAG GAG ACT GGA GGC TTC CAG GAG GCA CCA CTG GCC TAT GAT His Pro Glu Glu Thr Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp 340 345 350 355	1292
GCT ATC TGG GCC TTG GCT TTG GCC TTG AAC AAG ACG TCT GGA CGA GGT Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly 360 365 370	1340
GGT CGT TCC GGC GTG CGC CTG GAG GAC TTT AAC TAC AAC AAC CAG ACC Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr 375 380 385	1388
ATT ACA GAC CAG ATC TAC CGG GCC ATG AAC TCC TCC TTT GAG GGC Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly 390 395 400	1436

- 69 -

CTC TAC AAT GAC CCC ATC AAG ATC ATT CTC ATG CCT GGC TGT AGT TCT	620		
Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser			
120	125	130	
GTC TCC ACA CTT GTA GCT GAG GCT GCC CGG ATG TGG AAC CTT ATT GTG	668		
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val			
135	140	145	
CTC TCA TAT GGC TCC AGT TCA CCA GCC TTG TCA AAC CGA CAG CGG TTT	716		
Leu Ser Tyr Gly Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe			
150	155	160	
CCC ACG TTC TTC CGG ACG CAT CCA TCC GCC ACA CTC CAC AAT CCC ACC	764		
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr			
165	170	175	
CGG GTG AAA CTC TTC GAA AAG TGG GGC TGG AAG AAG ATC GCT ACC ATC	812		
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile			
180	185	190	195
CAA CAG ACC ACC GAG GTC TTC ACC TCA ACG CTG GAT GAC CTG GAG GAG	860		
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu			
200	205	210	
CGA GTG AAA GAG GCT GGG ATC GAG ATC ACT TTC CGA CAG AGT TTC TTC	908		
Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe			
215	220	225	
TCG GAT CCA GCT GTG CCT GTT AAA AAC CTG AAG CGT CAA GAT GCT CGA	956		
Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg			
230	235	240	
ATC ATC GTG GGA CTT TTC TAT GAG ACG GAA GCC CGG AAA GTT TTT TGT	1004		
Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys			
245	250	255	

- 70 -

GAG GTC TAT AAG GAA AGG CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC	1052		
Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu			
260	265	270	275
ATC GGG TGG TAT GCT GAC AAC TGG TTC AAG ACC TAT GAC CCG TCA ATC	1100		
Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Thr Tyr Asp Pro Ser Ile			
280	285	290	
AAT TGT ACA GTG GAA GAA ATG ACC GAG GCG GTG GAG GGC CAC ATC ACC	1148		
Asn Cys Thr Val Glu Glu Met Thr Glu Ala Val Glu Gly His Ile Thr			
295	300	305	
ACG GAG ATT GTC ATG CTG AAC CCT GCC AAC ACC CGA AGC ATT TCC AAC	1196		
Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn			
310	315	320	
ATG ACG TCA CAG GAA TTT GTG GAG AAA CTA ACC AAG CGG CTG AAA AGA	1244		
Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg			
325	330	335	
CAC CCC GAG GAG ACT GGA GGC TTC CAG GAG GCA CCA CTG GCC TAT GAT	1292		
His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp			
340	345	350	355
GCT ATC TGG GCC TTG GCT TTG GCC TTG AAC AAG ACG TCT GGA GGA GGT	1340		
Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly			
360	365	370	
GGT CGT TCC GGC GTG CGC CTG GAG GAC TTT AAC TAC AAC AAC CAG ACC	1388		
Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr			
375	380	385	
ATT ACA GAC CAG ATC TAC CGG GCC ATG AAC TCC TCC TTT GAG GGC	1436		
Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly			
390	395	400	

- 71 -

GTT TCT GGC CAT GTG GTC TTT GAT GCC AGC GGC TCC CGG ATG GCA TGG			1484
Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp			
405	410	415	
ACA CTT ATC GAG CAG CTA CAG GGC GGC AGC TAC AAG AAG ATC GGC TAC			1532
Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys Ile Gly Tyr			
420	425	430	435
TAC GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACG GAC AAG TGG			1580
Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp			
440	445	450	
ATT GGA GGG TCT CCC CCA GCT GAC CAG ACC TTG GTC ATC AAG ACA TTC			1628
Ile Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe			
455	460	465	
CGT TTC CTG TCT CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC			1676
Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser			
470	475	480	
CTG GGC ATT GTT CTT GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC			1724
Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn			
485	490	495	
TCC CAC GTT CGT TAT ATC CAG AAC TCC CAG CCC AAC CTG AAC AAT CTG			1772
Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu			
500	505	510	515
ACT GCT GTG GGC TGC TCA CTG GCA CTG GCT GCT GTC TTC CCT CTC GGG			1820
Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly			
520	525	530	
CTG GAT GGT TAC CAC ATA GGG AGA AGC CAG TTC CCG TTT GTC TGC CAG			1868
Leu Asp Gly Tyr His Ile Gly Arg Ser Gln Phe Pro Phe Val Cys Gln			
535	540	545	

- 72 -

GCC CGC CTT TGG CTC TTG GGC TTG GGC TTT AGT CTG GGC TAT GGC TCT Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser 550	555	560	1916
ATG TTC ACC AAG ATC TGG TGG GTC CAC ACA GTC TTC ACG AAG AAG GAG Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu 565	570	575	1964
GAG AAG AAG GAG TGG AGG AAG ACC CTA GAG CCC TGG AAA CTC TAT GCC Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala 580	585	590	2012
ACT GTG GGC CTG CTG GTG GGC ATG GAT GTC CTG ACT CTT GCC ATC TGG Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp 600	605	610	2060
CAG ATT GTG GAC CCC TTG CAC CGA ACC ATT GAG ACT TTT GCC AAG GAG Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu 615	620	625	2108
GAA CCA AAG GAA GAC ATC GAT GTC TCC ATT CTG CCC CAG TTG GAG CAC Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His 630	635	640	2156
TGC AGC TCC AAG AAG ATG AAT ACG TGG CTT GGC ATT TTC TAT GGT TAC Cys Ser Ser Lys Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr 645	650	655	2204
AAG GGG CTG CTG CTG CTG GGA ATC TTT CTT GCT TAC GAA ACC AAG Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys 660	665	670	2252
AGC GTG TCC ACT GAA AAG ATC AAT GAC CAC AGG GCC GTG GGC ATG GCT Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala 680	685	690	2300

- 71 -

GTT TCT GGC CAT GTG GTC TTT GAT GCC AGC GGC TCC CGG ATG GCA TGG			1484
Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp			
405	410	415	
ACA CTT ATC GAG CAG CTA CAG GGC GGC AGC TAC AAG AAG ATC GGC TAC			1532
Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys Ile Gly Tyr			
420	425	430	435
TAC GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACG GAC AAG TGG			1580
Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp			
440	445	450	
ATT GGA GGG TCT CCC CCA GCT GAC CAG ACC TTG GTC ATC AAG ACA TTC			1628
Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe			
455	460	465	
CGT TTC CTG TCT CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC			1676
Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser			
470	475	480	
CTG GGC ATT GTT CTT GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC			1724
Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn			
485	490	495	
TCC CAC GTT CGT TAT ATC CAG AAC TCC CAG CCC AAC CTG AAC AAT CTG			1772
Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu			
500	505	510	515
ACT GCT GTG GGC TGC TCA CTG GCA CTG GCT GCT GTC TTC CCT CTC GGG			1820
Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly			
520	525	530	
CTG GAT GGT TAC CAC ATA GGG AGA AGC CAG TTC CCG TTT GTC TGC CAG			1868
Leu Asp Gly Tyr His Ile Gly Arg Ser Gln Phe Pro Phe Val Cys Gln			
535	540	545	

- 72 -

GCC CGC CTT TGG CTC TTG GGC TTG GGC TTT AGT CTG GGC TAT GGC TCT Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser 550                       555                       560	1916
ATG TTC ACC AAG ATC TGG TGG GTC CAC ACA GTC TTC ACG AAG AAG GAG Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu 565                       570                       575	1964
GAG AAG AAG GAG TGG AGG AAG ACC CTA GAG CCC TGG AAA CTC TAT GCC Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala 580                       585                       590                       595	2012
ACT GTG GGC CTG CTG GTG GGC ATG GAT GTC CTG ACT CTT GCC ATC TGG Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp 600                       605                       610	2060
CAG ATT GTG GAC CCC TTG CAC CGA ACC ATT GAG ACT TTT GCC AAG GAG Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu 615                       620                       625	2108
GAA CCA AAG GAA GAC ATC GAT GTC TCC ATT CTG CCC CAG TTG GAG CAC Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His 630                       635                       640	2156
TGC AGC TCC AAG AAG ATG AAT ACG TGG CTT GGC ATT TTC TAT GGT TAC Cys Ser Ser Lys Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr 645                       650                       655	2204
AAG GGG CTG CTG CTG CTG GGA ATC TTT CTT GCT TAC GAA ACC AAG Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys 660                       665                       670                       675	2252
AGC GTG TCC ACT GAA AAG ATC AAT GAC CAC AGG GCC GTG GGC ATG GCT Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala 680                       685                       690	2300

- 73 -

ATC TAC AAT GTC GCG GTC CTG TGT CTC ATC ACT GCT CCT GTG ACC ATG Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met	695	700	705	2348	
ATC CTT TCC AGT CAG CAG GAC GCA GCC TTT GCC TTT GCC TCT CTG GCC Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala	710	715	720	2396	
ATC GTG TTC TCT TCC TAC ATC ACT CTG GTT GTG CTC TTT GTG CCC AAG Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys	725	730	735	2444	
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCT GAA ACG CAG GAC Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Thr Gln Asp	740	745	750	755	2492
ACC ATG AAA ACA GGA TCA TCC ACC AAC AAC AAC GAG GAA GAG AAG TCC Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser	760	765	770	2540	
CGA CTG TTT GAG AAG GAA AAC CGA GAA CTG GAA AAG ATC ATC GCT GAG Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu	775	780	785	2588	
AAA GAG GAG CGC GTC TCT GAA CTG CGC CAT CAG CTC CAG TCT CGG CAG Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln	790	795	800	2636	
CAA CTC CGC TCA CGG CGC CAC CCC CCA ACA CCC CCA GAT CCC TCT GGG Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Asp Pro Ser Gly	805	810	815	2684	
GGC CTT CCC AGG GGA CCC TCT GAG CCC CCT GAC CGG CTT AGC TGT GAT Gly Leu Pro Arg Gly Pro Ser Glu Pro Pro Asp Arg Leu Ser Cys Asp	820	825	830	835	2732

- 74 -

GGG AGT CGA GTA CAT TTG CTT TAC AAG TGAGGGGGCA TGGAGAAAGGA 2779  
Gly Ser Arg Val His Leu Leu Tyr Lys

840

TCTCCCTGAA TCTCAATAAA GCAGTGAAACA GTAAACTTTC CAGCACACTG GCGGCCGC 2837

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

(A) LENGTH: 844 amino acids

(B) TYPE: amino acid

(D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Gly Pro Gly Gly Pro Gys Thr Pro Val Gly Trp Pro Leu Pro Leu  
1 5 10 15

Leu Leu Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser  
20 25 30

Pro His Leu Pro Arg Pro His Pro Arg Val Pro Pro His Pro Ser Ser  
35 40 45

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly  
50 55 60

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu  
65 70 75 80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu  
85 90 95

- 73 -

ATC TAC AAT GTC GCG GTC CTG TGT CTC ATC ACT GCT CCT GTG ACC ATG Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met	695	700	705	2348	
ATC CTT TCC AGT CAG CAG GAC GCA GCC TTT GCC TTT GCC TCT CTG GCC Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala	710	715	720	2396	
ATC GTG TTC TCT TCC TAC ACT CTG GTT GTG CTC TTT GTG CCC AAG Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys	725	730	735	2444	
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCT GAA ACG CAG GAC Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Thr Gln Asp	740	745	750	755	2492
ACC ATG AAA ACA GGA TCA TCC ACC AAC AAC AAC GAG GAA GAG AAG TCC Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser	760	765	770	2540	
CGA CTG TIG GAG AAG GAA AAC CGA GAA CTG GAA AAG ATC ATC GCT GAG Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu.	775	780	785	2588	
AAA GAG GAG CGC GTC TCT GAA CTG CGC CAT CAG CTC CAG TCT CGG CAG Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln	790	795	800	2636	
CAA CTC CGC TCA CGG CGC CAC CCC CCA ACA CCC CCA GAT CCC TCT GGG Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Asp Pro Ser Gly	805	810	815	2684	
GGC CTT CCC AGG GGA CCC TCT GAG CCC CCT GAC CGG CTT AGC TGT GAT Gly Leu Pro Arg Gly Pro Ser Glu Pro Pro Asp Arg Leu Ser Cys Asp	820	825	830	835	2732

- 74 -

GGG AGT CGA GTA CAT TTG CTT TAC AAG TGAGGGGGCA TGGAGAAAGGA 2779  
Gly Ser Arg Val His Leu Leu Tyr Lys  
840

TCTCCCTGAA TCTCAATAAA GCAGTGAAACA GTAAACTTTC CAGCACACTG GCGGCCGC 2837

(2) INFORMATION FOR SEQ ID NO: 6:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 844 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 6:

Met Gly Pro Gly Gly Pro Cys Thr Pro Val Gly Trp Pro Leu Pro Leu  
1 5 10 15

Leu Leu Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser  
20 25 30

Pro His Leu Pro Arg Pro His Pro Arg Val Pro Pro His Pro Ser Ser  
35 40 45

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly  
50 55 60

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu  
65 70 75 80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu  
85 90 95

- 75 -

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu  
100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly  
115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn  
130 135 140

Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg  
145 150 155 160

Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His  
165 170 175

Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile  
180 185 190

Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp  
195 200 205

Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln  
210 215 220

Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln  
225 230 235 240

Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys  
245 250 255

Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val  
260 265 270

Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Thr Tyr Asp  
275 280 285

- 76 -

Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu Ala Val Glu Gly  
290 295 300

His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser  
305 310 315 320

Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg  
325 330 335

Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu  
340 345 350

Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser  
355 360 365

Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn  
370 375 380

Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser  
385 390 395 400

Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg  
405 410 415

Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys  
420 425 430

Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr  
435 440 445

Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile  
450 455 460

Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val  
465 470 475 480

- 75 -

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu  
100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly  
115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn  
130 135 140

Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg  
145 150 155 160

Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His  
165 170 175

Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile  
180 185 190

Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp  
195 200 205

Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln  
210 215 220

Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln  
225 230 235 240

Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys  
245 250 255

Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val  
260 265 270

Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Thr Tyr Asp  
275 280 285

- 76 -

Pro Ser Ile Asn Cys Thr Val Glu Glu Met Thr Glu Ala Val Glu Gly  
290 295 300

His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser  
305 310 315 320

Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu  
340 345 350

Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser  
355 360 365

Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn  
370 375 380

Asn	Gln	Thr	Ile	Thr	Asp	Gln	Ile	Tyr	Arg	Ala	Met	Asn	Ser	Ser	Ser
385					390						395				400

Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg  
405 410 415

Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys  
420 425 430

Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr  
435 440 445

Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile  
450 455 460

Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val  
465 470 475 480

- 77 -

Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn  
485 490 495

Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu  
500 505 510

Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Ala Val Phe  
515 520 525

Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser Gln Phe Pro Phe  
530 535 540

Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly  
545 550 555 560

Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr  
565 570 575

Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys  
580 585 590

Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu  
595 600 605

Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe  
610 615 620

Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln  
625 630 635 640

Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp Leu Gly Ile Phe  
645 650 655

Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr  
660 665 670

- 78 -

Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val  
675 680 685

Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro  
690 695 700

Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala  
705 710 715 720

Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe  
725 730 735

Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu  
740 745 750

Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu  
755 760 765

Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile  
770 775 780

Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln  
785 790 795 800

Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Asp  
805 810 815

Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro Pro Asp Arg Leu  
820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
835 840

- 77 -

Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn  
485 490 495

Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu  
500 505 510

Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Ala Val Phe  
515 520 525

Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Ser Gln Phe Pro Phe  
530 535 540

Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly  
545 550 555 560

Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr  
565 570 575

Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys  
580 585 590

Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu  
595 600 605

Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe  
610 615 620

Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln  
625 630 635 640

Leu Glu His Cys Ser Ser Lys Lys Met Asn Thr Trp Leu Gly Ile Phe  
645 650 655

Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr  
660 665 670

- 78 -

Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val  
675 680 685

Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro  
690 695 700

Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala  
705 710 715 720

Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe  
725 730 735

Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu  
740 745 750

Thr Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu  
755 760 765

Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile  
770 775 780

Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln  
785 790 795 800

Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Asp  
805 810 815

Pro Ser Gly Gly Leu Pro Arg Gly Pro Ser Glu Pro Pro Asp Arg Leu  
820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
835 840

- 79 -

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2924 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1b human

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 169..2700

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 169..2700

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGCCGTAGGA AGCCAACCTT CCCTGTTCT CCGGGGCCCT CGCCCCCTCC TCCCCACAAA

60

ATCAGGGATG GAGGCGCCTC CCCGGCACCC TCTTAGCAGC CCTCCCCAGG AAAAGTGTCC

120

- 80 -

CCCCTGAGCT CCTAACGCTC CCCAACAGCT ACCCCTGCCCG CCCACGCC ATG GGG CCC  
 Met Gly Pro  
 1

GGG GCC CCT TTT GCC CGG GTG GGG TGG CCA CTG CCG CTT CTG GTT GTG 225  
 Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu Leu Val Val  
 5 10 15

ATG GCG GCA GGG GTG GCT CCG GTG TGG GCC TCC CAC TCC CCC CAT CTC 273  
 Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser Pro His Leu  
 20 25 30 35

CCG CGG CCT CAC TCG CGG GTC CCC CCG CAC CCC TCC TCA GAA CGG CGC 321  
 Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser Ser Glu Arg Arg  
 40 45 50

GCA GTG TAC ATC GGG GCA CTG TTT CCC ATG AGC GGG GGC TGG CCA GGG 369  
 Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly  
 55 60 65

GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTG AAT 417  
 Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn  
 70 75 80

AGC CGC AGG GAC ATC CTG CCG GAC TAT GAG CTC AAG CTC ATC CAC CAC 465  
 Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His  
 85 90 95

GAC AGC AAG TGT GAT CCA GGC CAA GCC ACC AAG TAC CTA TAT GAG CTG 51  
 Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu  
 100 105 110 115

CTC TAC AAC GAC CCT ATC AAG ATC ATC CTT ATG CCT GGC TGC AGC TCT 56  
 Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser  
 120 125 130

- 79 -

(2) INFORMATION FOR SEQ ID NO: 7:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 2924 base pairs
- (B) TYPE: nucleic acid
- (C) STRANDEDNESS: double
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: cDNA to mRNA

(iii) HYPOTHETICAL: NO

(iv) ANTI-SENSE: NO

(vi) ORIGINAL SOURCE:

- (A) ORGANISM: Homo sapiens

(vii) IMMEDIATE SOURCE:

- (B) CLONE: GABABR1b human

(ix) FEATURE:

- (A) NAME/KEY: CDS
- (B) LOCATION: 169..2700

(ix) FEATURE:

- (A) NAME/KEY: mat\_peptide
- (B) LOCATION: 169..2700

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 7:

GGCCGTAGGA AGCCAACCTT CCCTGCTTCT CGGGGGCCCT CGCCCCCTCC TCCCCACAAA

60

ATCAGGGATG GAGGGCGCTC CCCGGCACCC TCTTAGCAGC CCTCCCCAGG AAAAGTGTCC

120

- 80 -

CCCCTGAGCT CCTAACGGCTC CCCAACAGCT ACCCCTGCC	CCCACGCC ATG GGG CCC	177
Met Gly Pro		
	1	
GGG GCC CCT TTT GCC CGG GTG GGG TGG CCA CTG CCG CTT CTG GTT GTG		225
Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu Leu Val Val		
5	10	15
ATG GCG GCA GGG GTG GCT CCG GTG TGG GCC TCC CAC TCC CCC CAT CTC		273
Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser Pro His Leu		
20	25	30
		35
CCG CGG CCT CAC TCG CGG GTC CCC CCG CAC CCC TCC TCA GAA CGG CGC		321
Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser Ser Glu Arg Arg		
40	45	50
GCA GTG TAC ATC GGG GCA CTG TTT CCC ATG AGC GGG GGC TGG CCA GGG		369
Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly Trp Pro Gly		
55	60	65
GGC CAG GCC TGC CAG CCC GCG GTG GAG ATG GCG CTG GAG GAC GTG AAT		417
Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu Asp Val Asn		
70	75	80
AGC CGC AGG GAC ATC CTG CCG GAC TAT GAG CTC AAG CTC ATC CAC CAC		465
Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu Ile His His		
85	90	95
GAC AGC AAG TGT GAT CCA GGC CAA GCC ACC AAG TAC CTA TAT GAG CTG		513
Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu Tyr Glu Leu		
100	105	110
		115
CTC TAC AAC GAC CCT ATC AAG ATC ATC CTT ATG CCT GGC TGC AGC TCT		561
Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly Cys Ser Ser		
120	125	130

- 81 -

GTC TCC ACG CTG GTG GCT GAG GCT GCT AGG ATG TGG AAC CTC ATT GTG			609
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val			
135	140	145	
CTT TCC TAT GGC TCC AGC TCA CCA GCC CTG TCA AAC CGG CAG CGT TTC			657
Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe			
150	155	160	
CCC ACT TTC TTC CGA ACG CAC CCA TCA GCC ACA CTC CAC AAC CCT ACC			705
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr			
165	170	175	
CGC GTG AAA CTC TTT GAA AAG TGG GGC TGG AAG AAG ATT GCT ACC ATC			753
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile			
180	185	190	195
CAG CAG ACC ACT GAG GTC TTC ACT TCG ACT CTG GAC GAC CTG GAG GAA			801
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu			
200	205	210	
CGA GTG AAG GAG GCT GGA ATT GAG ATT ACT TTC CGC CAG AGT TTC TTC			849
Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe			
215	220	225	
TCA GAT CCA GCT GTG CCC GTC AAA AAC CTG AAG CGC CAG GAT GCC CGA			897
Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg			
230	235	240	
ATC ATC GTG GGA CTT TTC TAT GAG ACT GAA GCC CGG AAA GTT TTT TGT			945
Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys			
245	250	255	
GAG GTG TAC AAG GAG CGT CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC			993
Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu			
260	265	270	275

- 82 -

ATT GGG TGG TAT GCT GAC AAT TGG TTC AAG ATC TAC GAC CCT TCT ATC Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile	280	285	290	1041
AAC TGC ACA GTG GAT GAG ATG ACT GAG GCG GTG GAG GGC CAC ATC ACA Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr	295	300	305	1089
ACT GAG ATT GTC ATG CTG AAT CCT GCC AAT ACC CGC AGC ATT TCC AAC Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn	310	315	320	1137
ATG ACA TCC CAG GAA TTT GTG GAG AAA CTA ACC AAG CGA CTG AAA AGA Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg	325	330	335	1185
CAC CCT GAG GAG ACA GGA GGC TTC CAG GAG GCA CCG CTG GCC TAT GAT His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp	340	345	350	1233
GCC ATC TGG GCC TTG GCA CTG GCC CTG AAC AAG ACA TCT GGA GGA GGC Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly	360	365	370	1281
GGC CGT TCT GGT GTG CGC CTG GAG GAC TTC AAC TAC AAC AAC CAG ACC Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr	375	380	385	1329
ATT ACC GAC CAA ATC TAC CGG GCA ATG AAC TCT TCG TCC TTT GAG GGT Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly	390	395	400	1377
GTC TCT GGC CAT GTG GTG TTT GAT GCC AGC GGC TCT CGG ATG GCA TGG Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp	405	410	415	1425

- 81 -

GTC TCC ACG CTG GTG GCT GAG GCT GCT AGG ATG TGG AAC CTC ATT GTG			609
Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn Leu Ile Val			
135	140	145	
CTT TCC TAT GGC TCC AGC TCA CCA GCC CTG TCA AAC CGG CAG CGT TTC			657
Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg Gln Arg Phe			
150	155	160	
CCC ACT TTC TTC CGA ACG CAC CCA TCA GCC ACA CTC CAC AAC CCT ACC			705
Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His Asn Pro Thr			
165	170	175	
CGC GTG AAA CTC TTT GAA AAG TGG GGC TGG AAG AAG ATT GCT ACC ATC			753
Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile Ala Thr Ile			
180	185	190	195
CAG CAG ACC ACT GAG GTC TTC ACT TCG ACT CTG GAC GAC CTG GAG GAA			801
Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp Leu Glu Glu			
200	205	210	
CGA GTG AAG GAG GCT GGA ATT GAG ATT ACT TTC CGC CAG AGT TTC TTC			849
Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln Ser Phe Phe			
215	220	225	
TCA GAT CCA GCT GTG CCC GTC AAA AAC CTG AAG CGC CAG GAT GCC CGA			897
Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln Asp Ala Arg			
230	235	240	
ATC ATC GTG GGA CTT TTC TAT GAG ACT GAA GCC CGG AAA GTT TTT TGT			945
Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys Val Phe Cys			
245	250	255	
GAG GTG TAC AAG GAG CGT CTC TTT GGG AAG AAG TAC GTC TGG TTC CTC			993
Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val Trp Phe Leu			
260	265	270	275

- 82 -

ATT GGG TGG TAT GCT GAC AAT TGG TTC AAG ATC TAC GAC CCT TCT ATC  
 Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp Pro Ser Ile  
 280 285 290 1041

AAC TGC ACA GTG GAT GAG ATG ACT GAG GCG GTG GAG GGC CAC ATC ACA  
 Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly His Ile Thr  
 295 300 305 1089

ACT GAG ATT GTC ATG CTG AAT CCT GCC AAT ACC CGC AGC ATT TCC AAC  
 Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser Ile Ser Asn  
 310 315 320 1137

ATG ACA TCC CAG GAA TTT GTG GAG AAA CTA ACC AAG CGA CTG AAA AGA  
 Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg Leu Lys Arg  
 325 330 335 1185

CAC CCT GAG GAG ACA GGA GGC TTC CAG GAG GCA CCG CTG GCC TAT GAT  
 His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu Ala Tyr Asp  
 340 345 350 355 1233

GCC ATC TGG GCC TTG GCA CTG GCC CTG AAC AAG ACA TCT GGA GGA GGC  
 Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser Gly Gly  
 360 365 370 1281

GGC CGT TCT GGT GTG CGC CTG GAG GAC TTC AAC TAC AAC AAC CAG ACC  
 Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn Asn Gln Thr  
 375 380 385 1321

ATT ACC GAC CAA ATC TAC CCG GCA ATG AAC TCT TCG TCC TTT GAG GGT  
 Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Phe Glu Gly  
 390 395 400 1371

GTG TCT GGC CAT GTG GTG TTT GAT GCC AGC GGC TCT CGG ATG GCA TGG  
 Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg Met Ala Trp  
 405 410 415 1421

- 83 -

ACG CTT ATC GAG CAG CTT CAG GGT GGC AGC TAC AAG AAG ATT GGC TAC Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys Ile Gly Tyr 420 425 430 435	1473
TAT GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACA GAT AAA TGG Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp 440 445 450	1521
ATT GGA GGG TCC CCC CCA GCT GAC CAG ACC CTG GTC ATC AAG ACA TTC Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe 455 460 465	1569
CGC TTC CTG TCA CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser 470 475 480	1617
CTG GGC ATT GTC CTA GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn 485 490 495	1665
TCA CAT GTC CGT TAT ATC CAG AAC TCA CAG CCC AAC CTG AAC AAC CTG Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu 500 505 510 515	1713
ACT GCT GTG GGC TGC TCA CTG GCT TTA GCT GCT GTC TTC CCC CTG GGG Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly 520 525 530	1761
CTC GAT GGT TAC CAC ATT GGG AGG AAC CAG TTT CCT TTC GTC TGC CAG Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln 535 540 545	1809
GCC CGC CTC TGG CTC CTG GGC CTG GGC TTT AGT CTG GGC TAC GGT TCC Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser 550 555 560	1857

- 84 -

ATG TTC ACC AAG ATT TGG TGG GTC CAC ACG GTC TTC ACA AAG AAG GAA Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu 565                       570                       575	1905
GAA AAG AAG GAG TGG AGG AAG ACT CTG GAA CCC TGG AAG CTG TAT GCC Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala 580                       585                       590                       595	1953
ACA GTG GGC CTG CTG GTG GGC ATG GAT GTC CTC ACT CTC GCC ATC TGG Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp 600                       605                       610	2001
CAG ATC GTG GAC CCT CTG CAC CGG ACC ATT GAG ACA TTT GCC AAG GAG Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu 615                       620                       625	2049
GAA CCT AAG GAA GAT ATT GAC GTC TCT ATT CTG CCC CAG CTG GAG CAT Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His 630                       635                       640	2097
TGC AGC TCC AGG AAG ATG AAT ACA TGG CTT GGC ATT TTC TAT GGT TAC Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr 645                       650                       655	2145
AAG GGG CTG CTG CTG CTG GGA ATC TTC CTT GCT TAT GAG ACC AAG Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys 660                       665                       670                       675	2193
AGT GTG TCC ACT GAG AAG ATC AAT GAT CAC CGG GCT GTG GGC ATG GCT Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala 680                       685                       690	2241
ATC TAC AAT GTG GCA GTC CTG TGC CTC ATC ACT GCT CCT GTC ACC ATG Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met 695                       700                       705	2289

- 83 -

ACG CTT ATC GAG CAG CTT CAG GGT GGC AGC TAC AAG AAG ATT GGC TAC			1473
Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys Ile Gly Tyr			
420	425	430	435
TAT GAC AGC ACC AAG GAT GAT CTT TCC TGG TCC AAA ACA GAT AAA TGG			1521
Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr Asp Lys Trp			
440	445	450	
ATT GGA GGG TCC CCC CCA GCT GAC CAG ACC CTG GTC ATC AAG ACA TTC			1569
Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile Lys Thr Phe			
455	460	465	
CGC TTC CTG TCA CAG AAA CTC TTT ATC TCC GTC TCA GTT CTC TCC AGC			1617
Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val Leu Ser Ser			
470	475	480	
CTG GGC ATT GTC CTA GCT GTT GTC TGT CTG TCC TTT AAC ATC TAC AAC			1665
Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn Ile Tyr Asn			
485	490	495	
TCA CAT GTC CGT TAT ATC CAG AAC TCA CAG CCC AAC CTG AAC AAC CTG			1713
Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu Asn Asn Leu			
500	505	510	515
ACT GCT GTG GGC TGC TCA CTG GCT TTA GCT GCT GTC TTC CCC CTG GGG			1761
Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Val Phe Pro Leu Gly			
520	525	530	
CTC GAT GGT TAC CAC ATT GGG AGG AAC CAG TTT CCT TTC GTC TGC CAG			1809
Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe Val Cys Gln			
535	540	545	
GCC CGC CTC TGG CTC CTG GGC CTG GGC TTT AGT CTG GGC TAC GGT TCC			1857
Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly Tyr Gly Ser			
550	555	560	

- 84 -

ATG TTC ACC AAG ATT TGG TGG GTC CAC ACG GTC TTC ACA AAG AAG GAA Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr Lys Lys Glu 565                       570                       575	1905
GAA AAG AAG GAG TGG AGG AAG ACT CTG GAA CCC TGG AAG CTG TAT GCC Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys Leu Tyr Ala 580                       585                       590                       595	1953
ACA GTG GGC CTG CTG GTG GGC ATG GAT GTC CTC ACT CTC GCC ATC TGG Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu Ala Ile Trp 600                       605                       610	2001
CAG ATC GTG GAC CCT CTG CAC CGG ACC ATT GAG ACA TTT GCC AAG GAG Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe Ala Lys Glu 615                       620                       625	2049
GAA CCT AAG GAA GAT ATT GAC GTC TCT ATT CTG CCC CAG CTG GAG CAT Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln Leu Glu His 630                       635                       640	2097
TGC AGC TCC AGG AAG ATG AAT ACA TGG CTT GGC ATT TTC TAT GGT TAC Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe Tyr Gly Tyr 645                       650                       655	2145
AAG GGG CTG CTG CTG CTG GGA ATC TTC CTT GCT TAT GAG ACC AAG Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr Glu Thr Lys 660                       665                       670                       675	2193
AGT GTG TCC ACT GAG AAG ATC AAT GAT CAC CGG GCT GTG GGC ATG GCT Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val Gly Met Ala 680                       685                       690	2241
ATC TAC AAT GTG GCA GTC CTG TGC CTC ATC ACT GCT CCT GTC ACC ATG Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro Val Thr Met 695                       700                       705	2289

- 85 -

ATT CTG TCC AGC CAG CAG GAT GCA GCC TTT GCC TTT GCC TCT CTT GCC Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala	2337
710                    715                    720	
ATA GTT TTC TCC TCC TAT ATC ACT CTT GTG CTC TTT GTG CCC AAG Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys	2385
725                    730                    735	
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCG GAG GCG CAG GAC Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp	2433
740                    745                    750                    755	
ACC ATG AAG ACA GGG TCA TCG ACC AAC AAC GAG GAG GAG AAG TCC Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser	2481
760                    765                    770	
CGG CTG TTG GAG AAG GAG AAC CGT GAA CTG GAA AAG ATC ATT GCT GAG Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu	2529
775                    780                    785	
AAA GAG GAG CGT GTC TCT GAA CTG CGC CAT CAA CTC CAG TCT CGG CAG Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln	2577
790                    795                    800	
CAG CTC CGC TCC CGG CGC CAC CCA CCG ACA CCC CCA GAA CCC TCT GGG Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly	2625
805                    810                    815	
GGC CTG CCC AGG GGA CCC CCT GAG CCC CCC GAC CGG CTT AGC TGT GAT Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp	2673
820                    825                    830                    835	
GGG AGT CGA GTG CAT TTG CTT TAT AAG TGAGGGTAGG GTGAGGGAGG Gly Ser Arg Val His Leu Leu Tyr Lys	2720
840	
ACAGGCCAGT AGGGGGAGGG AAAGGGAGAG CGGAAGGGCA GGGGACTCAG GAAGCAGGGG	2780

- 86 -

GTCCCCATCC CCAGCTGGGA AGAACATGCT ATCCAATCTC ATCTCTTGTAAATAACATGTC	2840
CCCCTGTGAG TTCTGGGCTG ATTTGGGTCT CTCATACCTC TGGGAAACAG ACCTTTTCT	2900
CTCTTACTGC TTCATGTAAT TTTC	2924

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 844 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu  
1 5 10 15

Leu Val Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser  
20 25 30

Pro His Leu Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser Ser  
35 40 45

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly  
50 55 60

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu  
65 70 75 80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu  
85 90 95

- 85 -

ATT CTG TCC AGC CAG CAG GAT GCA GCC TTT GCC TTT GCC TCT CTT GCC Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala Ser Leu Ala	2337
710                    715                    720	
ATA GTT TTC TCC TCC TAT ATC ACT CTT GTT GTG CTC TTT GTG CCC AAG Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe Val Pro Lys	2385
725                    730                    735	
ATG CGC AGG CTG ATC ACC CGA GGG GAA TGG CAG TCG GAG GCG CAG GAC Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu Ala Gln Asp	2433
740                    745                    750                    755	
ACC ATG AAG ACA GGG TCA TCG ACC AAC AAC GAG GAG GAG AAG TCC Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu Glu Lys Ser	2481
760                    765                    770	
CGG CTG TTG GAG AAG GAG AAC CGT GAA CTG GAA AAG ATC ATT GCT GAG Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile Ile Ala Glu	2529
775                    780                    785	
AAA GAG GAG CGT GTC TCT GAA CTG CGC CAT CAA CTC CAG TCT CGG CAG Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln Ser Arg Gln	2577
790                    795                    800	
CAG CTC CGC TCC CGG CGC CAC CCA CCG ACA CCC CCA GAA CCC TCT GGG Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu Pro Ser Gly	2625
805                    810                    815	
GGC CTG CCC AGG GGA CCC CCT GAG CCC CCC GAC CGG CTT AGC TGT GAT Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu Ser Cys Asp	2673
820                    825                    830                    835	
GGG AGT CGA GTG CAT TTG CTT TAT AAG TGAGGGTAGG GTGAGGGAGG Gly Ser Arg Val His Leu Leu Tyr Lys	2720
840	
ACAGGCCAGT AGGGGGAGGG AAAGGGAGAG CGGAAGGGCA GGGGACTCAG GAAGCAGGGG	2780

- 86 -

GTCCCCATCC CCAGCTGGGA AGAACATGCT ATCCAATCTC ATCTCTTGTAAATAACATGTC	2840
CCCCTGTGAG TTCTGGGCTG ATTTGGGTCT CTCATAACCTC TGGGAAACAG ACCTTTTCT	2900
CTCTTACTGC TTCATGTAAT TTTG	2924

(2) INFORMATION FOR SEQ ID NO: 8:

(i) SEQUENCE CHARACTERISTICS:

- (A) LENGTH: 844 amino acids
- (B) TYPE: amino acid
- (D) TOPOLOGY: linear

(ii) MOLECULE TYPE: protein

(xi) SEQUENCE DESCRIPTION: SEQ ID NO: 8:

Met Gly Pro Gly Ala Pro Phe Ala Arg Val Gly Trp Pro Leu Pro Leu			
1	5	10	15

Leu Val Val Met Ala Ala Gly Val Ala Pro Val Trp Ala Ser His Ser			
20	25	30	

Pro His Leu Pro Arg Pro His Ser Arg Val Pro Pro His Pro Ser Ser			
35	40	45	

Glu Arg Arg Ala Val Tyr Ile Gly Ala Leu Phe Pro Met Ser Gly Gly			
50	55	60	

Trp Pro Gly Gly Gln Ala Cys Gln Pro Ala Val Glu Met Ala Leu Glu			
65	70	75	80

Asp Val Asn Ser Arg Arg Asp Ile Leu Pro Asp Tyr Glu Leu Lys Leu			
85	90	95	

- 87 -

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu  
100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly  
115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn  
130 135 140

Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg  
145 150 155 160

Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His  
165 170 175

Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile  
180 185 190

Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp  
195 200 205

Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln.  
210 215 220

Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln  
225 230 235 240

Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys  
245 250 255

Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val  
260 265 270

Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp  
275 280 285

- 88 -

Pro Ser Ile Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly  
290 295 300

His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser  
305 310 315 320

Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg  
325 330 335

Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu  
340 345 350

Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Ala Leu Asn Lys Thr Ser  
355 360 365

Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn  
370 375 380

Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser  
385 390 395 400

Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg  
405 410 415

Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Gly Ser Tyr Lys Lys  
420 425 430

Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr  
435 440 445

Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile  
450 455 460

Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val  
465 470 475 480

- 87 -

Ile His His Asp Ser Lys Cys Asp Pro Gly Gln Ala Thr Lys Tyr Leu  
100 105 110

Tyr Glu Leu Leu Tyr Asn Asp Pro Ile Lys Ile Ile Leu Met Pro Gly  
115 120 125

Cys Ser Ser Val Ser Thr Leu Val Ala Glu Ala Ala Arg Met Trp Asn  
130 135 140

Leu Ile Val Leu Ser Tyr Gly Ser Ser Ser Pro Ala Leu Ser Asn Arg  
145 150 155 160

Gln Arg Phe Pro Thr Phe Phe Arg Thr His Pro Ser Ala Thr Leu His  
165 170 175

Asn Pro Thr Arg Val Lys Leu Phe Glu Lys Trp Gly Trp Lys Lys Ile  
180 185 190

Ala Thr Ile Gln Gln Thr Thr Glu Val Phe Thr Ser Thr Leu Asp Asp  
195 200 205

Leu Glu Glu Arg Val Lys Glu Ala Gly Ile Glu Ile Thr Phe Arg Gln.  
210 215 220

Ser Phe Phe Ser Asp Pro Ala Val Pro Val Lys Asn Leu Lys Arg Gln  
225 230 235 240

Asp Ala Arg Ile Ile Val Gly Leu Phe Tyr Glu Thr Glu Ala Arg Lys  
245 250 255

Val Phe Cys Glu Val Tyr Lys Glu Arg Leu Phe Gly Lys Lys Tyr Val  
260 265 270

Trp Phe Leu Ile Gly Trp Tyr Ala Asp Asn Trp Phe Lys Ile Tyr Asp  
275 280 285

- 88 -

Pro Ser Ile Asn Cys Thr Val Asp Glu Met Thr Glu Ala Val Glu Gly  
290 295 300

His Ile Thr Thr Glu Ile Val Met Leu Asn Pro Ala Asn Thr Arg Ser  
305 310 315 320

Ile Ser Asn Met Thr Ser Gln Glu Phe Val Glu Lys Leu Thr Lys Arg  
325 330 335

Leu Lys Arg His Pro Glu Glu Thr Gly Gly Phe Gln Glu Ala Pro Leu  
340 345 350

Ala Tyr Asp Ala Ile Trp Ala Leu Ala Leu Asn Lys Thr Ser  
355 360 365

Gly Gly Gly Arg Ser Gly Val Arg Leu Glu Asp Phe Asn Tyr Asn  
370 375 380

Asn Gln Thr Ile Thr Asp Gln Ile Tyr Arg Ala Met Asn Ser Ser Ser  
385 390 395 400

Phe Glu Gly Val Ser Gly His Val Val Phe Asp Ala Ser Gly Ser Arg  
405 410 415

Met Ala Trp Thr Leu Ile Glu Gln Leu Gln Gly Ser Tyr Lys Lys  
420 425 430

Ile Gly Tyr Tyr Asp Ser Thr Lys Asp Asp Leu Ser Trp Ser Lys Thr  
435 440 445

Asp Lys Trp Ile Gly Gly Ser Pro Pro Ala Asp Gln Thr Leu Val Ile  
450 455 460

Lys Thr Phe Arg Phe Leu Ser Gln Lys Leu Phe Ile Ser Val Ser Val  
465 470 475 480

- 89 -

Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn  
485 490 495

Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu  
500 505 510

Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Leu Ala Ala Val Phe  
515 520 525

Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe  
530 535 540

Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly  
545 550 555 560

Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr  
565 570 575

Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys  
580 585 590

Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu  
595 600 605

Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe  
610 615 620

Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln  
625 630 635 640

Leu Glu His Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe  
645 650 655

Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr  
660 665 670

- 90 -

Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val  
675 680 685

Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro  
690 695 700

Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala  
705 710 715 720

Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe  
725 730 735

Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu  
740 745 750

Ala Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu  
755 760 765

Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile  
770 775 780

Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln  
785 790 795 800

Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu  
805 810 815

Pro Ser Gly Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu  
820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
835 840

- 89 -

Leu Ser Ser Leu Gly Ile Val Leu Ala Val Val Cys Leu Ser Phe Asn  
485 490 495

Ile Tyr Asn Ser His Val Arg Tyr Ile Gln Asn Ser Gln Pro Asn Leu  
500 505 510

Asn Asn Leu Thr Ala Val Gly Cys Ser Leu Ala Ala Ala Val Phe  
515 520 525

Pro Leu Gly Leu Asp Gly Tyr His Ile Gly Arg Asn Gln Phe Pro Phe  
530 535 540

Val Cys Gln Ala Arg Leu Trp Leu Leu Gly Leu Gly Phe Ser Leu Gly  
545 550 555 560

Tyr Gly Ser Met Phe Thr Lys Ile Trp Trp Val His Thr Val Phe Thr  
565 570 575

Lys Lys Glu Glu Lys Lys Glu Trp Arg Lys Thr Leu Glu Pro Trp Lys  
580 585 590

Leu Tyr Ala Thr Val Gly Leu Leu Val Gly Met Asp Val Leu Thr Leu  
595 600 605

Ala Ile Trp Gln Ile Val Asp Pro Leu His Arg Thr Ile Glu Thr Phe  
610 615 620

Ala Lys Glu Glu Pro Lys Glu Asp Ile Asp Val Ser Ile Leu Pro Gln  
625 630 635 640

Leu Glu His Cys Ser Ser Arg Lys Met Asn Thr Trp Leu Gly Ile Phe  
645 650 655

Tyr Gly Tyr Lys Gly Leu Leu Leu Leu Gly Ile Phe Leu Ala Tyr  
660 665 670

- 90 -

Glu Thr Lys Ser Val Ser Thr Glu Lys Ile Asn Asp His Arg Ala Val  
675 680 685

Gly Met Ala Ile Tyr Asn Val Ala Val Leu Cys Leu Ile Thr Ala Pro  
690 695 700

Val Thr Met Ile Leu Ser Ser Gln Gln Asp Ala Ala Phe Ala Phe Ala  
705 710 715 720

Ser Leu Ala Ile Val Phe Ser Ser Tyr Ile Thr Leu Val Val Leu Phe  
725 730 735

Val Pro Lys Met Arg Arg Leu Ile Thr Arg Gly Glu Trp Gln Ser Glu  
740 745 750

Ala Gln Asp Thr Met Lys Thr Gly Ser Ser Thr Asn Asn Asn Glu Glu  
755 760 765

Glu Lys Ser Arg Leu Leu Glu Lys Glu Asn Arg Glu Leu Glu Lys Ile  
770 775 780

Ile Ala Glu Lys Glu Glu Arg Val Ser Glu Leu Arg His Gln Leu Gln  
785 790 795 800

Ser Arg Gln Gln Leu Arg Ser Arg Arg His Pro Pro Thr Pro Pro Glu  
805 810 815

Pro Ser Gly Gly Leu Pro Arg Gly Pro Pro Glu Pro Pro Asp Arg Leu  
820 825 830

Ser Cys Asp Gly Ser Arg Val His Leu Leu Tyr Lys  
835 840

- 91 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 1B  
D-38124 Braunschweig  
Germany

Date of deposit

17 May 1996 (17.05.96)

Accession Number

DSM 10689

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 

We request the Expert Solution where available

## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

Authorized officer

  
C.A.J.A. PASCHE

For International Bureau use only

 This sheet was received by the International Bureau on:

Authorized officer

- 92 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 18  
D-38124 Braunschweig  
Germany

Date of deposit

21 February 1997 (21.02.97)

Accession Number

DSM 11421

## C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet 

We request the Expert Solution where available

## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

Authorized officer


  
C.A.M. PASCHE

For International Bureau use only

 This sheet was received by the International Bureau on:

Authorized officer

- 91 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 1B  
D-38124 Braunschweig  
Germany

Date of deposit

17 May 1996 (17.05.96)

Accession Number

DSM 10689

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 

We request the Expert Solution where available

## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

Authorized officer

  
C.A.J.A. PASCHE

For International Bureau use only

 This sheet was received by the International Bureau on:

Authorized officer

- 92 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 1B  
D-38124 Braunschweig  
Germany

Date of deposit

21 February 1997 (21.02.97)

Accession Number

DSM 11421

## C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet 

We request the Expert Solution where available

## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

Authorized officer


  
C.A.J.M. PASCHE

For International Bureau use only

 This sheet was received by the International Bureau on:

Authorized officer

- 93 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 1B  
D-38124 Braunschweig  
Germany

Date of deposit

21 February 1997 (21.02.97)

Accession Number

DSM 11422

C. ADDITIONAL INDICATIONS (leave blank if not applicable) This information is continued on an additional sheet 

We request the Expert Solution where available

D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

For International Bureau use only

 This sheet was received by the International Bureau on:


Authorized officer


  
C.A.J.A. PASCHE

- 94 -


What is claimed is:

1. A purified GABA<sub>B</sub> receptor or receptor protein.
2. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is capable of specific binding to at least one of the selective GABA<sub>B</sub> receptor antagonists of Formulae I or II:



$[^{125}\text{I}]$ CGP62413

I



$[^{125}\text{I}]$ CGP71872

II

3. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is encoded by any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5 and SEQ ID No. 7, or by a nucleic acid clone selected from the group consisting of clones deposited at the DSMZ under accession numbers DSM 10689, DSM 11421 and DSM 11422.
4. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 having substantial homology to any one of the amino acid sequences set forth in the group consisting of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6 and SEQ ID No. 8.
5. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is a human GABA<sub>B</sub> receptor or receptor protein.

- 93 -

## INDICATIONS RELATING TO A DEPOSITED MICROORGANISM

(PCT Rule 13bis)

A. The indications made below relate to the microorganism referred to in the description  
on page 40, line 20-29

## B. IDENTIFICATION OF DEPOSIT

Further deposits are identified on an additional sheet 

Name of depositary institution

Deutsche Sammlung von Mikroorganismen und  
Zellkulturen (DSMZ)

Address of depositary institution (including postal code and country)

Mascheroder Weg 1B  
D-38124 Braunschweig  
Germany

Date of deposit

21 February 1997 (21.02.97)

Accession Number

DSM 11422

## C. ADDITIONAL INDICATIONS (leave blank if not applicable)

This information is continued on an additional sheet 

We request the Expert Solution where available

## D. DESIGNATED STATES FOR WHICH INDICATIONS ARE MADE (if the indications are not for all designated States)

## E. SEPARATE FURNISHING OF INDICATIONS (leave blank if not applicable)

The indications listed below will be submitted to the International Bureau later (specify the general nature of the indications e.g., "Accession Number of Deposit")

For receiving Office use only

 This sheet was received with the international application

For International Bureau use only

 This sheet was received by the International Bureau on:

Authorized officer


  
 C.A.J.A. PASCHE

Authorized officer


- 94 -

What is claimed is:

1. A purified GABA<sub>B</sub> receptor or receptor protein.
2. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is capable of specific binding to at least one of the selective GABA<sub>B</sub> receptor antagonists of Formulae I or II:



I



II

3. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is encoded by any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5 and SEQ ID No. 7, or by a nucleic acid clone selected from the group consisting of clones deposited at the DSMZ under accession numbers DSM 10689, DSM 11421 and DSM 11422.
4. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 having substantial homology to any one of the amino acid sequences set forth in the group consisting of SEQ ID No. 2, SEQ ID No. 4, SEQ ID No. 6 and SEQ ID No. 8.
5. A GABA<sub>B</sub> receptor or receptor protein according to claim 1 which is a human GABA<sub>B</sub> receptor or receptor protein.

- 95 -

6. A GABA<sub>B</sub> receptor or receptor protein according to claim 5 having substantially the same amino acid sequence as set forth in SEQ ID No. 8.
7. An isolated nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein.
8. A method for identifying a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein, comprising the steps of:
  - preparing an expression library encoding cDNA molecules which potentially encode a GABA<sub>B</sub> receptor or receptor protein;
  - screening the expression library with a specific ligand capable of binding to a GABA<sub>B</sub> receptor or receptor protein; and
  - isolating the cDNA clone encoding a GABA<sub>B</sub> receptor or receptor protein.
9. A method for identifying a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein, comprising the steps of:
  - preparing a library encoding cDNA or genomic DNA molecules which potentially encode a GABA<sub>B</sub> receptor or receptor protein;
  - screening the library by hybridisation with a nucleic acid probe which is capable of hybridising to any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3 , SEQ ID No. 5 and SEQ ID No. 7; and
  - identifying the nucleic acid molecules which hybridise to the probe.
10. A method for screening compounds or mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptor activity, comprising the steps of:
  - preparing a test system comprising a recombinant GABA<sub>B</sub> receptor or receptor protein;
  - exposing the test system to the compound or mixture of compounds;
  - identifying the compound or mixture of compounds which causes modulation of GABA<sub>B</sub> receptor activity as measured by the test system.
11. A method for screening compounds or mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptor expression, comprising the steps of:
  - providing an expression system comprising a test gene operably linked to control sequences normally associated with a gene encoding a GABA<sub>B</sub> receptor or receptor protein;

- 96 -

identifying the compounds which cause a change in the level of expression of the test gene.

12. A nucleic acid complementary to the nucleic acid of claim 7.
13. A nucleic acid probe which is capable of hybridising to any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3, SEQ ID No. 5 and SEQ ID No. 7, under conditions of low stringency.
14. A nucleic acid according to claim 13 which is an antisense nucleic acid.
15. A method according to claim 8 wherein the specific ligand is the compound of Formula I or the compound of Formula II.
16. A replicable nucleic acid vector comprising a coding sequence consisting of a nucleic acid according to claim 7 operably linked to suitable control sequences.
17. A host cell transformed with a vector according to claim 16.
18. An antibody specific for GABA<sub>B</sub> receptor or receptor protein.
19. A transgenic non-human mammal which has been modified to modulate the expression of GABA<sub>B</sub> receptor or receptor protein.
20. The selective GABA<sub>B</sub> receptor antagonist of Formula I.
21. The selective GABA<sub>B</sub> receptor antagonist of Formula II.

- 95 -


6. A GABA<sub>B</sub> receptor or receptor protein according to claim 5 having substantially the same amino acid sequence as set forth in SEQ ID No. 8.
7. An isolated nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein.
8. A method for identifying a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein, comprising the steps of:
  - preparing an expression library encoding cDNA molecules which potentially encode a GABA<sub>B</sub> receptor or receptor protein;
  - screening the expression library with a specific ligand capable of binding to a GABA<sub>B</sub> receptor or receptor protein; and
  - isolating the cDNA clone encoding a GABA<sub>B</sub> receptor or receptor protein.
9. A method for identifying a nucleic acid encoding a GABA<sub>B</sub> receptor or receptor protein, comprising the steps of:
  - preparing a library encoding cDNA or genomic DNA molecules which potentially encode a GABA<sub>B</sub> receptor or receptor protein;
  - screening the library by hybridisation with a nucleic acid probe which is capable of hybridising to any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3 , SEQ ID No. 5 and SEQ ID No. 7; and
  - identifying the nucleic acid molecules which hybridise to the probe.
10. A method for screening compounds or mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptor activity, comprising the steps of:
  - preparing a test system comprising a recombinant GABA<sub>B</sub> receptor or receptor protein;
  - exposing the test system to the compound or mixture of compounds;
  - identifying the compound or mixture of compounds which causes modulation of GABA<sub>B</sub> receptor activity as measured by the test system.
11. A method for screening compounds or mixtures of compounds which are potential modulators of GABA<sub>B</sub> receptor expression, comprising the steps of:
  - providing an expression system comprising a test gene operably linked to control sequences normally associated with a gene encoding a GABA<sub>B</sub> receptor or receptor protein;

- 96 -

identifying the compounds which cause a change in the level of expression of the test gene.


12. A nucleic acid complementary to the nucleic acid of claim 7.
13. A nucleic acid probe which is capable of hybridising to any one of the nucleic acid sequences set forth in the group consisting of SEQ ID No. 1, SEQ ID No. 3 , SEQ ID No. 5 and SEQ ID No. 7, under conditions of low stringency.
14. A nucleic acid according to claim 13 which is an antisense nucleic acid.
15. A method according to claim 8 wherein the specific ligand is the compound of Formula I or the compound of Formula II.
16. A replicable nucleic acid vector comprising a coding sequence consisting of a nucleic acid according to claim 7 operably linked to suitable control sequences.
17. A host cell transformed with a vector according to claim 16.
18. An antibody specific for GABA<sub>B</sub> receptor or receptor protein.
19. A transgenic non-human mammal which has been modified to modulate the expression of GABA<sub>B</sub> receptor or receptor protein.
20. The selective GABA<sub>B</sub> receptor antagonist of Formula I.
21. The selective GABA<sub>B</sub> receptor antagonist of Formula II.

1/6

**Figure 1a**


2/6

FIGURE 1B




1/6

Figure 1a




2/6

FIGURE 1B




3/6


Figure 2




4/6

**Figure 3**



3/6

**Figure 2**


4/6

**Figure 3**



5/6




6 / 6

**Figure 5**

5/6




[<sup>125</sup>]CGP71872  
CGP54626A



muscimol	1 μM	GABA <sub>A</sub> receptor
bicuculline	100 μM	
GABA	10 μM	
APPA	10 μM	
L-baclofen	10 μM	GABA <sub>B</sub> receptor
D-baclofen	10 μM	
CGP71872	1 μM	
CGP54626A	1 μM	
CGP35348	1 mM	GABA <sub>C</sub> receptor inhibitor
CACA	10 μM	
SK&F89976A	10 μM	
L-glutamate	1 mM	

6 / 6

**Figure 5**

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/01370

A. CLASSIFICATION OF SUBJECT MATTER				
IPC 6	C12N15/12	C07K14/705	C07K16/28	G01N33/68
	C12N15/11	A01K67/027		C07F9/30

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	KAUPMANN K ET AL: "Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors [see comments]" NATURE, MAR 20 1997, 386 (6622) P239-46, ENGLAND, XP002032306 & Comment in Nature 1997 Mar 20;386(6622)223-224 see the whole document --- NAKAYASU H ET AL: "Immunoaffinity purification and characterization of gamma-aminobutyric acid (GABA)B receptor from bovine cerebral cortex." J BIOL CHEM, APR 25 1993, 268 (12) P8658-64, UNITED STATES, XP002032307 see the whole document --- -/-/	1-18
X		1,5,10, 11,18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubt on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- \*&\* document member of the same patent family

4

Date of the actual completion of the international search

10 June 1997

Date of mailing of the international search report

25.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
Fax: (+ 31-70) 340-3016

Authorized officer

Nauche, S

## INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/01370

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KURIYAMA K ET AL: "Structure and function of cerebral GABA <sub>A</sub> and GABA <sub>B</sub> receptors." NEUROSCI RES, JUL 1993, 17 (2) P91-9, IRELAND, XP000674902 see page 96, column 2, line 8 - page 97, column 2, line 16 ---	1,5,10, 11,16
P,X	HIROUCHI, MASAAKI ET AL: "Molecular biological approaches to the GABA <sub>B</sub> receptor" PHARMACOL. REV. COMMUN., 1996, 151, XP000675068 see the whole document ---	1,5,10, 11,16
X	GASPARINI P.: "Hereditary hemochromatosis : generation of a transcription map within a refined and extended map of HLA 1 class region" GENOMICS, vol. 31, 1996, pages 319-326, XP000675389 & EMBL database EMEST6:Hsgt545, accession number : X90542; 30 april 1996 see the whole document ---	3,4,13, 14
A	EP 0 569 333 A (CIBA GEIGY AG) 10 November 1993 -----	

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/EP 97/01370

A. CLASSIFICATION OF SUBJECT MATTER		C07K14/705	C07K16/28	G01N33/68	C07F9/30
IPC 6	C12N15/12 C12N15/11	A01K67/027			

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 C07K C07F

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	<p>KAUPMANN K ET AL: "Expression cloning of GABA(B) receptors uncovers similarity to metabotropic glutamate receptors [see comments]"            NATURE, MAR 20 1997, 386 (6622) P239-46,            ENGLAND, XP002032306            &amp; Comment in Nature 1997 Mar            20;386(6622)223-224            see the whole document            ---</p>	1-18
X	<p>NAKAYASU H ET AL: "Immunoaffinity purification and characterization of gamma-aminobutyric acid (GABA)B receptor from bovine cerebral cortex."            J BIOL CHEM, APR 25 1993, 268 (12)            P8658-64, UNITED STATES, XP002032307            see the whole document            ---            -/-</p>	1,5,10, 11,18

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

\* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*&\* document member of the same patent family

4

Date of the actual completion of the international search

10 June 1997

Date of mailing of the international search report

25.09.97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
 NL - 2280 HV Rijswijk  
 Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl.  
 Fax (+ 31-70) 340-3016

Authorized officer

Nauche, S

## INTERNATIONAL SEARCH REPORT

International Application No

PCT/EP 97/01370

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	KURIYAMA K ET AL: "Structure and function of cerebral GABA <sub>A</sub> and GABA <sub>B</sub> receptors." NEUROSCI RES, JUL 1993, 17 (2) P91-9, IRELAND, XP000674902 see page 96, column 2, line 8 - page 97, column 2, line 16 ---	1,5,10, 11,16
P,X	HIROUCHI, MASAAKI ET AL: "Molecular biological approaches to the GABA <sub>B</sub> receptor" PHARMACOL. REV. COMMUN., 1996, 151, XP000675068 see the whole document ---	1,5,10, 11,16
X	GASPARINI P.: "Hereditary hemochromatosis : generation of a transcription map within a refined and extended map of HLA 1 class region" GENOMICS, vol. 31, 1996, pages 319-326, XP000675389 & EMBL database EMEST6:Hsgt545, accession number : X90542; 30 april 1996 see the whole document ---	3,4,13, 14
A	EP 0 569 333 A (CIBA GEIGY AG) 10 November 1993 -----	

## INTERNATIONAL SEARCH REPORT

International application No.

PCT/EP 97/01370

### Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:
  
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
  
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

### Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-18 :A GABA<sub>A</sub> receptor, sequence encoding said receptor. Expression vector and recombinant host cells for the production of GABA<sub>A</sub> receptor. Screening for ligands of the GABA<sub>A</sub> receptor. Antibodies immunoreactive with GABA<sub>A</sub> receptor 88-2B Transgenic non-human mammal expressing said receptor.
  2. Claims 19,20 :GABA<sub>A</sub> receptor antagonists.
- 
1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  
  2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
  
  3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
  
  
  4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-18

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
- No protest accompanied the payment of additional search fees.

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/01370

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
EP 0569333 A	10-11-93	AU	3711293 A	11-11-93
		CA	2095708 A	09-11-93
		JP	6032793 A	08-02-94
		NZ	247561 A	26-07-95
		US	5332729 A	26-07-94
		US	5424441 A	13-06-95
		ZA	9303206 A	08-11-93

**Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)**

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1.  Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely.
2.  Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3.  Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

**Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)**

This International Searching Authority found multiple inventions in this international application, as follows:

1. Claims 1-18 : A GABA<sub>A</sub> receptor, sequence encoding said receptor. Expression vector and recombinant host cells for the production of GABA<sub>A</sub> receptor. Screening for ligands of the GABA<sub>A</sub> receptor. Antibodies immunoreactive with GABA<sub>A</sub> receptor 88-2B Transgenic non-human mammal expressing said receptor.
  2. Claims 19,20 :GABA<sub>A</sub> receptor antagonists.
1.  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
  2.  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3.  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1-18

**Remark on Protest**

- The additional search fees were accompanied by the applicant's protest.  
 No protest accompanied the payment of additional search fees.

**THIS PAGE BLANK (USPTO)**

## INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/EP 97/01370

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0569333 A	10-11-93	AU 3711293 A	11-11-93
		CA 2095708 A	09-11-93
		JP 6032793 A	08-02-94
		NZ 247561 A	26-07-95
		US 5332729 A	26-07-94
		US 5424441 A	13-06-95
		ZA 9303206 A	08-11-93

**THIS PAGE BLANK (USPTO)**